Table 1.

Population	Screening specifics	Guideline group, yr of recommendation
Population	Screening specifics	USPSTF, 2018	ACOG, 2016	ACS, 2020
Persons at average risk	Age to start screening	21 yrs	21 yrs	25 yrs
	Age to end screening	65 yrs	65 yrs	65 yrs
	Age to end screening	If three consecutive negative cytology tests or two negative cytology plus HPV tests or two negative HPV tests (ACS) with the most recent within the previous 5 yrs and no abnormal tests within the previous 10 yrs (ACS) and no CIN 2 or CIN 3 within the previous 25 yrs
	Screening test options and intervals	Aged 21–65 yrs: Cytology alone every 3 yrs or Aged 21–29 yrs: Cytology alone every 3 yrs Aged 30–65 yrs: Cytology plus HPV testing every 5 yrs or Aged 21–29 yrs: Cytology alone every 3 yrs Aged 30–65: HPV testing alone every 5 yrs*		HPV testing alone every 5 yrs or Cytology plus HPV testing every 5 yrs or Cytology alone every 3 yrs
	Preferred strategies	Cytology alone every 3 yrs and HPV testing alone every 5 yrs (equally preferred)	Cytology plus HPV testing every 5 yrs	HPV testing alone every 5 yrs
	Previous hysterectomy with removal of cervix	Screening not recommended after hysterectomy for benign indications Surveillance testing recommended for previous diagnosis of high-grade precancer, AIS, or cancer
Persons with an immunocompromising medical condition^† (e.g., HIV infection or solid organ transplantation)	Age to start screening	No specific recommendation	Within 1 yr of onset of sexual activity or, if already sexually active, within the first year after HIV or other immunocompromising medical condition diagnosis but no later than age 21 yrs
	Age to end screening		None; lifelong screening recommended
	Screening test options and intervals		Aged 21–65 yrs: Cytology every year; after three consecutive annual normal cytology test results, screening can be every 3 yrs or Aged 21–29 yrs: Cytology every year Aged 30–65 yrs: Cytology plus HPV testing every 3 yrs
	Previous hysterectomy with removal of cervix		Not specified
Persons with in utero exposure to diethylstilbestrol^§	Age to start screening	No specific recommendation	Not specified	No specific recommendation
	Age to end screening		Not specified
	Screening test options and intervals		Cytology alone annually
	Previous hysterectomy with removal of cervix		Not specified
Persons who have received HPV vaccination	No changes to the screening approaches above
Population	Screening specifics	ASCCP, 2019, and ACOG, 2020
Persons with a diagnosis of CIN 2 or CIN 3 (histologic HSIL^¶) within the previous 25 yrs	Age to start screening	Not applicable
	Age to end screening	May end at age 65 yrs if CIN diagnosis ≥25 yrs ago and criteria for ending screening met, otherwise continue screening past age 65 yrs Continued screening for ≥25 yrs after diagnosis is acceptable if patient is in good health
	Screening test options and intervals	Initial surveillance: HPV testing alone or cytology plus HPV testing at 6, 18, and 30 mos or Cytology at 6, 12, 18, 24, and 30 mos Long-term surveillance: HPV testing alone or cytology plus HPV testing every 3 yrs or Cytology alone annually Continue for ≥25 yrs from the initial CIN diagnosis, even if extends past age 65 yrs Routine screening can resume after the posttreatment surveillance period
	Previous hysterectomy with removal of cervix	HPV testing alone or cytology plus HPV testing every 3 yrs or Cytology alone annually Continue for ≥25 yrs from the initial CIN diagnosis, even if extends past age 65 yrs

TABLE 1. Cervical cancer screening and surveillance recommendations

Source: Perkins R, Guido R, Saraiya M, et al. Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016–2020. J Womens Health (Larchmt) 2021;30:5–13.
Abbreviations: ACS = American Cancer Society; ACOG = American College of Obstetricians and Gynecologists; AIS = adenocarcinoma in situ; ASCCP = American Society for Colposcopy and Cervical Pathology; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; USPSTF = U.S. Preventive Services Task Force.
*Considered an alternative screening strategy by ACOG.
^†Panel for Opportunistic Infections, ACOG, 2016.
^§ACOG, 2016.
^¶Either by cytology or by histology; includes a persistent cytologic diagnosis of atypical squamous cells, cannot rule out HSIL.

Table 2.

Current HPV result	Current Pap test result	Previous result	Management by 2012 guidelines	Management by 2019 guidelines
Negative	ASC-US	Unknown or HPV negative*	Repeat Pap plus HPV testing in 3 yrs	Repeat HPV test with or without concurrent Pap test in 3 yrs
Negative	LSIL	Unknown or HPV negative*	Repeat Pap plus HPV testing in 1 yr preferred, colposcopy acceptable	Repeat HPV test with or without concurrent Pap test in 1 yr
Negative	ASC-H	Noncontributory	Colposcopy	Colposcopy
Noncontributory	AGC	Noncontributory	Colposcopy	Colposcopy
Positive	NILM	Unknown or HPV negative*	Repeat Pap plus HPV testing in 1 yr	Repeat HPV test with or without concurrent Pap test in 1 yr
Positive	NILM	HPV positive^†	Colposcopy	Colposcopy
Positive for genotype HPV 16, HPV 18, or both	NILM	Noncontributory	Colposcopy	Colposcopy
Positive for genotype HPV 16, HPV 18, or both	ASC-US or LSIL	Noncontributory	Not applicable, genotyping not recommended for ASC-US or LSIL in 2012	Colposcopy
Positive	ASC-US or LSIL	Unknown or HPV positive	Colposcopy	Colposcopy
Positive	ASC-US or LSIL	Negative screening results with HPV testing or HPV plus Pap testing within the previous 5 yrs	Colposcopy	Repeat HPV test with or without concurrent Pap test in 1 yr^§
Positive	ASC-US or LSIL	Colposcopy confirming the absence of high-grade lesion within the past yr	Colposcopy	Repeat HPV test with or without concurrent Pap test in 1 yr^§
Positive	ASC-H	Noncontributory	Colposcopy	Colposcopy or expedited treatment
Positive untyped, positive for genotype other than HPV 16, or negative	HSIL	Noncontributory	Colposcopy or expedited treatment	Colposcopy or expedited treatment
Positive for genotype HPV 16	HSIL	Noncontributory	Colposcopy or expedited treatment	Expedited treatment^¶

TABLE 2. Comparison of 2012 and 2019 consensus recommendations for management of common abnormalities — American Society for Colposcopy and Cervical Pathology

Sources: Massad LS, Einstein MH, Huh WK, et al.; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121:829–46; Perkins RB, Guido RS, Castle PE, et al; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31; Perkins R, Guido R, Saraiya M, et al. Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016–2020. J Womens Health (Larchmt) 2021;30:5–13.
Abbreviations: AGC = atypical glandular cells; AIS = adenocarcinoma in situ; ASC-H = atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion; ASC-US = atypical squamous cells of undetermined significance; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-grade squamous intraepithelial lesion; NILM = negative for intraepithelial lesion or malignancy; Pap = Papanicolaou.
*Colposcopy may be warranted for patients with a history of high-grade lesions (CIN 2 or CIN 3, histologic or cytologic HSIL, ASC-H, AGC, or AIS).
^†Previous Pap test results do not modify the recommendation; colposcopy is always recommended for two consecutive HPV-positive tests
^§Negative HPV test or cotest (HPV plus Pap test) results only reduce risk sufficiently to defer colposcopy if performed for screening purposes within the last 5 years. Colposcopy is still warranted if negative HPV test or cotest results occurred in the context of surveillance for a previous abnormal result.
^¶Expedited treatment is preferred for nonpregnant patients aged ≥25 years. Colposcopy with biopsy is an acceptable option if desired by patient after shared decision-making.

Table 3.

Vaccine	Trade name (manufacturer)	Age group (yrs)	Dose	Route	Schedule	Booster
Hep A inactivated (2 doses)	Havrix (GlaxoSmithKline)	1–18	0.5 mL (720 ELISA units inactivated HAV)	IM	0, 6–12 mos	None
Hep A inactivated (2 doses)	Havrix (GlaxoSmithKline)	≥19	1 mL (1,440 ELISA units inactivated HAV	IM	0, 6–12 mos	None
Hep A inactivated (2 doses)	Vaqta (Merck)	1–18	0.5 mL (25 units HAV antigen)	IM	0, 6–18 mos	None
Hep A inactivated (2 doses)	Vaqta (Merck)	≥19	1 mL (50 units HAV antigen)	IM	0, 6–18 mos	None
Combined Hep A and Hep B* (3 doses)	Twinrix (GlaxoSmithKline)	≥18 (primary)	1 mL (720 ELISA units inactivated plus 20 μg HBsAg	IM	0, 1, 6 mos	None
Combined Hep A and Hep B* (3 doses)	Twinrix (GlaxoSmithKline)	≥18 (accelerated)	1 mL (720 ELISA units inactivated plus 20 μg HBsAg	IM	0, 7, 21–30 days	12 mos

TABLE 3. Vaccines for preventing hepatitis A infection

Source: Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020;69(No. RR-5).
Abbreviations: ELISA = enzyme-linked immunosorbent assay; HAV = hepatitis A virus; HBsAg = hepatitis B surface antigen; Hep A = hepatitis A; Hep B = hepatitis B; IM= intramuscular.
*Combined Hep A and Hep B vaccine (Twinrix) should not be used as postexposure prophylaxis.

Table 4.

Indication and age group	Risk category and health status	Hepatitis A vaccine	IG*
Postexposure prophylaxis
0–11 mos	Healthy	No	0.1 mL/kg body weight
12 mos to 40 yrs	Healthy	1 dose^†	None
>40 yrs	Healthy	1 dose^†	0.1 mL/kg body weight^§
≥12 mos	Immunocompromised or chronic liver disease	1 dose^†	0.1 mL/kg body weight^¶
≥12 mos	Vaccine contraindicated**	No	0.1 mL/kg body weight
Pre-exposure protection (e.g., travel)^††
<6 mos	Healthy	No	0.1–0.2 mL/kg body weight^§§
6–11 mos	Healthy	1 dose^¶¶	None
12 mos to 40 yrs	Healthy	1 dose***	None
>40 yrs	Healthy	1 dose***	0.1–0.2 mL/kg body weight^{§§,†††}
>6 mos	Immunocompromised or chronic liver disease	1 dose***	0.1–0.2 mL/kg body weight^{§§,†††}
>6 mos	Persons who elect not to receive vaccine or for whom vaccine is contraindicated**	No	0.1–0.2 mL/kg body weight^§§

TABLE 4. Recommendations for hepatitis A postexposure prophylaxis and pre-exposure protection, by age group and risk category — Advisory Committee on Immunization Practices, 2020

Source: Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020;69(No. RR-5).
Abbreviations: HAV = hepatitis A virus; IG = immune globulin.
*Measles, mumps, and rubella vaccine should not be administered for ≥2 weeks before and 6 months after administration of IG.
^†A second dose of hepatitis A vaccine is not required for postexposure prophylaxis; however, for long-term immunity, the vaccination series should be completed with a second dose ≥6 months after the first dose.
^§The provider's risk assessment should determine the need for IG administration. If the provider's risk assessment determines that both vaccine and IG are warranted, hepatitis A vaccine and IG should be administered simultaneously at different anatomic sites (e.g., separate limbs).
^¶Vaccine and IG should be administered simultaneously at different anatomic sites (e.g., separate limbs).
**Life-threatening allergic reaction to a previous dose of hepatitis A vaccine or allergy to any vaccine component.
^††IG should be considered before travel for persons with special risk factors for either HAV infection or severe disease from HAV infection.
^§§0.1 mL/kg body weight for travel ≤1 month; 0.2 mL/kg body weight for travel ≤2 months; 0.2 mL/kg every 2 months for travel of ≥2 months' duration.
^¶¶This dose should not be counted toward the routine 2-dose series, which should be initiated at age 12 months.
***For persons not previously vaccinated with hepatitis A vaccine, administer dose as soon as travel is considered and complete the series according to routine schedule if the next dose is needed before travel.
^†††Can be administered on the basis of the provider's risk assessment.

Table 5.

Serologic marker				Interpretation
HBsAg	Total anti-HBc	IgM anti-HBc	Anti-HBs	Interpretation
-	-	-	-	Never infected
+^†	-	-	-	Early acute infection; transient (≤18 days) after vaccination
+	+	+	-	Acute infection
-	+	+	-	Acute resolving infection
-	+	-	+	Recovered from past infection and immune
+	+	-	-	Chronic infection
-	+	-	-	Past infection; low-level chronic infection^§; passive transfer to infant born to HBsAg-positive mother; false positive (no infection)
-	-	-	+	Immune if concentration is >10 mIU/mL after vaccination, passive transfer after HBIG administration

TABLE 5. Interpretation of serologic test results* for hepatitis B virus infection

Source: Adapted from Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1).
Abbreviations: anti-HBc = antibody to hepatitis B core antigen; anti-HBs = antibody to hepatitis B surface antigen; HBIG = hepatitis B immune globulin; HBsAg = hepatitis B surface antigen; IgM = immunoglobulin M.
*- = negative test result; + = positive test result.
^†To ensure that an HBsAg-positive test result is not false positive, samples with repeatedly reactive HBsAg results should be tested with a neutralizing confirmatory test cleared by the Food and Drug Administration.
^§Persons positive for only anti-HBc are unlikely to be infectious, except under unusual circumstances involving direct percutaneous exposure to large quantities of blood (e.g., blood transfusion or organ transplantation) or mutant HBsAg-related infection.

Table 6.

Age group (yrs)	Single-antigen vaccine						Combination vaccine
	Recombivax HB		Engerix-B		Heplisav-B*		Twinrix^†
	Dose (μg)^§	Volume (mL)	Dose (μg)^§	Volume (mL)	Dose (μg)^§	Volume (mL)	Dose (μg)^§	Volume (mL)
Infants (<1)	5	0.5	10	0.5	—^¶	—^¶	NA	NA
Children (1–10)	5	0.5	10	0.5	—^¶	—^¶	NA	NA
Adolescents (11–15)	10**	1.0	NA	NA	—^¶	—^¶	NA	NA
Adolescents (11–19)	5	0.5	10	0.5	—^¶	—^¶	NA	NA
Adults (≥18)	—^††	—^††	—^††	—^††	20*	0.5	20^†	1
Adults (≥20)	10	1	20	1	20^†	0.5	20^†	1
Hemodialysis patients and other immunocompromised persons (<20^§§)	5	0.5	10	0.5	20	0.5	NA	NA
Hemodialysis patients and other immunocompromised persons (≥20)	40^¶¶	1	40***	2.0	20	0.5	NA	NA

TABLE 6. Recommended doses of licensed formulations of hepatitis B vaccines

Source: Adapted from Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1).
Abbreviation: NA = not applicable.
*Administered on a 2-dose schedule.
^†Combined hepatitis A and B vaccines. This vaccine is recommended for persons aged ≥18 years who are at increased risk for both hepatitis B and hepatitis A virus infections.
^§Recombinant hepatitis B surface antigen protein dose.
^¶Heplisav-B should not be used for vaccination of infants, children, or adolescents because the safety and effectiveness of Heplisav-B has not been established in persons aged <8 years and is not approved for use in these populations.
**Adult formulation administered on a 2-dose schedule.
^††Engerix-B and Recombivax HB are approved for use in persons of all ages.
^§§Higher doses might be more immunogenic; however, no specific recommendations have been made.
^¶¶Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
***Two 1.0-mL doses administered at one site, on a 4-dose schedule at 0, 1, 2, and 6 months.

Table 7.

Source of exposure	Unvaccinated person^§	Previously vaccinated person^¶
HBsAg-positive source Percutaneous (e.g., bite or needlestick) or mucosal exposure to HBsAg-positive blood or body fluids or Sex or needle-sharing contact with an HBsAg-positive person or Victim of sexual assault or abuse by an assailant who is HBsAg positive	Administer hepatitis B vaccine series and HBIG	Complete hepatitis B vaccine series and HBIG, if vaccine series not completed or Administer hepatitis B vaccine booster dose, if previous vaccination without testing**
Source with unknown HBsAg status Percutaneous (e.g., bite or needlestick) or mucosal exposure to potentially infectious blood or body fluids from a source with unknown HBsAg status or Sex or needle-sharing contact with person with unknown HBsAg status or Victim of sexual assault or abuse by a perpetrator with unknown HBsAg status	Administer hepatitis B vaccine series	Complete hepatitis B vaccine series

TABLE 7. Guidelines for postexposure prophylaxis* of persons with nonoccupational exposure† to blood or body fluids that contain blood, by exposure type and hepatitis B vaccination status

Sources: CDC. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 2013;62(No. RR-10); CDC. Postexposure prophylaxis to prevent hepatitis B virus infection. MMWR Recomm Rep 2006;55(No. RR-16).
Abbreviations: HBIG = hepatitis B immune globulin; HBsAg = hepatitis B surface antigen.
*When indicated, immunoprophylaxis should be initiated as soon as possible, preferably within 24 hours. Studies are limited regarding the maximum interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures or 14 days for sexual exposures. The hepatitis B vaccine series should be completed. These guidelines apply to nonoccupational exposures.
^†These guidelines apply to nonoccupational exposures.
^§A person who is in the process of being vaccinated but who has not completed the vaccine series should complete the series and receive treatment for hepatitis B as indicated.
^¶A person who has written documentation of a complete hepatitis B vaccine series and who did not receive postvaccination testing.
**No booster dose is needed for persons who have written documentation of hepatitis B vaccine series with serologic response.

Table 8.

Infection	Evidence for sexual abuse	Recommended action
Gonorrhea*	Diagnostic	Report^†
Syphilis*	Diagnostic	Report^†
HIV^§	Diagnostic	Report^†
Chlamydia trachomatis*	Diagnostic	Report^†
Trichomonas vaginalis*	Diagnostic	Report^†
Anogenital herpes	Suspicious	Consider report^†,¶
Condylomata acuminata (anogenital warts)*	Suspicious	Consider report^†,¶,**
Anogenital molluscum contagiosum	Inconclusive	Medical follow-up
Bacterial vaginosis	Inconclusive	Medical follow-up

TABLE 8. Implications of commonly encountered sexually transmitted or sexually associated infections for diagnosis and reporting of sexual abuse among infants and prepubertal children

Sources: Adapted from Kellogg N; American Academy of Pediatrics Committee on Child Abuse and Neglect. The evaluation of child abuse in children. Pediatrics 2005;16:506–12; Adams JA, Farst KJ, Kellogg ND. Interpretation of medical findings in suspected child abuse: an update for 2018. J Pediatr Adolesc Gynecol 2018;31:225–31.
*If unlikely to have been perinatally acquired and vertical transmission, which is rare, is excluded.
^†Reports should be made to the local or state agency mandated to receive reports of suspected child abuse or neglect.
^§If unlikely to have been acquired perinatally or through transfusion.
^¶Unless a clear history of autoinoculation exists.
**Report if evidence exists to suspect abuse, including history, physical examination, or other identified infections. Lesions appearing for the first time in a child aged >5 years are more likely to have been caused by sexual transmission.

Box 1.

1. Partners "Are you currently having sex of any kind?" "What is the gender(s) of your partner(s)?" 2. Practices "To understand any risks for sexually transmitted infections (STIs), I need to ask more specific questions about the kind of sex you have had recently." "What kind of sexual contact do you have or have you had?" "Do you have vaginal sex, meaning 'penis in vagina' sex?" "Do you have anal sex, meaning 'penis in rectum/anus' sex?" "Do you have oral sex, meaning 'mouth on penis/vagina'?" 3. Protection from STIs "Do you and your partner(s) discuss prevention of STIs and human immunodeficiency virus (HIV)?" "Do you and your partner(s) discuss getting tested?" For condoms: "What protection methods do you use? In what situations do you use condoms?" 4. Past history of STIs "Have you ever been tested for STIs and HIV?" "Have you ever been diagnosed with an STI in the past?" "Have any of your partners had an STI?" Additional questions for identifying HIV and viral hepatitis risk: "Have you or any of your partner(s) ever injected drugs?" "Is there anything about your sexual health that you have questions about?" 5. Pregnancy intention "Do you think you would like to have (more) children in the future?" "How important is it to you to prevent pregnancy (until then)?" "Are you or your partner using contraception or practicing any form of birth control?" "Would you like to talk about ways to prevent pregnancy?"

1. Partners

"Are you currently having sex of any kind?"
"What is the gender(s) of your partner(s)?"

2. Practices

"To understand any risks for sexually transmitted infections (STIs), I need to ask more specific questions about the kind of sex you have had recently."
"What kind of sexual contact do you have or have you had?"
- "Do you have vaginal sex, meaning 'penis in vagina' sex?"
- "Do you have anal sex, meaning 'penis in rectum/anus' sex?"
- "Do you have oral sex, meaning 'mouth on penis/vagina'?"

3. Protection from STIs

"Do you and your partner(s) discuss prevention of STIs and human immunodeficiency virus (HIV)?"
"Do you and your partner(s) discuss getting tested?"
For condoms:
- "What protection methods do you use? In what situations do you use condoms?"

4. Past history of STIs

"Have you ever been tested for STIs and HIV?"
"Have you ever been diagnosed with an STI in the past?"
"Have any of your partners had an STI?"

Additional questions for identifying HIV and viral hepatitis risk:

"Have you or any of your partner(s) ever injected drugs?"
"Is there anything about your sexual health that you have questions about?"

5. Pregnancy intention

"Do you think you would like to have (more) children in the future?"
"How important is it to you to prevent pregnancy (until then)?"
"Are you or your partner using contraception or practicing any form of birth control?"
"Would you like to talk about ways to prevent pregnancy?"

BOX 1. The Five P’s approach for health care providers obtaining sexual histories: partners, practices, protection from sexually transmitted infections, past history of sexually transmitted infections, and pregnancy intention

Box 2.

Gastrointestinal symptoms Headache Pruritis without rash Localized rash Delayed onset rash (>24 hours) Symptoms unknown Family history of penicillin or another drug allergy Patient denies allergy but it is on the medical record

Gastrointestinal symptoms
Headache
Pruritis without rash
Localized rash
Delayed onset rash (>24 hours)
Symptoms unknown
Family history of penicillin or another drug allergy
Patient denies allergy but it is on the medical record

BOX 2. Low-risk history in patients who report penicillin allergy

Box 3.

Major determinant Benzylpenicilloyl polylysine injection (Pre-Pen) (AllerQuest) (6 × 10⁻⁵M) Minor determinant precursors Benzylpenicillin G (10⁻²M, 3.3 mg/mL, 10,000 units/mL) Benzylpenicilloate (10⁻²M, 3.3 mg/mL) Benzylpenicilloate (or penicilloyl propylamine) (10⁻²M, 3.3 mg/mL) Aged penicillin is not an adequate source of minor determinants. Penicillin G should either be freshly prepared or come from a fresh-frozen source. Positive control Commercial histamine for scratch testing (1.0 mg/mL) Negative control Diluent (usually saline) or allergen diluent

Major determinant

Benzylpenicilloyl polylysine injection (Pre-Pen) (AllerQuest) (6 × 10⁻⁵M)

Minor determinant precursors

Benzylpenicillin G (10⁻²M, 3.3 mg/mL, 10,000 units/mL)
Benzylpenicilloate (10⁻²M, 3.3 mg/mL)
Benzylpenicilloate (or penicilloyl propylamine) (10⁻²M, 3.3 mg/mL)

Aged penicillin is not an adequate source of minor determinants. Penicillin G should either be freshly prepared or come from a fresh-frozen source.
Positive control

Commercial histamine for scratch testing (1.0 mg/mL)

Negative control

Diluent (usually saline) or allergen diluent

BOX 3. Skin test reagents for identifying persons at risk for adverse reactions to penicillin

Source: Adapted from Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987;107:204–15.

Box 4.

Uncomplicated vulvovaginal candidiasis (VVC) Sporadic or infrequent VVC and Mild-to-moderate VVC and Likely to be Candida albicans and Nonimmunocompromised women Complicated VVC Recurrent VVC (three or more episodes of symptomatic VVC in <1 year) or Severe VVC or Non–albicans candidiasis or Women with diabetes, immunocompromising conditions (e.g., HIV infection), underlying immunodeficiency, or immunosuppressive therapy (e.g., corticosteroids)

Uncomplicated vulvovaginal candidiasis (VVC)

Sporadic or infrequent VVC

and

Mild-to-moderate VVC

and

Likely to be Candida albicans

and

Nonimmunocompromised women

Complicated VVC

Recurrent VVC (three or more episodes of symptomatic VVC in <1 year)

Severe VVC

Non–albicans candidiasis

Women with diabetes, immunocompromising conditions (e.g., HIV infection), underlying immunodeficiency, or immunosuppressive therapy (e.g., corticosteroids)

BOX 4. Classification of vulvovaginal candidiasis

Source: Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203–11.

Box 5.

Children All children aged 12–23 months Unvaccinated children and adolescents aged 2–18 years Persons at increased risk for hepatitis A virus (HAV) infection International travelers Men who have sex with men Persons who use injecting or noninjecting drugs (i.e., all those who use illegal drugs) Persons with occupational risk for exposure Persons who anticipate close personal contact with an international adoptee Persons experiencing homelessness Persons at increased risk for severe disease from HAV infection Persons with chronic liver disease Persons with HIV infection Other persons recommended for vaccination Pregnant women at risk for HAV infection or severe outcome from HAV infection Any persons who requests a vaccine Vaccination during outbreaks Unvaccinated persons in outbreak settings who are at risk for HAV infection or at risk for severe disease from HAV Implementation strategies for settings providing services to adults Persons in settings that provide services to adults where a high proportion of those persons have risk factors for HAV infection Hepatitis A vaccination is no longer recommended by the Advisory Committee on Immunization Practices Persons who receive blood products for clotting disorders (e.g., hemophilia)

Children

All children aged 12–23 months
Unvaccinated children and adolescents aged 2–18 years

Persons at increased risk for hepatitis A virus (HAV) infection

International travelers
Men who have sex with men
Persons who use injecting or noninjecting drugs (i.e., all those who use illegal drugs)
Persons with occupational risk for exposure
Persons who anticipate close personal contact with an international adoptee
Persons experiencing homelessness

Persons at increased risk for severe disease from HAV infection

Persons with chronic liver disease
Persons with HIV infection

Other persons recommended for vaccination

Pregnant women at risk for HAV infection or severe outcome from HAV infection
Any persons who requests a vaccine

Vaccination during outbreaks

Unvaccinated persons in outbreak settings who are at risk for HAV infection or at risk for severe disease from HAV

Implementation strategies for settings providing services to adults

Persons in settings that provide services to adults where a high proportion of those persons have risk factors for HAV infection

Hepatitis A vaccination is no longer recommended by the Advisory Committee on Immunization Practices

Persons who receive blood products for clotting disorders (e.g., hemophilia)

BOX 5. Populations recommended for hepatitis A vaccination — Advisory Committee on Immunization Practices, 2020

Source: Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020;69(No. RR-5).

Workowski KA, Bolan GA; CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3). PMID:26042815
Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for providing quality sexually transmitted diseases clinical services, 2020. MMWR Recomm Rep 2020;68(No. RR-5). PMID:31899459 https://doi.org/10.15585/mmwr.rr6805a1
CDC. A guide to taking a sexual history. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/std/treatment/sexualhistory.pdf
Henderson JT, Senger CA, Henninger M, Bean SI, Redmond N, O'Connor EA. Behavioral counseling interventions to prevent sexually transmitted infections: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2020;324:682–99. PMID:32809007 https://doi.org/10.1001/jama.2020.10371
Kamb ML, Fishbein M, Douglas JM Jr, et al.; Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280:1161–7. PMID:9777816 https://doi. org/10.1001/jama.280.13.1161
Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA 2013;310:1701–10. PMID:24150466 https://doi.org/10.1001/jama.2013.280034
Brookmeyer KA, Hogben M, Kinsey J. The role of behavioral counseling in sexually transmitted disease prevention program settings. Sex Transm Dis 2016;43(Suppl 1):S102–12. PMID:26779681 https://doi. org/10.1097/OLQ.0000000000000327
Patel P, Bush T, Mayer K, et al.; SUN Study Investigators. Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in care. Sex Transm Dis 2012;39:470–4. PMID:22592834 https://doi.org/10.1097/OLQ.0b013e31824b3110
Warner L, Klausner JD, Rietmeijer CA, et al.; Safe in the City Study Group. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med 2008;5:e135. PMID:18578564 https://doi.org/10.1371/journal. pmed.0050135
Mustanski B, Parsons JT, Sullivan PS, Madkins K, Rosenberg E, Swann G. Biomedical and behavioral outcomes of Keep It Up!: an ehealth HIV prevention program RCT. Am J Prev Med 2018;55:151–8. PMID:29937115 https://doi.org/10.1016/j.amepre.2018.04.026
Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698–702. PMID:31415491 https://doi.org/10.15585/mmwr.mm6832a3
Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1). PMID:29939980 https://doi.org/10.15585/mmwr. rr6701a1
Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep 2019;68:153–6. PMID:30763295 https://doi.org/10.15585/mmwr.mm6806a6
Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;(1):CD003255. PMID:11869658 https://doi.org/10.1002/14651858.CD003255
Giannou FK, Tsiara CG, Nikolopoulos GK, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res 2016;16:489–99. PMID:26488070 https://doi.org/10.1586/14737167.2016.1102635
Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2015;68:337–44. PMID:25469526 https://doi.org/10.1097/QAI.0000000000000461
Johnson WD, O'Leary A, Flores SA. Per-partner condom effectiveness against HIV for men who have sex with men. AIDS 2018;32:1499–505. PMID:29794493 https://doi.org/10.1097/QAD.0000000000001832
Crosby RA, Charnigo RA, Weathers C, Caliendo AM, Shrier LA. Condom effectiveness against non-viral sexually transmitted infections: a prospective study using electronic daily diaries. Sex Transm Infect 2012;88:484–9. PMID:23002192 https://doi.org/10.1136/sextrans-2012-050618
Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004;82:454–61. PMID:15356939
Warner L, Stone KM, Macaluso M, Buehler JW, Austin HD. Condom use and risk of gonorrhea and chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006;33:36–51. PMID:16385221 https://doi.org/10.1097/01. olq.0000187908.42622.fd
Bernabe-Ortiz A, Carcamo CP, Scott JD, Hughes JP, Garcia PJ, Holmes KK. HBV infection in relation to consistent condom use: a population-based study in Peru. PLoS One 2011;6:e24721. PMID:21931828 https://doi.org/10.1371/journal.pone.0024721
Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004;104:761–9. PMID:15458899 https://doi.org/10.1097/01.AOG.0000139512.37582.17
Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis 2009;49:515–21. PMID:19583516 https://doi. org/10.1086/600878
Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645–54. PMID:16790697 https://doi.org/10.1056/NEJMoa053284
Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003;107:804–10. PMID:14566831 https://doi.org/10.1002/ijc.11473
Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003;107:811–6. PMID:14566832 https://doi.org/10.1002/ijc.11474
Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis 2009;36:401–5. PMID:19455075 https://doi.org/10.1097/OLQ.0b013e3181a396eb
Hernández-Romieu AC, Siegler AJ, Sullivan PS, Crosby R, Rosenberg ES. How often do condoms fail? A cross-sectional study exploring incomplete use of condoms, condom failures and other condom problems among black and white MSM in southern U.S.A. Sex Transm Infect 2014;90:602–7. PMID:25080511 https://doi.org/10.1136/sextrans-2014-051581
D'Anna LH, Margolis AD, Warner L, et al.; Safe City Study Group. Condom use problems during anal sex among men who have sex with men (MSM): findings from the Safe in the City study. AIDS Care 2012;24:1028–38. PMID:22519680 https://doi.org/10.1080/095401 21.2012.668285
Steiner MJ, Cates W Jr, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis 1999;26:459–62. PMID:10494937 https://doi.org/10.1097/00007435-199909000-00007
Kowal D, Hatcher RA, Nelson AL, et al., eds. Contraceptive technology. 21st ed. Atlanta, GA: Managing Contraception; 2017.
Gallo MF, Kilbourne-Brook M, Coffey PS. A review of the effectiveness and acceptability of the female condom for dual protection. Sex Health 2012;9:18–26. PMID:22348629 https://doi.org/10.1071/SH11037
Mantell JE, Kelvin EA, Exner TM, Hoffman S, Needham S, Stein ZA. Anal use of the female condom: does uncertainty justify provider inaction? AIDS Care 2009;21:1185–94. PMID:20024779 https://doi. org/10.1080/09540120902730005
Rosenberg MJ, Davidson AJ, Chen JH, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health 1992;82:669–74. PMID:1566944 https://doi.org/10.2105/AJPH.82.5.669
de Bruyn G, Shiboski S, van der Straten A, et al.; MIRA Team. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect 2011;87:301–5. PMID:21447515 https://doi.org/10.1136/sti.2010.047142
Ramjee G, van der Straten A, Chipato T, et al.; MIRA team. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008;3:e3488. PMID:18941533 https://doi.org/10.1371/journal. pone.0003488
Lusti-Narasimhan M, Merialdi M, Holt B. Multipurpose prevention technologies: maximising positive synergies. BJOG 2014;121:251. PMID:24393212 https://doi.org/10.1111/1471-0528.12606
Ahmed K, Baeten JM, Beksinska M, et al.; Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet 2019;394:303–13. PMID:31204114 https://doi.org/10.1016/S0140-6736(19)31288-7
Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. Eur J Contracept Reprod Health Care 2018;23:326–34. PMID:30247084 https://doi. org/10.1080/13625187.2018.1508650
Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002;2:613–7. PMID:12383611 https://doi.org/10.1016/S1473-3099(02)00396-1
McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329–37. PMID:20851460 https://doi.org/10.1016/S0140-6736(10)61086-0
Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977–87. PMID:19059048 https://doi.org/10.1016/S0140-6736(08)61842-5
Van Damme L, Govinden R, Mirembe FM, et al.; CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463–72. PMID:18669425 https://doi.org/10.1056/NEJMoa0707957
Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474. PMID:18213382 https://doi.org/10.1371/journal.pone.0001474
Cottrell ML, Kashuba AD. Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol 2014;54:603–15. PMID:24664786 https://doi.org/10.1002/jcph.292
Abdool Karim SS, Abdool Karim Q, Kharsany ABM, et al.; CAPRISA 004 Trial Group. Tenofovir gel for the prevention of herpes simplex virus Type 2 infection. N Engl J Med 2015;373:530–9. PMID:26244306 https://doi.org/10.1056/NEJMoa1410649
Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168–74. Erratum in: Science 2011;333:524. PMID:20643915 https://doi.org/10.1126/science.1193748
Marrazzo JM, Ramjee G, Richardson BA, et al.; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372:509–18. PMID:25651245 https://doi.org/10.1056/NEJMoa1402269
Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2018;18:1241–50. PMID:30507409 https://doi.org/10.1016/S1473-3099(18)30428-6
Baeten JM, Palanee-Phillips T, Brown ER, et al.; MTN-020–ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 2016;375:2121–32. PMID:26900902 https://doi.org/10.1056/NEJMoa1506110
Nel A, van Niekerk N, Kapiga S, et al.; Ring Study Team. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med 2016;375:2133–43. PMID:27959766 https://doi. org/10.1056/NEJMoa1602046
Cranston RD, Lama JR, Richardson BA, et al.; MTN-017 Protocol Team. MTN-017: a rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin Infect Dis 2017;64:614–20. PMID:27986684
Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis 1994;19:274–8. PMID:7986899 https://doi.org/10.1093/clinids/19.2.274
Fihn SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol 1996;144:512–20. PMID:8781467 https://doi.org/10.1093/oxfordjournals.aje.a008958
Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS 2016;30:2665–83. PMID:27500670 https://doi.org/10.1097/QAD.0000000000001228
Kiweewa FM, Brown E, Mishra A, et al.; MTN-020/ASPIRE Study Team. Acquisition of sexually transmitted infections among women using a variety of contraceptive options: a prospective study among high-risk African women. J Int AIDS Soc 2019;22:e25257. PMID:30816632 https://doi.org/10.1002/jia2.25257
McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. Hormonal contraceptives and the acquisition of sexually transmitted infections: an updated systematic review. Sex Transm Dis 2019;46:290–6. PMID:30628946 https://doi.org/10.1097/OLQ.0000000000000975
Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3). PMID:27467196 https://doi.org/10.15585/mmwr.rr6503a1
Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-4). PMID:27467319 https://doi.org/10.15585/mmwr. rr6504a1
Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod 2012;27:1994–2000. PMID:22570193 https://doi.org/10.1093/humrep/des140
Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev 2019;1:CD001324. PMID:30661244
Marcell AV, Waks AB, Rutkow L, McKenna R, Rompalo A, Hogan MT. What do we know about males and emergency contraception? A synthesis of the literature. Perspect Sex Reprod Health 2012;44:184–93. PMID:22958663 https://doi.org/10.1363/4418412
Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657–66. PMID:17321311 https://doi.org/10.1016/S0140-6736(07)60313-4
Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643–56. PMID:17321310 https://doi. org/10.1016/S0140-6736(07)60312-2
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298. Erratum in: PLoS Med 2006;3:298. PMID:16231970 https://doi.org/10.1371/journal.pmed.0020298
Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009;360:1298–309. PMID:19321868 https://doi.org/10.1056/NEJMoa0802556
Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009;199:14–9. PMID:19086814 https://doi.org/10.1086/595566
Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009;199:958–64. PMID:19220143 https://doi.org/10.1086/597208
Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012;26:609–15. PMID:22210632 https://doi. org/10.1097/QAD.0b013e3283504a3f
Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS 2012;26:1141–9. PMID:22382150 https://doi.org/10.1097/QAD.0b013e328352d116
World Health Organization/UNAIDS. New data on male circumcision and HIV prevention: policy and programme implications [Internet]. Geneva, Switzerland: WHO/UNAIDS Technical Consultation on Male Circumcision and HIV Prevention: Research Implications for Policy and Programming; 2007. https://www.who.int/hiv/pub/malecircumcision/research_implications/en/
American Urological Association. Circumcision policy statement [Internet]. Linthicum, MD: American Urological Association; 2017. https://www.auanet.org/guidelines/guidelines/circumcision
Yuan T, Fitzpatrick T, Ko NY, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health 2019;7:e436–47. PMID:30879508 https://doi.org/10.1016/S2214-109X(18)30567-9
Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013;64:79–86. PMID:23466649 https://doi. org/10.1097/QAI.0b013e31828ece33
Grant RM, Lama JR, Anderson PL, et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587–99. PMID:21091279 https://doi. org/10.1056/NEJMoa1011205
Baeten JM, Donnell D, Ndase P, et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399–410. PMID:22784037 https://doi.org/10.1056/NEJMoa1108524
Thigpen MC, Kebaabetswe PM, Paxton LA, et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34. PMID:22784038 https://doi.org/10.1056/NEJMoa1110711
Choopanya K, Martin M, Suntharasamai P, et al.; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083–90. PMID:23769234 https://doi.org/10.1016/S0140-6736(13)61127-7
Molina JM, Charreau I, Spire B, et al.; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 2017;4:e402–10. PMID:28747274 https://doi.org/10.1016/S2352-3018(17)30089-9
CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
Jones J, Weiss K, Mermin J, et al. Proportion of incident human immunodeficiency virus cases among men who have sex with men attributable to gonorrhea and chlamydia: a modeling analysis. Sex Transm Dis 2019;46:357–63. PMID:31095100 https://doi.org/10.1097/OLQ.0000000000000980
Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis 2013;57:1203–9. PMID:23800942 https://doi.org/10.1093/cid/cit437
Pathela P, Braunstein SL, Blank S, Shepard C, Schillinger JA. The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men. Clin Infect Dis 2015;61:281–7. PMID:25870333 https://doi.org/10.1093/cid/civ289
Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;321:2214–30. PMID:31184746 https://doi.org/10.1001/jama.2019.2591
Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 2016;176:75–84. PMID:26571482 https://doi.org/10.1001/jamainternmed.2015.4683
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53–60. PMID:26364263 https://doi.org/10.1016/S0140-6736(15)00056-2
Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis 2015;61:1601–3. PMID:26334052 https://doi. org/10.1093/cid/civ778
Celum C, Wald A, Lingappa JR, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427–39. PMID:20089951 https://doi.org/10.1056/NEJMoa0904849
Celum C, Wald A, Hughes J, et al.; HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109–19. PMID:18572080 https://doi.org/10.1016/S0140-6736(08)60920-4
Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis 2015;42:98–103. PMID:25585069 https://doi.org/10.1097/OLQ.0000000000000216
Grant JS, Stafylis C, Celum C, et al. Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis 2020;70:1247–53. PMID:31504345 https://doi.org/10.1093/cid/ciz866
Myer L, Kuhn L, Stein ZA, Wright TC Jr, Denny L. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005;5:786–94. PMID:16310150 https://doi.org/10.1016/S1473-3099(05)70298-X
Molina JM, Charreau I, Chidiac C, et al.; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018;18:308–17. PMID:29229440 https://doi.org/10.1016/S1473-3099(17)30725-9
Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. PMID:21767103 https://doi.org/10.1056/NEJMoa1105243
Rodger AJ, Cambiano V, Bruun T, et al.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016;316:171–81. PMID:27404185 https://doi.org/10.1001/jama.2016.5148
Bavinton BR, Pinto AN, Phanuphak N, et al.; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018;5:e438–47. PMID:30025681 https://doi.org/10.1016/S2352-3018(18)30132-2
Rodger AJ, Cambiano V, Bruun T, et al.; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393:2428–38. PMID:31056293 https://doi. org/10.1016/S0140-6736(19)30418-0
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, AIDSinfo. https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultandAdolescentGL.pdf
Golden MR, Kerani RP, Stenger M, et al. Effect of expedited partner therapy (EPT) on chlamydial prevalence: the Washington State Community-Level Trial. Presented at the STD Prevention Conference, Minneapolis, MN; March 12–15, 2012.
Philip SS, Yu X, Donnell D, Vittinghoff E, Buchbinder S. Serosorting is associated with a decreased risk of HIV seroconversion in the EXPLORE Study Cohort. PLoS One 2010;5:e12662. PMID:20844744 https://doi.org/10.1371/journal.pone.0012662
Vallabhaneni S, Li X, Vittinghoff E, Donnell D, Pilcher CD, Buchbinder SP. Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One 2012;7:e45718. PMID:23056215 https://doi.org/10.1371/journal. pone.0045718
Jin F, Prestage GP, Templeton DJ, et al. The impact of HIV seroadaptive behaviors on sexually transmissible infections in HIV-negative homosexual men in Sydney, Australia. Sex Transm Dis 2012;39:191–4. PMID:22337105 https://doi.org/10.1097/OLQ.0b013e3182401a2f
Hotton AL, Gratzer B, Mehta SD. Association between serosorting and bacterial sexually transmitted infection among HIV-negative men who have sex with men at an urban lesbian, gay, bisexual, and transgender health center. Sex Transm Dis 2012;39:959–64. PMID:23191950 https://doi.org/10.1097/OLQ.0b013e31826e870d
Anderson C, Gallo MF, Hylton-Kong T, et al. Randomized controlled trial on the effectiveness of counseling messages for avoiding unprotected sexual intercourse during sexually transmitted infection and reproductive tract infection treatment among female sexually transmitted infection clinic patients. Sex Transm Dis 2013;40:105–10. PMID:23321990 https://doi.org/10.1097/OLQ.0b013e31827938a1
Golden MR, Hogben M, Handsfield HH, St Lawrence JS, Potterat JJ, Holmes KK. Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003;30:490–6. PMID:12782949 https://doi.org/10.1097/00007435-200306000-00004
Katz DA, Dombrowski JC, Kerani RP, et al. Integrating HIV testing as an outcome of STD partner services for men who have sex with men. AIDS Patient Care STDS 2016;30:208–14. PMID:27158848 https://doi.org/10.1089/apc.2016.0027
Katz DA, Dombrowski JC, Barry M, Spellman D, Bell TR, Golden MR. STD partner services to monitor and promote HIV pre-exposure prophylaxis use among men who have sex with men. J Acquir Immune Defic Syndr 2019;80:533–41. PMID:30649032 https://doi.org/10.1097/QAI.0000000000001952
Bocour A, Renaud TC, Udeagu CC, Shepard CW. HIV partner services are associated with timely linkage to HIV medical care. AIDS 2013;27:2961–3. PMID:24189585 https://doi.org/10.1097/QAD.0000000000000031
Tesoriero JM, Johnson BL, Hart-Malloy R, et al. Improving retention in HIV care through New York's expanded partner services Data-to- Care pilot. J Public Health Manag Pract 2017;23:255–63. PMID:27902561 https://doi.org/10.1097/PHH.0000000000000483
Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ 2007;334:354. PMID:17237298 https://doi. org/10.1136/bmj.39079.460741.7C
CDC. Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep 2008;57(No. RR-9). PMID:18987617
Thurman AR, Shain RN, Holden AE, Champion JD, Perdue ST, Piper JM. Partner notification of sexually transmitted infections: a large cohort of Mexican American and African American women. Sex Transm Dis 2008;35:136–40. PMID:17898679 https://doi.org/10.1097/OLQ.0b013e318151498f
Kissinger PJ, Niccolai LM, Magnus M, et al. Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. Sex Transm Dis 2003;30:75–82. PMID:12514447 https://doi.org/10.1097/00007435-200301000-00015
Smith SG, Zhang X, Basile KC, et al. The National Intimate Partner and Sexual Violence Survey: 2015 data brief—updated release. Atlanta GA: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control; 2018. https://www.cdc.gov/violenceprevention/pdf/2015data-brief508.pdf
Wilson TE, Hogben M, Malka ES, et al. A randomized controlled trial for reducing risks for sexually transmitted infections through enhanced patient-based partner notification. Am J Public Health 2009;99(Suppl 1):S104–10. PMID:18556619 https://doi.org/10.2105/AJPH.2007.112128
Yu YY, Frasure-Williams JA, Dunne EF, Bolan G, Markowitz L, Bauer HM. Chlamydia partner services for females in California family planning clinics. Sex Transm Dis 2011;38:913–8. PMID:21934563 https://doi.org/10.1097/OLQ.0b013e3182240366
Mickiewicz T, Al-Tayyib A, Thrun M, Rietmeijer C. Implementation and effectiveness of an expedited partner therapy program in an urban clinic. Sex Transm Dis 2012;39:923–9. PMID:23169171 https://doi.org/10.1097/OLQ.0b013e3182756f20
Kachur R, Strona FV, Kinsey J, Collins D. Introducing technology into partner services: a toolkit for programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. https://www.cdc.gov/std/program/ips/ips-toolkit-12-28-2015.pdf
Kachur R, Hall W, Coor A, Kinsey J, Collins D, Strona FV. The use of technology for sexually transmitted disease partner services in the United States: a structured review. Sex Transm Dis 2018;45:707–12. PMID:29771868 https://doi.org/10.1097/OLQ.0000000000000864
Pellowski J, Mathews C, Kalichman MO, Dewing S, Lurie MN, Kalichman SC. Advancing partner notification through electronic communication technology: a review of acceptability and utilization research. J Health Commun 2016;21:629–37. PMID:27144318 https://doi.org/10.1080/10810730.2015.1128020
Borchardt LN, Pickett ML, Tan KT, Visotcky AM, Drendel AL. Expedited partner therapy: pharmacist refusal of legal prescriptions. Sex Transm Dis 2018;45:350–3. PMID:29465689 https://doi.org/10.1097/OLQ.0000000000000751
Qin JZ, Diniz CP, Coleman JS. Pharmacy-level barriers to implementing expedited partner therapy in Baltimore, Maryland. Am J Obstet Gynecol 2018;218:504.e1–6. PMID:29410060 https://doi.org/10.1016/j.ajog.2018.01.036
Schillinger J, Slutsker J, Tsang L, et al. Do prescriptions for expedited partner therapy get filled? Findings from a multi-jurisdictional evaluation, US, 2017–2018. Sex Transm Infect 2019;95(Suppl 1):A107.
Slutsker JS, Tsang LB, Schillinger JA. Do prescriptions for expedited partner therapy for chlamydia get filled? Findings from a multi-jurisdictional evaluation, United States, 2017–2019. Sex Transm Dis 2020;47:376–82. PMID:32149956 https://doi.org/10.1097/OLQ.0000000000001163
Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005;352:676–85. PMID:15716561 https://doi.org/10.1056/NEJMoa041681
Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003;30:49–56. PMID:12514443 https://doi.org/10.1097/00007435-200301000-00011
Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005;41:623–9. PMID:16080084 https://doi.org/10.1086/432476
Cameron ST, Glasier A, Scott G, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. Hum Reprod 2009;24:888–95. PMID:19136481 https://doi.org/10.1093/humrep/den475
Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis 2006;33:445–50. PMID:16531939 https://doi.org/10.1097/01.olq.0000204511.84485.4c
Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010;37:392–6. PMID:20453720 https://doi.org/10.1097/OLQ.0b013e3181dd1691
Stephens SC, Bernstein KT, Katz MH, Philip SS, Klausner JD. The effectiveness of patient-delivered partner therapy and chlamydial and gonococcal reinfection in San Francisco. Sex Transm Dis 2010;37:525– 9. PMID:20502392 https://doi.org/10.1097/OLQ.0b013e3181d8920f
Kerani RP, Fleming M, DeYoung B, Golden MR. A randomized, controlled trial of inSPOT and patient-delivered partner therapy for gonorrhea and chlamydial infection among men who have sex with men. Sex Transm Dis 2011;38:941–6. PMID:21934569 https://doi.org/10.1097/OLQ.0b013e318223fcbc
Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis 2005;40:787–93. PMID:15736009 https://doi.org/10.1086/428043
McNulty A, Teh MF, Freedman E. Patient delivered partner therapy for chlamydial infection—what would be missed? Sex Transm Dis 2008;35:834–6. PMID:18580822 https://doi.org/10.1097/OLQ.0b013e3181761993
Schillinger J, Jamison K, Slutsker J, et al. STI and HIV infections among MSM reporting exposure to gonorrhea or chlamydia: implications for expedited partner therapy. Sex Transm Infect 2019;95(Suppl 1) :A107. http://dx.doi.org/10.1136/sextrans-2019-sti.272
Turner AN, Feldblum PJ, Hoke TH. Baseline infection with a sexually transmitted disease is highly predictive of reinfection during follow-up in Malagasy sex workers. Sex Transm Dis 2010;37:559–62. PMID:20716996 https://doi.org/10.1097/OLQ.0b013e3181d70a03
Peterman TA, Tian LH, Metcalf CA, et al.; RESPECT-2 Study Group. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006;145:564–72. PMID:17043338 https://doi.org/10.7326/0003-4819-145-8-200610170-00005
Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2326–36. PMID:31184701 https://doi.org/10.1001/jama.2019.6587
Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1- infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, AIDSinfo; 2014. https://npin.cdc.gov/publication/recommendations-use-antiretroviral-drugs-pregnant-hiv-1-infected-women-maternal-health
Committee on Obstetric Practice HIV Expert Work Group. ACOG Committee opinion no. 752: prenatal and perinatal human immunodeficiency virus testing. Obstet Gynecol 2018;132:e138–42. PMID:30134428 https://doi.org/10.1097/AOG.0000000000002825
CDC. Sexually transmitted disease surveillance 2019 [Internet]. Atlanta GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/std/statistics/2019/default.htm
Warren HP, Cramer R, Kidd S, Leichliter JS. State requirements for prenatal syphilis screening in the United States, 2016. Matern Child Health J 2018;22:1227–32. PMID:30019155 https://doi.org/10.1007/s10995-018-2592-0
Lin JS, Eder M, Bean S. Screening for syphilis infection in pregnant women: a reaffirmation evidence update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 167. AHRQ Publication No. 18–05238-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2018.
Neblett Fanfair R, Tao G, Owusu-Edusei K, Gift TL, Bernstein KT. Suboptimal prenatal syphilis testing among commercially insured women in the United States, 2013. Sex Transm Dis 2017;44:219–21. PMID:28282647 https://doi.org/10.1097/OLQ.0000000000000569
Patel CG, Huppert JS, Tao G. Provider adherence to syphilis testing recommendations for women delivering a stillbirth. Sex Transm Dis 2017;44:685–90. PMID:28876321 https://doi.org/10.1097/OLQ.0000000000000656
Matthias JM, Rahman MM, Newman DR, Peterman TA. Effectiveness of prenatal screening and treatment to prevent congenital syphilis, Louisiana and Florida, 2013–2014. Sex Transm Dis 2017;44:498–502. PMID:28703731 https://doi.org/10.1097/OLQ.0000000000000638
Albright CM, Emerson JB, Werner EF, Hughes BL. Third-trimester prenatal syphilis screening: a cost-effectiveness analysis. Obstet Gynecol 2015;126:479–85. PMID:26244531 https://doi.org/10.1097/AOG.0000000000000997
Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2019;322:349–54. PMID:31334800 https://doi.org/10.1001/jama.2019.9365
LeFevre ML; US Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:902–10. PMID:25243785 https://doi.org/10.7326/M14-1981
Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. Increased risk for mother-to-infant transmission of hepatitis C virus among Medicaid recipients—Wisconsin, 2011–2015. MMWR Morb Mortal Wkly Rep 2017;66:1136–9. PMID:29072864 https://doi.org/10.15585/mmwr.mm6642a3
Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth—Tennessee and United States, 2009–2014. MMWR Morb Mortal Wkly Rep 2017;66:470–3. PMID:28493860 https://doi.org/10.15585/mmwr.mm6618a3
Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 2018;141:e20173273. PMID:29720535 https://doi.org/10.1542/peds.2017-3273
Gowda C, Kennedy S, Glover C, Prasad MR, Wang L, Honegger JR. Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. Paediatr Perinat Epidemiol 2018;32:401–10. PMID:29972246 https://doi.org/10.1111/ppe.12481
Waruingi W, Mhanna MJ, Kumar D, Abughali N. Hepatitis C virus universal screening versus risk based selective screening during pregnancy. J Neonatal Perinatal Med 2015;8:371–8. PMID:26836823 https://doi.org/10.3233/NPM-15915024
Boudova S, Mark K, El-Kamary SS. Risk-based hepatitis C screening in pregnancy is less reliable than universal screening: a retrospective chart review. Open Forum Infect Dis 2018;5:ofy043. PMID:29564364 https://doi.org/10.1093/ofid/ofy043
Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep 2020;69(No. RR-2). PMID:32271723 https://doi.org/10.15585/mmwr.rr6902a1
Moyer VA; US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:349–57. PMID:23798026 https://doi.org/10.7326/0003-4819-159-5-201309030-00672
Perkins RB, Guido RS, Castle PE, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31. PMID:32243307 https://doi.org/10.1097/LGT.0000000000000525
Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for bacterial vaginosis in pregnant persons to prevent preterm delivery: US Preventive Services Task Force recommendation statement. JAMA 2020;323:1286–92. PMID:32259236 https://doi.org/10.1001/jama.2020.2684
American Academy of Pediatrics Committee on Fetus and Newborn; American College of Obstetrics and Gynecology Committee on Obstetric Practice. Guidelines for perinatal care. Kilpatrick SJ, Papile LA, eds. 8th ed. Itasca, IL: American Academy of Pediatrics and Washington, DC: American College of Obstetrics and Gynecology; 2017.
Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2018;320:911–7. PMID:30193283 https://doi.org/10.1001/jama.2018.11785
Bibbins-Domingo K, Grossman DC, Curry SJ, et al.; US Preventive Services Task Force. Serologic screening for genital herpes infection: US Preventive Services Task Force recommendation statement. JAMA 2016;316:2525–30. PMID:27997659 https://doi.org/10.1001/jama.2016.16776
Selph SS, Bougatsos C, Dana T, Grusing S, Chou R. Screening for HIV infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;321:2349–60. PMID:31184704 https://doi.org/10.1001/jama.2019.2593
Henderson JT, Webber EM, Bean SI. Screening for Hepatitis B infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;322:360–2. PMID:31334780 https://doi.org/10.1001/jama.2019.1655
Leichliter JS, Dittus PJ, Copen CE, Aral SO. Trends in factors indicating increased risk for STI among key subpopulations in the United States, 2002–2015. Sex Transm Infect 2020;96:121–3. PMID:31350378 https://doi.org/10.1136/sextrans-2019-054045
Committee on Adolescence; Council on Clinical and Information Technology; Blythe MJ, Del Beccaro MA. Standards for health information technology to ensure adolescent privacy. Pediatrics 2012;130:987–90. PMID:23109684 https://doi.org/10.1542/peds.2012-2580
ACOG Committee Opinion no. 599: Committee on Adolescent Health Care: adolescent confidentiality and electronic health records. Obstet Gynecol 2014;123:1148–50. PMID:24785881 https://doi.org/10.1097/01.AOG.0000446825.08715.98
Thompson LA, Martinko T, Budd P, Mercado R, Schentrup AM. Meaningful use of a confidential adolescent patient portal. J Adolesc Health 2016;58:134–40. PMID:26802988 https://doi.org/10.1016/j.jadohealth.2015.10.015
Society for Adolescent Health and Medicine; American Academy of Pediatrics. Confidentiality protections for adolescents and young adults in the health care billing and insurance claims process. J Adolesc Health 2016;58:374–7. PMID:26903437 https://doi.org/10.1016/j.jadohealth.2015.12.009
Bamberger DM, Graham G, Dennis L, Gerkovich MM. Extragenital gonorrhea and chlamydia among men and women according to type of sexual exposure. Sex Transm Dis 2019;46:329–34. PMID:30676485 https://doi.org/10.1097/OLQ.0000000000000967
Chan PA, Robinette A, Montgomery M, et al. Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol 2016;2016:5758387. PMID:27366021 https://doi.org/10.1155/2016/5758387
Owusu-Edusei K Jr, Hoover KW, Gift TL. Cost-effectiveness of opt-out chlamydia testing for high-risk young women in the U.S. Am J Prev Med 2016;51:216–24. PMID:26952078 https://doi.org/10.1016/j.amepre.2016.01.007
DiClemente RJ, Sales JM, Danner F, Crosby RA. Association between sexually transmitted diseases and young adults' self-reported abstinence. Pediatrics 2011;127:208–13. PMID:21199852 https://doi.org/10.1542/peds.2009-0892
Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;320:674–86. PMID:30140884 https://doi.org/10.1001/jama.2018.10897
Committee on Practice Bulletins—Gynecology. Practice bulletin no. 157: cervical cancer screening and prevention. Obstet Gynecol 2016;127:e1–20. PMID:26695583 https://doi.org/10.1097/AOG.0000000000001263
Benard VB, Watson M, Castle PE, Saraiya M. Cervical carcinoma rates among young females in the United States. Obstet Gynecol 2012;120:1117–23. PMID:23090530 https://doi.org/10.1097/AOG.0b013e31826e4609
Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 2020;70:321–46. PMID:32729638 https://doi.org/10.3322/caac.21628
Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2203–13. PMID:31184747 https://doi.org/10.1001/jama.2019.6390
Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR. Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet 2012;380:378–87. PMID:22819653 https://doi.org/10.1016/S0140-6736(12)60835-6
Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005;39:82–9. PMID:15851918 https://doi.org/10.1097/01.qai.0000134740.41585.f4
Paz-Bailey G, Mendoza MC, Finlayson T, et al.; NHBS Study Group. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. AIDS 2016;30:1985–90. PMID:27149088 https://doi.org/10.1097/QAD.0000000000001139
Spicknall IH, Gift TL, Bernstein KT, Aral SO. Sexual networks and infection transmission networks among men who have sex with men as causes of disparity and targets of prevention. Sex Transm Infect 2017;93:307–8. PMID:28389442 https://doi.org/10.1136/sextrans-2016-052676
Glick SN, Morris M, Foxman B, et al. A comparison of sexual behavior patterns among men who have sex with men and heterosexual men and women. J Acquir Immune Defic Syndr 2012;60:83–90. PMID:22522237 https://doi.org/10.1097/QAI.0b013e318247925e
Goodreau SM, Golden MR. Biological and demographic causes of high HIV and sexually transmitted disease prevalence in men who have sex with men. Sex Transm Infect 2007;83:458–62. PMID:17855487 https://doi.org/10.1136/sti.2007.025627
Chew Ng RA, Samuel MC, Lo T, et al. Sex, drugs (methamphetamines), and the Internet: increasing syphilis among men who have sex with men in California, 2004–2008. Am J Public Health 2013;103:1450–6. PMID:23153138 https://doi.org/10.2105/AJPH.2012.300808
Bernstein KT, Stephens SC, Strona FV, Kohn RP, Philip SS. Epidemiologic characteristics of an ongoing syphilis epidemic among men who have sex with men, San Francisco. Sex Transm Dis 2013;40:11–7. PMID:23254114 https://doi.org/10.1097/OLQ.0b013e31827763ea
Cohen SE, Chew Ng RA, Katz KA, et al. Repeat syphilis among men who have sex with men in California, 2002–2006: implications for syphilis elimination efforts. Am J Public Health 2012;102:e1–8. PMID:22095364 https://doi.org/10.2105/AJPH.2011.300383
Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance—The Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 2016;65(No. SS-7). PMID:27414503 https://doi.org/10.15585/mmwr.ss6507a1
Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. Ann Intern Med 2013;158:321–8. PMID:23460055 https://doi.org/10.7326/0003-4819-158-5-201303050-00004
Newman LM, Dowell D, Bernstein K, et al. A tale of two gonorrhea epidemics: results from the STD Surveillance Network. Public Health Rep 2012;127:282–92. PMID:22547859 https://doi.org/10.1177/003335491212700308
Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol 2017;27:238–43. PMID:28325538 https://doi.org/10.1016/j.annepidem.2017.02.003
Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS 2014;28:1509–19. PMID:24809629 https://doi.org/10.1097/QAD.0000000000000298
Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006;20:731–9. PMID:16514304 https://doi.org/10.1097/01.aids.0000216374.61442.55
Ackers ML, Greenberg AE, Lin CY, et al. High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities. PLoS One 2012;7:e34972. PMID:22529964 https://doi.org/10.1371/journal.pone.0034972
Zetola NM, Bernstein KT, Wong E, Louie B, Klausner JD. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. J Acquir Immune Defic Syndr 2009;50:546–51. PMID:19367993 https://doi.org/10.1097/QAI.0b013e318195bd2b
Solomon MM, Mayer KH, Glidden DV, et al.; iPrEx Study Team. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis 2014;59:1020–6. PMID:24928295 https://doi.org/10.1093/cid/ciu450
Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3–17. PMID:10448335 https://doi.org/10.1136/sti.75.1.3
Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73–83. PMID:16327322 https://doi.org/10.1097/01. aids.0000198081.09337.a7
Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006;82:121–6. PMID:16581736 https://doi.org/10.1136/sti.2005.015040
Hoots BE, Wejnert C, Martin A, et al.; NHBS Study Group. Undisclosed HIV infection among MSM in a behavioral surveillance study. AIDS 2019;33:913–8. PMID:30649053 https://doi.org/10.1097/QAD.0000000000002147
Dolling DI, Desai M, McOwan A, et al.; PROUD Study Group. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials 2016;17:163. PMID:27013513 https://doi.org/10.1186/s13063-016-1286-4
Oldenburg CE, Nunn AS, Montgomery M, et al. Behavioral changes following uptake of HIV pre-exposure prophylaxis among men who have sex with men in a clinical setting. AIDS Behav 2018;22:1075–9. PMID:28150120 https://doi.org/10.1007/s10461-017-1701-1
Montaño MA, Dombrowski JC, Dasgupta S, et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. AIDS Behav 2019;23:548–55. PMID:30117076 https://doi.org/10.1007/s10461-018-2252-9
Traeger MW, Schroeder SE, Wright EJ, et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis 2018;67:676–86. PMID:29509889 https://doi.org/10.1093/cid/ciy182
Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis 2017;65:712–8. PMID:28505240 https://doi.org/10.1093/cid/cix439
Tang EC, Vittinghoff E, Philip SS, et al. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis. AIDS 2020;34:1181–6. PMID:32205724 https://doi.org/10.1097/QAD.0000000000002522
Barbee LA, Khosropour CM, Dombrowksi JC, Golden MR. New human immunodeficiency virus diagnosis independently associated with rectal gonorrhea and chlamydia in men who have sex with men. Sex Transm Dis 2017;44:385–9. PMID:28608786 https://doi.org/10.1097/OLQ.0000000000000614
Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010;53:537–43. PMID:19935075 https://doi.org/10.1097/QAI.0b013e3181c3ef29
Barbee LA, Khosropour CM, Dombrowski JC, Manhart LE, Golden MR. An estimate of the proportion of symptomatic gonococcal, chlamydial and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case-control study. Sex Transm Infect 2016;92:155–60. PMID:26297719 https://doi.org/10.1136/sextrans-2015-052214
Lafferty WE, Hughes JP, Handsfield HH. Sexually transmitted diseases in men who have sex with men. Acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. Sex Transm Dis 1997;24:272–8. PMID:9153736 https://doi.org/10.1097/00007435-199705000-00007
Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009;49:1793–7. PMID:19911970 https://doi.org/10.1086/648427
Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010–2012. Clin Infect Dis 2014;58:1564–70. PMID:24647015 https://doi.org/10.1093/cid/ciu184
Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005;41:67–74. PMID:15937765 https://doi.org/10.1086/430704
Koedijk FD, van Bergen JE, Dukers-Muijrers NH, van Leeuwen AP, Hoebe CJ, van der Sande MA; Dutch STI centres. The value of testing multiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006–2010. Int J STD AIDS 2012;23:626–31. PMID:23033514 https://doi.org/10.1258/ijsa.2012.011378
Barbee LA, Dombrowski JC, Kerani R, Golden MR. Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis 2014;41:168–72. PMID:24521722 https://doi.org/10.1097/OLQ.0000000000000093
Danby CS, Cosentino LA, Rabe LK, et al. Patterns of extragenital chlamydia and gonorrhea in women and men who have sex with men reporting a history of receptive anal intercourse. Sex Transm Dis 2016;43:105–9. PMID:26766527 https://doi.org/10.1097/OLQ.0000000000000384
van der Helm JJ, Hoebe CJ, van Rooijen MS, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis 2009;36:493–7. PMID:19617869 https://doi.org/10.1097/OLQ.0b013e3181a44b8c
Alexander S, Ison C, Parry J, et al.; Brighton Home Sampling Kits Steering Group. Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex Transm Infect 2008;84:488–92. PMID:19028953 https://doi.org/10.1136/sti.2008.031443
Freeman AH, Bernstein KT, Kohn RP, Philip S, Rauch LM, Klausner JD. Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. Sex Transm Dis 2011;38:1036–9. PMID:21992980 https://doi.org/10.1097/OLQ.0b013e318227713e
Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection. Sex Transm Dis 2013;40:366–71. PMID:23588125 https://doi.org/10.1097/OLQ.0b013e318284e544
Jenness SM, Weiss KM, Prasad P, Zlotorzynska M, Sanchez T. Bacterial sexually transmitted infection screening rates by symptomatic status among men who have sex with men in the United States: a hierarchical Bayesian analysis. Sex Transm Dis 2019;46:25–30. PMID:30044334 https://doi.org/10.1097/OLQ.0000000000000896
Hoover KW, Butler M, Workowski K, et al.; Evaluation Group for Adherence to STD and Hepatitis Screening. STD screening of HIV-infected MSM in HIV clinics. Sex Transm Dis 2010;37:771–6. PMID:20585275 https://doi.org/10.1097/OLQ.0b013e3181e50058
de Voux A, Bernstein KT, Bradley H, Kirkcaldy RD, Tie Y, Shouse RL; Medical Monitoring Project. Syphilis testing among sexually active men who have sex with men and who are receiving medical care for human immunodeficiency virus in the United States: Medical Monitoring Project, 2013–2014. Clin Infect Dis 2019;68:934–9. PMID:29985985 https://doi.org/10.1093/cid/ciy571
Gray RT, Hoare A, Prestage GP, Donovan B, Kaldor JM, Wilson DP. Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis 2010;37:298–305. PMID:20393383 https://doi.org/10.1097/OLQ.0b013e3181ca3c0a
Tuite AR, Fisman DN, Mishra S. Screen more or screen more often? Using mathematical models to inform syphilis control strategies. BMC Public Health 2013;13:606. PMID:23800206 https://doi.org/10.1186/1471-2458-13-606
Tuite A, Fisman D. Go big or go home: impact of screening coverage on syphilis infection dynamics. Sex Transm Infect 2016;92:49–54. PMID:25954016 https://doi.org/10.1136/sextrans-2014-052001
Tuite AR, Shaw S, Reimer JN, Ross CP, Fisman DN, Mishra S. Can enhanced screening of men with a history of prior syphilis infection stem the epidemic in men who have sex with men? A mathematical modelling study. Sex Transm Infect 2018;94:105–10. PMID:28705938 https://doi.org/10.1136/sextrans-2017-053201
Raifman JR, Gebo KA, Mathews WC, et al.; HIV Research Network. Gonorrhea and chlamydia case detection increased when testing increased in a multisite US HIV cohort, 2004–2014. J Acquir Immune Defic Syndr 2017;76:409–16. PMID:28777262 https://doi.org/10.1097/QAI.0000000000001514
Barbee LA, Dhanireddy S, Tat SA, Marrazzo JM. Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary care. Sex Transm Dis 2015;42:590–4. PMID:26372931 https://doi.org/10.1097/OLQ.0000000000000320
McMillan A, Young H, Moyes A. Rectal gonorrhoea in homosexual men: source of infection. Int J STD AIDS 2000;11:284–7. PMID:10824935 https://doi.org/10.1177/095646240001100502
Chow EP, Cornelisse VJ, Read TR, Chen MY, Bradshaw CS, Fairley CK. Saliva use in sex: associations with use of smartphone dating applications in men who have sex with men. Int J STD AIDS 2018;29:362–6. PMID:28835197 https://doi.org/10.1177/0956462417727669
Cornelisse VJ, Priest D, Fairley CK, et al. The frequency of kissing as part of sexual activity differs depending on how men meet their male casual sexual partners. Int J STD AIDS 2018;29:598–602. PMID:29256822 https://doi.org/10.1177/0956462417748717
Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA 2020;324:2415–22. PMID:33320230 https://doi.org/10.1001/jama.2020.22980
Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010;52:1497–505. PMID:20635398 https://doi.org/10.1002/hep.23808
Wandeler G, Gsponer T, Bregenzer A, et al.; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012;55:1408–16. PMID:22893583 https://doi.org/10.1093/cid/cis694
Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis 2013;56:1480–7. PMID:23386630 https://doi.org/10.1093/cid/cit054
Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009;23:F1–7. PMID:19542864 https://doi.org/10.1097/QAD.0b013e32832e5631
Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 2012;55:279–90. PMID:22491339 https://doi.org/10.1093/cid/cis382
Taylor LE, DeLong AK, Maynard MA, et al. Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. AIDS Patient Care STDS 2011;25:571–7. PMID:21859307 https://doi.org/10.1089/apc.2011.0106
Kaul R, Kimani J, Nagelkerke NJ, et al.; Kibera HIV Study Group. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004;291:2555–62. PMID:15173146 https://doi.org/10.1001/jama.291.21.2555
Ong JJ, Baggaley RC, Wi TE, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1917134. PMID:31825501 https://doi.org/10.1001/jamanetworkopen.2019.17134
Paz-Bailey G, Hoots BE, Xia M, Finlayson T, Prejean J, Purcell DW; NHBS Study Group. Trends in Internet use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2017;75(Suppl 3):S288–95. PMID:28604430 https://doi.org/10.1097/QAI.0000000000001404
Badal HJ, Stryker JE, DeLuca N, Purcell DW. Swipe right: dating website and app use among men who have sex with men. AIDS Behav 2018;22:1265–72. PMID:28884248 https://doi.org/10.1007/s10461-017-1882-7
Chan PA, Crowley C, Rose JS, et al. A network analysis of sexually transmitted diseases and online hookup sites among men who have sex with men. Sex Transm Dis 2018;45:462–8. PMID:29465663 https://doi.org/10.1097/OLQ.0000000000000784
Beymer MR, Weiss RE, Bolan RK, et al. Sex on demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles County. Sex Transm Infect 2014;90:567–72. PMID:24926041 https://doi.org/10.1136/sextrans-2013-051494
Medina MM, Crowley C, Montgomery MC, et al. Disclosure of HIV serostatus and pre-exposure prophylaxis use on internet hookup sites among men who have sex with men. AIDS Behav 2019;23:1681–8. PMID:30267365 https://doi.org/10.1007/s10461-018-2286-z
Chan PA, Towey C, Poceta J, et al. Online hookup sites for meeting sexual partners among men who have sex with men in Rhode Island, 2013: a call for public health action. Public Health Rep 2016;131:264–71. PMID:26957661 https://doi.org/10.1177/003335491613100210
Lampkin D, Crawley A, Lopez TP, Mejia CM, Yuen W, Levy V. Reaching suburban men who have sex with men for STD and HIV services through online social networking outreach: a public health approach. J Acquir Immune Defic Syndr 2016;72:73–8. PMID:27097365 https://doi.org/10.1097/QAI.0000000000000930
Sun CJ, Stowers J, Miller C, Bachmann LH, Rhodes SD. Acceptability and feasibility of using established geosocial and sexual networking mobile applications to promote HIV and STD testing among men who have sex with men. AIDS Behav 2015;19:543–52. PMID:25381563 https://doi.org/10.1007/s10461-014-0942-5
Dritz SK, Back AF. Letter: Shigella enteritis venereally transmitted. N Engl J Med 1974;291:1194. PMID:4608062 https://doi.org/10.1056/NEJM197411282912223
Aragón TJ, Vugia DJ, Shallow S, et al. Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis 2007;44:327–34. PMID:17205436 https://doi.org/10.1086/510593
Simms I, Field N, Jenkins C, et al. Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men— Shigella flexneri and S. sonnei in England, 2004 to end of February 2015. Euro Surveill 2015;20:21097. PMID:25953129 https://doi.org/10.2807/1560-7917.ES2015.20.15.21097
Gilbart VL, Simms I, Jenkins C, et al. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales. Sex Transm Infect 2015;91:598–602. PMID:25921020 https://doi.org/10.1136/sextrans-2015-052014
Narayan S, Galanis E; BC STEI Group. Are enteric infections sexually transmitted in British Columbia? Can Commun Dis Rep 2016;42:24–9. PMID:29770000 https://doi.org/10.14745/ccdr.v42i02a01
Mohan K, Hibbert M, Rooney G, et al. What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission? Sex Transm Infect 2018;94:67–71. PMID:28490580 https://doi.org/10.1136/sextrans-2016-052962
Hughes G, Silalang P, Were J, et al. Prevalence and characteristics of gastrointestinal infections in men who have sex with men diagnosed with rectal chlamydia infection in the UK: an 'unlinked anonymous' cross-sectional study. Sex Transm Infect 2018;94:518–21. PMID:28360379 https://doi.org/10.1136/sextrans-2016-053057
O'Sullivan B, Delpech V, Pontivivo G, et al. Shigellosis linked to sex venues, Australia. Emerg Infect Dis 2002;8:862–4. PMID:12141976 https://doi.org/10.3201/eid0808.010534
Marcus U, Zucs P, Bremer V, et al. Shigellosis—a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. Int J STD AIDS 2004;15:533–7. PMID:15307964 https://doi.org/10.1258/0956462041558221
Danila RN, Eikmeier DL, Robinson TJ, La Pointe A, DeVries AS. Two concurrent enteric disease outbreaks among men who have sex with men, Minneapolis-St Paul area. Clin Infect Dis 2014;59:987–9. PMID:24944234 https://doi.org/10.1093/cid/ciu478
Okame M, Adachi E, Sato H, et al. Shigella sonnei outbreak among men who have sex with men in Tokyo. Jpn J Infect Dis 2012;65:277–8. PMID:22627317 https://doi.org/10.7883/yoken.65.277
Wilmer A, Romney MG, Gustafson R, et al. Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada. HIV Med 2015;16:168–75. PMID:25656740 https://doi.org/10.1111/hiv.12191
CDC. Shigella sonnei outbreak among men who have sex with men— San Francisco, California, 2000–2001. MMWR Morb Mortal Wkly Rep 2001;50:922–6. PMID:11699845
Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999;5:820–3. PMID:10603219 https://doi.org/10.3201/eid0506.990614
Simms I, Gilbart VL, Byrne L, et al. Identification of verocytotoxin-producing Escherichia coli O117:H7 in men who have sex with men, England, November 2013 to August 2014. Euro Surveill 2014;19:20946. PMID:25375900 https://doi.org/10.2807/1560-7917. ES2014.19.43.20946
Quinn TC, Goodell SE, Fennell C, et al. Infections with Campylobacter jejuni and Campylobacter-like organisms in homosexual men. Ann Intern Med 1984;101:187–92. PMID:6547580 https://doi.org/10.7326/0003-4819-101-2-187
Gaudreau C, Pilon PA, Sylvestre J-L, Boucher F, Bekal S. Multidrug-resistant Campylobacter coli in men who have sex with men, Quebec, Canada, 2015. Emerg Infect Dis 2016;22:1661–3. PMID:27533504 https://doi.org/10.3201/eid2209.151695
Chen GJ, Lin KY, Hung CC, Chang SC. Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection. J Infect Dis 2017;215:1339–40. PMID:28329351 https://doi.org/10.1093/infdis/jix123
Lo YC, Ji DD, Hung CC. Prevalent and incident HIV diagnoses among Entamoeba histolytica-infected adult males: a changing epidemiology associated with sexual transmission—Taiwan, 2006–2013. PLoS Negl Trop Dis 2014;8:e3222. PMID:25299178 https://doi.org/10.1371/journal.pntd.0003222
Stark D, van Hal SJ, Matthews G, Harkness J, Marriott D. Invasive amebiasis in men who have sex with men, Australia. Emerg Infect Dis 2008;14:1141–3. PMID:18598643 https://doi.org/10.3201/eid1407.080017
Mitchell H, Hughes G. Recent epidemiology of sexually transmissible enteric infections in men who have sex with men. Curr Opin Infect Dis 2018;31:50–6. PMID:29251673 https://doi.org/10.1097/QCO.0000000000000423
Weatherburn P, Hickson F, Reid D, Torres-Rueda S, Bourne A. Motivations and values associated with combining sex and illicit drugs ('chemsex') among gay men in South London: findings from a qualitative study. Sex Transm Infect 2017;93:203–6. PMID:27519259 https://doi.org/10.1136/sextrans-2016-052695
Baker KS, Dallman TJ, Ashton PM, et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis 2015;15:913–21. PMID:25936611 https://doi.org/10.1016/S1473-3099(15)00002-X
Bowen A, Grass J, Bicknese A, Campbell D, Hurd J, Kirkcaldy RD. Elevated risk for antimicrobial drug-resistant Shigella infection among men who have sex with men, United States, 2011–2015. Emerg Infect Dis 2016;22:1613–6. PMID:27533624 https://doi.org/10.3201/eid2209.160624
Gaudreau C, Rodrigues-Coutlée S, Pilon PA, Coutlée F, Bekal S. Long-lasting outbreak of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subspecies jejuni from 2003 to 2013 in men who have sex with men, Quebec, Canada. Clin Infect Dis 2015;61:1549–52. PMID:26187024 https://doi.org/10.1093/cid/civ570
Muzny CA, Sunesara IR, Martin DH, Mena LA. Sexually transmitted infections and risk behaviors among African American women who have sex with women: does sex with men make a difference? Sex Transm Dis 2011;38:1118–25. PMID:22082722 https://doi.org/10.1097/OLQ.0b013e31822e6179
Eisenberg M. Differences in sexual risk behaviors between college students with same-sex and opposite-sex experience: results from a national survey. Arch Sex Behav 2001;30:575–89. PMID:11725456 https://doi.org/10.1023/A:1011958816438
Koh AS, Gómez CA, Shade S, Rowley E. Sexual risk factors among self-identified lesbians, bisexual women, and heterosexual women accessing primary care settings. Sex Transm Dis 2005;32:563–9. PMID:16118605 https://doi.org/10.1097/01.olq.0000175417.17078.21
Goodenow C, Szalacha LA, Robin LE, Westheimer K. Dimensions of sexual orientation and HIV-related risk among adolescent females: evidence from a statewide survey. Am J Public Health 2008;98:1051–8. PMID:18445809 https://doi.org/10.2105/AJPH.2005.080531
Muzny CA, Austin EL, Harbison HS, Hook EW 3rd. Sexual partnership characteristics of African American women who have sex with women; impact on sexually transmitted infection risk. Sex Transm Dis 2014;41:611–7. PMID:25211257 https://doi.org/10.1097/OLQ.0000000000000194
Riskind RG, Tornello SL, Younger BC, Patterson CJ. Sexual identity, partner gender, and sexual health among adolescent girls in the United States. Am J Public Health 2014;104:1957–63. PMID:25121821 https://doi.org/10.2105/AJPH.2014.302037
Schick V, Rosenberger JG, Herbenick D, Reece M. Sexual behaviour and risk reduction strategies among a multinational sample of women who have sex with women. Sex Transm Infect 2012;88:407–12. PMID:22563015 https://doi.org/10.1136/sextrans-2011-050404
Richters J, Prestage G, Schneider K, Clayton S. Do women use dental dams? Safer sex practices of lesbians and other women who have sex with women. Sex Health 2010;7:165–9. PMID:20465981 https://doi.org/10.1071/SH09072
Rowen TS, Breyer BN, Lin TC, Li CS, Robertson PA, Shindel AW. Use of barrier protection for sexual activity among women who have sex with women. Int J Gynaecol Obstet 2013;120:42–5. PMID:23106842 https://doi.org/10.1016/j.ijgo.2012.08.011
Lindley LL, Friedman DB, Struble C. Becoming visible: assessing the availability of online sexual health information for lesbians. Health Promot Pract 2012;13:472–80. PMID:21677116 https://doi.org/10.1177/1524839910390314
Chetcuti N, Beltzer N, Methy N, Laborde C, Velter A, Bajos N; CSF Group. Preventive care's forgotten women: life course, sexuality, and sexual health among homosexually and bisexually active women in France. J Sex Res 2013;50:587–97. PMID:22497621 https://doi.org/10.1080/00224499.2012.657264
Logie CH, Navia D, Loutfy MR. Correlates of a lifetime history of sexually transmitted infections among women who have sex with women in Toronto, Canada: results from a cross-sectional internet-based survey. Sex Transm Infect 2015;91:278–83. PMID:25477474 https://doi.org/10.1136/sextrans-2014-051745
Muzny CA, Kapil R, Austin EL, Hook EW, Geisler WM. Lower sexually transmissible infection prevalence among lifetime exclusive women who have sex with women compared with women who have sex with women and men. Sex Health 2014;11:592–3. PMID:25435197 https://doi.org/10.1071/SH14181
Muzny CA, Harbison HS, Pembleton ES, Austin EL. Sexual behaviors, perception of sexually transmitted infection risk, and practice of safe sex among southern African American women who have sex with women. Sex Transm Dis 2013;40:395–400. PMID:23588129 https://doi.org/10.1097/OLQ.0b013e31828caf34
Przedworski JM, McAlpine DD, Karaca-Mandic P, VanKim NA. Health and health risks among sexual minority women: an examination of 3 subgroups. Am J Public Health 2014;104:1045–7. PMID:24825204 https://doi.org/10.2105/AJPH.2013.301733
Brenick A, Romano K, Kegler C, Eaton LA. Understanding the influence of stigma and medical mistrust on engagement in routine healthcare among Black women who have sex with women. LGBT Health 2017;4:4–10. PMID:28113005 https://doi.org/10.1089/lgbt.2016.0083
Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000;76:345–9. PMID:11141849 https://doi.org/10.1136/sti.76.5.345
Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis 2002;185:1307–13. PMID:12001048 https://doi.org/10.1086/339884
Kellock D, O'Mahony CP. Sexually acquired metronidazole-resistant trichomoniasis in a lesbian couple. Genitourin Med 1996;72:60–1. PMID:8655171 https://doi.org/10.1136/sti.72.1.60
Muzny CA, Rivers CA, Mena LA, Schwebke JR. Genotypic characterization of Trichomonas vaginalis isolates among women who have sex with women in sexual partnerships. Sex Transm Dis 2012;39:556–8. PMID:22706219 https://doi.org/10.1097/OLQ.0b013e31824f1c49
Chan SK, Thornton LR, Chronister KJ, et al.; CDC. Likely female-to-female sexual transmission of HIV—Texas, 2012. MMWR Morb Mortal Wkly Rep 2014;63:209–12. PMID:24622284
Kwakwa HA, Ghobrial MW. Female-to-female transmission of human immunodeficiency virus. Clin Infect Dis 2003;36:e40–1. PMID:12539088 https://doi.org/10.1086/345462
Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol 2002;100:579–84. PMID:12220782 https://doi.org/10.1097/00006250-200209000-00029
Diamant AL, Schuster MA, McGuigan K, Lever J. Lesbians' sexual history with men: implications for taking a sexual history. Arch Intern Med 1999;159:2730–6. PMID:10597764 https://doi.org/10.1001/archinte.159.22.2730
Xu F, Sternberg MR, Markowitz LE. Women who have sex with women in the United States: prevalence, sexual behavior and prevalence of herpes simplex virus type 2 infection—results from national health and nutrition examination survey 2001–2006. Sex Transm Dis 2010;37:407–13. PMID:20531032 https://doi.org/10.1097/OLQ.0b013e3181db2e18
Everett BG, Higgins JA, Haider S, Carpenter E. Do sexual minorities receive appropriate sexual and reproductive health care and counseling? J Womens Health (Larchmt) 2019;28:53–62. PMID:30372369 https://doi.org/10.1089/jwh.2017.6866
Marrazzo JM, Koutsky LA, Stine KL, et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis 1998;178:1604– 9 . PMID:9815211 https://doi.org/10.1086/314494
Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001;91:947–52. PMID:11392939 https://doi.org/10.2105/AJPH.91.6.947
Bailey JV, Kavanagh J, Owen C, McLean KA, Skinner CJ. Lesbians and cervical screening. Br J Gen Pract 2000;50:481–2. PMID:10962789
Anderson TA, Schick V, Herbenick D, Dodge B, Fortenberry JD. A study of human papillomavirus on vaginally inserted sex toys, before and after cleaning, among women who have sex with women and men. Sex Transm Infect 2014;90:529–31. PMID:24739872 https://doi.org/10.1136/sextrans-2014-051558
Marrazzo JM, Stine K, Wald A. Prevalence and risk factors for infection with herpes simplex virus type-1 and -2 among lesbians. Sex Transm Dis 2003;30:890–5. PMID:14646636 https://doi.org/10.1097/01. OLQ.0000091151.52656.E5
Muzny CA, Schwebke JR. The clinical spectrum of Trichomonas vaginalis infection and challenges to management. Sex Transm Infect 2013;89:423–5. PMID:23543252 https://doi.org/10.1136/sextrans-2012-050893
Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis 2014;59:834–41. PMID:24928292 https://doi.org/10.1093/cid/ciu446
Singh D, Fine DN, Marrazzo JM. Chlamydia trachomatis infection among women reporting sexual activity with women screened in family planning clinics in the Pacific Northwest, 1997 to 2005. Am J Public Health 2011;101:1284–90. PMID:20724697 https://doi.org/10.2105/AJPH.2009.169631
Muzny CA, Kapil R, Austin EL, Brown L, Hook EW 3rd, Geisler WM. Chlamydia trachomatis infection in African American women who exclusively have sex with women. Int J STD AIDS 2016;27:978–83. PMID:26384942 https://doi.org/10.1177/0956462415604092
Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34:864–9. PMID:17621244 https://doi.org/10.1097/OLQ.0b013e318074e565
Evans AL, Scally AJ, Wellard SJ, Wilson JD. Prevalence of bacterial vaginosis in lesbians and heterosexual women in a community setting. Sex Transm Infect 2007;83:470–5. PMID:17611235 https://doi.org/10.1136/sti.2006.022277
Olson KM, Boohaker LJ, Schwebke JR, Aslibekyan S, Muzny CA. Comparisons of vaginal flora patterns among sexual behaviour groups of women: implications for the pathogenesis of bacterial vaginosis. Sex Health 2018;15:61–7. PMID:29212588 https://doi.org/10.1071/SH17087
Muzny CA, Lensing SY, Aaron KJ, Schwebke JR. Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women. Sex Transm Infect 2019;95:511–5. PMID:30872415 https://doi.org/10.1136/sextrans-2018-053824
Bradshaw CS, Walker SM, Vodstrcil LA, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis 2014;209:1562–72. PMID:24285846 https://doi.org/10.1093/infdis/jit664
Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis 2009;199:680–3. PMID:19199538 https://doi.org/10.1086/596632
Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis 2012;205:1580–8. PMID:22448002 https://doi.org/10.1093/infdis/jis242
Mitchell C, Manhart LE, Thomas K, Fiedler T, Fredricks DN, Marrazzo J. Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol 2012;2012:706540. Epub May 30, 2012. PMID:22693410 https://doi.org/10.1155/2012/706540
Mitchell C, Manhart LE, Thomas KK, Agnew K, Marrazzo JM. Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing Lactobacilli and Gardnerella vaginalis. Sex Transm Dis 2011;38:1137–44. PMID:22082725 https://doi.org/10.1097/OLQ.0b013e31822e6121
Fethers K, Twin J, Fairley CK, et al. Bacterial vaginosis (BV) candidate bacteria: associations with BV and behavioural practices in sexually-experienced and inexperienced women. PLoS One 2012;7:e30633. PMID:22363457 https://doi.org/10.1371/journal.pone.0030633
Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013;56:777–86. PMID:23243173 https://doi.org/10.1093/cid/cis1030
Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One 2010;5:e11139. PMID:20559445 https://doi.org/10.1371/journal.pone.0011139
Vodstrcil LA, Walker SM, Hocking JS, et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis 2015;60:1042–53. PMID:25516188 https://doi.org/10.1093/cid/ciu1130
Muzny CA, Blanchard E, Taylor CM, et al. Identification of key bacteria involved in the induction of incident bacterial vaginosis: a prospective study. J Infect Dis 2018;218:966–78. PMID:29718358 https://doi.org/10.1093/infdis/jiy243
Marrazzo JM, Thomas KK, Ringwood K. A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect 2011;87:399–405. PMID:21653935 https://doi.org/10.1136/sti.2011.049213
Bradshaw CS, Walker J, Fairley CK, et al. Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One 2013;8:e57688. PMID:23472099 https://doi.org/10.1371/journal.pone.0057688
Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. Curr Opin HIV AIDS 2014;9:168–73. PMID:24322537 https://doi.org/10.1097/COH.0000000000000030
White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med 2015;147:222–31. PMID:26599625 https://doi.org/10.1016/j.socscimed.2015.11.010
Radix AE, Lelutiu-Weinberger C, Gamarel KE. Satisfaction and healthcare utilization of transgender and gender non-conforming individuals in NYC: a community-based participatory study. LGBT Health 2014;1:302–8. PMID:26789858 https://doi.org/10.1089/lgbt.2013.0042
Rapues J, Wilson EC, Packer T, Colfax GN, Raymond HF. Correlates of HIV infection among transfemales, San Francisco, 2010: results from a respondent-driven sampling study. Am J Public Health 2013;103:1485–92. PMID:23763398 https://doi.org/10.2105/AJPH.2012.301109
Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med 2014;47:5–16. PMID:24317955 https://doi.org/10.1007/s12160-013-9565-8
Sevelius JM. Gender affirmation: a framework for conceptualizing risk behavior among transgender women of color. Sex Roles 2013;68:675–89. PMID:23729971 https://doi.org/10.1007/s11199-012-0216-5
Reisner SL, White Hughto JM, Pardee D, Sevelius J. Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males. Int J STD AIDS 2016;27:955–66. PMID:26384946 https://doi.org/10.1177/0956462415602418
Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism 2012;13:165–232. https://doi.org/10.1080/15532739.2011.700873
Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. Lancet 2016;388:390–400. PMID:27323925 https://doi.org/10.1016/S0140-6736(16)00683-8
Cahill S, Singal R, Grasso C, et al. Do ask, do tell: high levels of acceptability by patients of routine collection of sexual orientation and gender identity data in four diverse American community health centers. PLoS One 2014;9:e107104. PMID:25198577 https://doi.org/10.1371/journal.pone.0107104
Cahill SR, Baker K, Deutsch MB, Keatley J, Makadon HJ. Inclusion of sexual orientation and gender identity in Stage 3 Meaningful Use Guidelines: a huge step forward for LGBT health. LGBT Health 2016;3:100–2. PMID:26698386 https://doi.org/10.1089/lgbt.2015.0136
Tordoff DM, Morgan J, Dombrowski JC, Golden MR, Barbee LA. Increased ascertainment of transgender and non-binary patients using a 2-step versus 1-step gender identity intake question in an STD clinic setting. Sex Transm Dis 2019;46:254–9. PMID:30516726 https://doi.org/10.1097/OLQ.0000000000000952
Grant JM, Mottet LA, Tanis J. National transgender discrimination survey report on health and health care. Washington, DC: National Center for Transgender Equality and the National Gay and Lesbian Task Force; 2010. https://cancer-network.org/wp-content/uploads/2017/02/National_Transgender_Discrimination_Survey_ Report_on_health_and_health_care.pdf
Jaffee KD, Shires DA, Stroumsa D. Discrimination and delayed health care among transgender women and men: implications for improving medical education and health care delivery. Med Care 2016;54:1010–6. PMID:27314263 https://doi.org/10.1097/MLR.0000000000000583
Glick JL, Theall KP, Andrinopoulos KM, Kendall C. The role of discrimination in care postponement among trans-feminine individuals in the U.S. National Transgender Discrimination Survey. LGBT Health 2018;5:171–9. PMID:29589995 https://doi.org/10.1089/lgbt.2017.0093
Callander D, Cook T, Cornelisse V, et al. Trans and gender diverse people's experiences of sexual health care are associated with sexual health screening uptake. Sex Transm Infect 2019;95(Suppl 1):A64. https://sti.bmj.com/content/sextrans/95/Suppl_1.toc.pdf
Casey LS, Reisner SL, Findling MG, et al. Discrimination in the United States: experiences of lesbian, gay, bisexual, transgender, and queer Americans. Health Serv Res 2019;54(Suppl 2):1454–66. PMID:31659745 https://doi.org/10.1111/1475-6773.13229
Potter J, Peitzmeier SM, Bernstein I, et al. Cervical cancer screening for patients on the female-to-male spectrum: a narrative review and guide for clinicians. J Gen Intern Med 2015;30:1857–64. PMID:26160483 https://doi.org/10.1007/s11606-015-3462-8
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health 2019;109:e1–8. PMID:30496000 https://doi.org/10.2105/AJPH.2018.304727
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:214–22. PMID:23260128 https://doi.org/10.1016/S1473-3099(12)70315-8
Allan-Blitz LT, Konda KA, Calvo GM, et al. High incidence of extra-genital gonorrheal and chlamydial infections among high-risk men who have sex with men and transgender women in Peru. Int J STD AIDS 2018;29:568–76. PMID:29183269 https://doi.org/10.1177/0956462417744098
Hiransuthikul A, Janamnuaysook R, Sungsing T, et al. High burden of chlamydia and gonorrhoea in pharyngeal, rectal and urethral sites among Thai transgender women: implications for anatomical site selection for the screening of STI. Sex Transm Infect 2019;95:534–9. PMID:30982000 https://doi.org/10.1136/sextrans-2018-053835
Kojima N, Park H, Konda KA, et al. The PICASSO Cohort: baseline characteristics of a cohort of men who have sex with men and male-to-female transgender women at high risk for syphilis infection in Lima, Peru. BMC Infect Dis 2017;17:255. PMID:28399798 https://doi.org/10.1186/s12879-017-2332-x
Pitasi MA, Kerani RP, Kohn R, et al. Chlamydia, gonorrhea, and human immunodeficiency virus infection among transgender women and transgender men attending clinics that provide sexually transmitted disease services in six US cities: results from the Sexually Transmitted Disease Surveillance Network. Sex Transm Dis 2019;46:112–7. PMID:30278030 https://doi.org/10.1097/OLQ.0000000000000917
James S, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 US transgender survey. Washington, DC: National Center for Transgender Equality; 2016. https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf
Hadj-Moussa M, Ohl DA, Kuzon WM Jr. Feminizing genital gender-confirmation surgery. Sex Med Rev 2018;6:457–468.e2. PMID:29454634 https://doi.org/10.1016/j.sxmr.2017.11.005
Salgado CJ, Nugent A, Kuhn J, Janette M, Bahna H. Primary sigmoid vaginoplasty in transwomen: technique and outcomes. BioMed Res Int 2018;2018:4907208. PMID:29862275 https://doi.org/10.1155/2018/4907208
Radix AE, Harris AB, Belkind U, Ting J, Goldstein ZG. Chlamydia trachomatis infection of the neovagina in transgender women. Open Forum Infect Dis 2019;6:ofz470. PMID:32395566 https://doi.org/10.1093/ofid/ofz470
Elfering L, van der Sluis WB, Mermans JF, Buncamper ME. Herpes neolabialis: herpes simplex virus type 1 infection of the neolabia in a transgender woman. Int J STD AIDS 2017;28:841–3. PMID:28632111 https://doi.org/10.1177/0956462416685658
van der Sluis WB, Buncamper ME, Bouman MB, et al. Prevalence of neovaginal high-risk human papillomavirus among transgender women in the Netherlands. Sex Transm Dis 2016;43:503–5. PMID:27414682 https://doi.org/10.1097/OLQ.0000000000000476
Yang C, Liu S, Xu K, Xiang Q, Yang S, Zhang X. Condylomata gigantea in a male transsexual. Int J STD AIDS 2009;20:211–2. PMID:19255276 https://doi.org/10.1258/ijsa.2008.008213
Matsuki S, Kusatake K, Hein KZ, Anraku K, Morita E. Condylomata acuminata in the neovagina after male-to-female reassignment treated with CO₂ laser and imiquimod. Int J STD AIDS 2015;26:509–11. PMID:24970474 https://doi.org/10.1177/0956462414542476
Bodsworth NJ, Price R, Davies SC. Gonococcal infection of the neovagina in a male-to-female transsexual. Sex Transm Dis 1994;21:211–2. PMID:7974071 https://doi.org/10.1097/00007435-199407000-00005
Haustein UF. Pruritus of the artificial vagina of a transsexual patient caused by gonococcal infection [German]. Hautarzt 1995;46:858–9. PMID:8567271 https://doi.org/10.1007/s001050050354
Yamada K, Shida D, Kato T, Yoshida H, Yoshinaga S, Kanemitsu Y. Adenocarcinoma arising in sigmoid colon neovagina 53 years after construction. World J Surg Oncol 2018;16:88. PMID:29703260 https://doi.org/10.1186/s12957-018-1372-z
Hiroi H, Yasugi T, Matsumoto K, et al. Mucinous adenocarcinoma arising in a neovagina using the sigmoid colon thirty years after operation: a case report. J Surg Oncol 2001;77:61–4. PMID:11344485 https://doi.org/10.1002/jso.1067
Heller DS. Lesions of the neovagina—a review. J Low Genit Tract Dis 2015;19:267–70. PMID:26111041 https://doi.org/10.1097/LGT.0000000000000110
Scheim AI, Bauer GR, Travers R. HIV-related sexual risk among transgender men who are gay, bisexual, or have sex with men. J Acquir Immune Defic Syndr 2017;74:e89–96. PMID:27798432 https://doi.org/10.1097/QAI.0000000000001222
Sevelius J. "There's no pamphlet for the kind of sex I have": HIV-related risk factors and protective behaviors among transgender men who have sex with nontransgender men. J Assoc Nurses AIDS Care 2009;20:398–410. PMID:19732698 https://doi.org/10.1016/j.jana.2009.06.001
Pitasi MA, Oraka E, Clark H, Town M, DiNenno EA. HIV testing among transgender women and men—27 states and Guam, 2014–2015. MMWR Morb Mortal Wkly Rep 2017;66:883–7. PMID:28837547 https://doi.org/10.15585/mmwr.mm6633a3
Reisner SL, Perkovich B, Mimiaga MJ. A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men. AIDS Patient Care STDS 2010;24:501–13. PMID:20666586 https://doi.org/10.1089/apc.2010.0059
Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102:3869–903. PMID:28945902 https://doi.org/10.1210/jc.2017-01658
Deutsch M, ed. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. San Francisco, CA: University of California San Francisco, Department of Family and Community Medicine, Center of Excellence for Transgender Care; 2016. https://transcare.ucsf.edu/sites/transcare.ucsf.edu/files/Transgender-PGACG-6-17-16.pdf
Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med 2014;29:778–84. PMID:24424775 https://doi.org/10.1007/s11606-013-2753-1
Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med 2014;47:808–12. PMID:25455121 https://doi.org/10.1016/j.amepre.2014.07.031
Reisner SL, Deutsch MB, Peitzmeier SM, et al. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One 2018;13:e0190172. PMID:29538411 https://doi.org/10.1371/journal.pone.0190172
CDC. Surveillance for viral hepatitis—United States, Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/hepatitis/statistics/2017surveillance/pdfs/2017HepSurveillanceRpt.pdf
Kouyoumdjian FG, Leto D, John S, Henein H, Bondy S. A systematic review and meta-analysis of the prevalence of chlamydia, gonorrhoea and syphilis in incarcerated persons. Int J STD AIDS 2012;23:248–54. PMID:22581947 https://doi.org/10.1258/ijsa.2011.011194
CDC. Evaluation of large jail STD screening programs, 2008–2009. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. https://www.cdc.gov/std/publications/JailScreening2011.pdf
Pathela P, Hennessy RR, Blank S, Parvez F, Franklin W, Schillinger JA. The contribution of a urine-based jail screening program to citywide male chlamydia and gonorrhea case rates in New York City. Sex Transm Dis 2009;36(Suppl):S58–61. PMID:17989586 https://doi.org/10.1097/OLQ.0b013e31815615bb
Joesoef MR, Weinstock HS, Kent CK, et al.; Corrections STD Prevalence Monitoring Group. Sex and age correlates of chlamydia prevalence in adolescents and adults entering correctional facilities, 2005: implications for screening policy. Sex Transm Dis 2009;36(Suppl):S67–71. PMID:19125147 https://doi.org/10.1097/OLQ.0b013e31815d6de8
Blank S, McDonnell DD, Rubin SR, et al. New approaches to syphilis control. Finding opportunities for syphilis treatment and congenital syphilis prevention in a women's correctional setting. Sex Transm Dis 1997;24:218–26. PMID:9101633 https://doi.org/10.1097/00007435-199704000-00006
Owusu-Edusei K Jr, Gift TL, Chesson HW, Kent CK. Investigating the potential public health benefit of jail-based screening and treatment programs for chlamydia. Am J Epidemiol 2013;177:463–73. PMID:23403986 https://doi.org/10.1093/aje/kws240
Spaulding AC, Miller J, Trigg BG, et al. Screening for sexually transmitted diseases in short-term correctional institutions: summary of evidence reviewed for the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Sex Transm Dis 2013;40:679–84. PMID:23945422 https://doi.org/10.1097/01.olq.0000431353.88464.ab
CDC. Male chlamydia screening consultation, March 28–29, 2006, meeting report. Atlanta, GA: US Department of Health and Human Services, CDC; 2007. https://www.cdc.gov/std/chlamydia/chlamydiascreening-males.pdf
Cole J, Hotton A, Zawitz C, Kessler H. Opt-out screening for Chlamydia trachomatis and Neisseria gonorrhoeae in female detainees at Cook County jail in Chicago, IL. Sex Transm Dis 2014;41:161–5. PMID:24521720 https://doi.org/10.1097/OLQ.0000000000000106
Shaikh RA, Simonsen KA, O'Keefe A, et al. Comparison of opt-in versus opt-out testing for sexually transmitted infections among inmates in a county jail. J Correct Health Care 2015;21:408–16. PMID:26285597 https://doi.org/10.1177/1078345815600447
Spaulding AC, Kim MJ, Corpening KT, Carpenter T, Watlington P, Bowden CJ. Establishing an HIV screening program led by staff nurses in a county jail. J Public Health Manag Pract 2015;21:538–45. PMID:25427254 https://doi.org/10.1097/PHH.0000000000000183
Rosen DL, Wohl DA, Golin CE, et al. Comparing HIV case detection in prison during opt-in vs. opt-out testing policies. J Acquir Immune Defic Syndr 2016;71:e85–8. PMID:26536318 https://doi.org/10.1097/QAI.0000000000000889
Gratrix J, Smyczek P, Bertholet L, et al. A cross-sectional evaluation of opt-in testing for sexually transmitted and blood-borne infections in three Canadian provincial correctional facilities: a missed opportunity for public health? Int J Prison Health 2019;15:273–81. PMID:31329036 https://doi.org/10.1108/IJPH-07-2018-0043
Sutcliffe S, Newman SB, Hardick A, Gaydos CA. Prevalence and correlates of Trichomonas vaginalis infection among female US federal prison inmates. Sex Transm Dis 2010;37:585–90. PMID:20803782 https://doi.org/10.1097/OLQ.0b013e3181de4113
Freeman AH, Katz KA, Pandori MW, et al. Prevalence and correlates of Trichomonas vaginalis among incarcerated persons assessed using a highly sensitive molecular assay. Sex Transm Dis 2010;37:165–8. PMID:20023598 https://doi.org/10.1097/OLQ.0b013e3181bcd3fc
Sosman J, Macgowan R, Margolis A, et al.; Project START Biologics Study Group. Sexually transmitted infections and hepatitis in men with a history of incarceration. Sex Transm Dis 2011;38:634–9. PMID:21844713 https://doi.org/10.1097/OLQ.0b013e31820bc86c
Javanbakht M, Stirland A, Stahlman S, et al. Prevalence and factors associated with Trichomonas vaginalis infection among high-risk women in Los Angeles. Sex Transm Dis 2013;40:804–7. PMID:24275733 https://doi.org/10.1097/OLQ.0000000000000026
Nijhawan AE, Chapin KC, Salloway R, et al. Prevalence and predictors of Trichomonas infection in newly incarcerated women. Sex Transm Dis 2012;39:973–8. PMID:23191953 https://doi.org/10.1097/OLQ.0b013e31826e8847
Nijhawan AE, DeLong AK, Celentano DD, et al. The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women. Sex Transm Dis 2011;38:1094–100. PMID:22082718 https://doi.org/10.1097/OLQ.0b013e31822ea147
Willers DM, Peipert JF, Allsworth JE, Stein MD, Rose JS, Clarke JG. Prevalence and predictors of sexually transmitted infection among newly incarcerated females. Sex Transm Dis 2008;35:68–72. PMID:18090178 https://doi.org/10.1097/OLQ.0b013e318154bdb2
Nijhawan AE, Salloway R, Nunn AS, Poshkus M, Clarke JG. Preventive healthcare for underserved women: results of a prison survey. J Womens Health (Larchmt) 2010;19:17–22. PMID:20088654 https://doi.org/10.1089/jwh.2009.1469
Binswanger IA, White MC, Pérez-Stable EJ, Goldenson J, Tulsky JP. Cancer screening among jail inmates: frequency, knowledge, and willingness. Am J Public Health 2005;95:1781–7. PMID:16186455 https://doi.org/10.2105/AJPH.2004.052498
Brinkley-Rubinstein L, Peterson M, Arnold T, et al. Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. PLoS One 2018;13:e0205593. PMID:30532275 https://doi.org/10.1371/journal.pone.0205593
Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, et al. The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. Curr HIV/AIDS Rep 2018;15:93–5. PMID:29516265 https://doi.org/10.1007/s11904-018-0389-9
Morrow KM; Project START Study Group. HIV, STD, and hepatitis risk behaviors of young men before and after incarceration. AIDS Care 2009;21:235–43. PMID:19229694 https://doi.org/10.1080/09540120802017586
Bryan AD, Magnan RE, Gillman AS, et al. Effect of including alcohol and cannabis content in a sexual risk-reduction intervention on the incidence of sexually transmitted infections in adolescents: a cluster randomized clinical trial. JAMA Pediatr 2018;172:e175621. PMID:29435591 https://doi.org/10.1001/jamapediatrics.2017.5621
DiClemente RJ, Davis TL, Swartzendruber A, et al. Efficacy of an HIV/STI sexual risk-reduction intervention for African American adolescent girls in juvenile detention centers: a randomized controlled trial. Women Health 2014;54:726–49. PMID:25190056 https://doi.org/10.1080/03630242.2014.932893
Fogel CI, Crandell JL, Neevel AM, et al. Efficacy of an adapted HIV and sexually transmitted infection prevention intervention for incarcerated women: a randomized controlled trial. Am J Public Health 2015;105:802–9. PMID:25211714 https://doi.org/10.2105/AJPH.2014.302105
Son J, Miller WM, Tossone K, Butcher F, Kuo K. The effect of interprofessional student-led reproductive health education on youths in juvenile detention. J Pediatr Adolesc Gynecol 2017;30:370–5. PMID:27871918 https://doi.org/10.1016/j.jpag.2016.11.002
Costumbrado J, Stirland A, Cox G, et al. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007–2010. Vaccine 2012;30:6878–82. PMID:22989688 https://doi.org/10.1016/j.vaccine.2012.09.006
Allison M, Musser B, Satterwhite C, Ault K, Kelly P, Ramaswamy M. Human papillomavirus vaccine knowledge and intention among adult inmates in Kansas, 2016–2017. Am J Public Health 2018;108:1000–2. PMID:29927651 https://doi.org/10.2105/AJPH.2018.304499
Lucas KD, Miller JL, Eckert V, Horne RL, Samuel MC, Mohle-Boetani JC. Risk, feasibility, and cost evaluation of a prisoner condom access pilot program in one California state prison. J Correct Health Care 2014;20:184–94. PMID:24934836 https://doi.org/10.1177/1078345814530869
Scott N, McBryde E, Kirwan A, Stoové M. Modelling the impact of condom distribution on the incidence and prevalence of sexually transmitted infections in an adult male prison system. PLoS One 2015;10:e0144869. PMID:26658518 https://doi.org/10.1371/journal.pone.0144869
Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257–64. PMID:8678387 https://doi.org/10.7326/0003-4819-125-4-199608150-00001
Henn A, Flateau C, Gallien S. Primary HIV infection: clinical presentation, testing, and treatment. Curr Infect Dis Rep 2017;19:37. PMID:28884279 https://doi.org/10.1007/s11908-017-0588-3
Robb ML, Eller LA, Kibuuka H, et al.; RV 217 Study Team. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med 2016;374:2120–30. PMID:27192360 https://doi.org/10.1056/NEJMoa1508952
Hoenigl M, Green N, Camacho M, et al. Signs or symptoms of acute HIV infection in a cohort undergoing community-based screening. Emerg Infect Dis 2016;22:532–4. PMID:26890854 https://doi.org/10.3201/eid2203.151607
Legarth RA, Ahlström MG, Kronborg G, et al. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr 2016;71:213–8. PMID:26334734 https://doi.org/10.1097/QAI.0000000000000825
Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 2016;73:39–46. PMID:27028501 https://doi.org/10.1097/QAI.0000000000001014
Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375:830–9. PMID:27424812 https://doi.org/10.1056/NEJMoa1600693
Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA 2018;320:379–96. PMID:30043070 https://doi.org/10.1001/jama.2018.8431
Seth P, Wang G, Sizemore E, Hogben M. HIV testing and HIV service delivery to populations at high risk attending sexually transmitted disease clinics in the United States, 2011–2013. Am J Public Health 2015;105:2374–81. PMID:26378854 https://doi.org/10.2105/AJPH.2015.302778
Benton S, Smith J, Wang F, Heitgerd J, Belcher L, Patel H. HIV testing, diagnosis, and linkage to care among persons tested in select CDC-funded health care and non-health care settings, 2012–2017. Presented at the National HIV Prevention Conference, Atlanta, GA: March 18–21, 2019.
Pathela P, Braunstein SL, Schillinger JA, Shepard C, Sweeney M, Blank S. Men who have sex with men have a 140-fold higher risk for newly diagnosed HIV and syphilis compared with heterosexual men in New York City. J Acquir Immune Defic Syndr 2011;58:408–16. PMID:21857351 https://doi.org/10.1097/QAI.0b013e318230e1ca
Chou R, Selph S, Dana T, et al. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012;157:706–18. PMID:23165662 https://doi.org/10.7326/0003-4819-157-10-201211200-00007
Branson BM, Handsfield HH, Lampe MA, et al.; CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(No. RR-14). PMID:16988643
DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men— United States, 2017. MMWR Morb Mortal Wkly Rep 2017;66:830–2. PMID:28796758 https://doi.org/10.15585/mmwr.mm6631a3
CDC. HIV-2 infection surveillance—United States, 1987–2009. MMWR Morb Mortal Wkly Rep 2011;60:985–8. PMID:21796096
Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191:1403–9. PMID:15809897 https://doi.org/10.1086/429411
Pilcher CD, Eron JJ Jr, Vemazza PL, et al. Sexual transmission during the incubation period of primary HIV infection. JAMA 2001;286:1713–4. PMID:11594895 https://doi.org/10.1001/jama.286.14.1713
Calabrese SK, Mayer KH. Providers should discuss U=U with all patients living with HIV. Lancet HIV 2019;6:e211–3. PMID:30772420 https://doi.org/10.1016/S2352-3018(19)30030-X
Gilbert P, Ciccarone D, Gansky SA, et al. Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. PLoS One 2008;3:e1988. PMID:18431475 https://doi.org/10.1371/journal.pone.0001988
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:e1–34. PMID:24235263 https://doi.org/10.1093/cid/cit665
DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997;25:292–8. PMID:9332527 https://doi.org/10.1086/514548
Lockett AE, Dance DA, Mabey DC, Drasar BS. Serum-free media for isolation of Haemophilus ducreyi. Lancet 1991;338:326. PMID:1677152 https://doi.org/10.1016/0140-6736(91)90473-3
Lewis DA, Mitjà O. Haemophilus ducreyi: from sexually transmitted infection to skin ulcer pathogen. Curr Opin Infect Dis 2016;29:52–7. PMID:26658654 https://doi.org/10.1097/QCO.0000000000000226
Romero L, Huerfano C, Grillo-Ardila CF. Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults. Cochrane Database Syst Rev 2017;12:CD012492. PMID:29226307 https://doi.org/10.1002/14651858.CD012492.pub2
Jessamine PG, Plummer FA, Ndinya Achola JO, et al. Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis Suppl 1990;69:181–6. PMID:2263893
Briggs GC. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.
Lewis DA. Epidemiology, clinical features, diagnosis and treatment of Haemophilus ducreyi—a disappearing pathogen? Expert Rev Anti Infect Ther 2014;12:687–96. PMID:24597521 https://doi.org/10.1586/14787210.2014.892414
Mitjà O, Lukehart SA, Pokowas G, et al. Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study. Lancet Glob Health 2014;2:e235–41. PMID:25103064 https://doi.org/10.1016/S2214-109X(14)70019-1
Marks M, Chi KH, Vahi V, et al. Haemophilus ducreyi associated with skin ulcers among children, Solomon Islands. Emerg Infect Dis 2014;20:1705–7. PMID:25271477 https://doi.org/10.3201/eid2010.140573
Ghinai R, El-Duah P, Chi KH, et al. A cross-sectional study of 'yaws' in districts of Ghana which have previously undertaken azithromycin mass drug administration for trachoma control. PLoS Negl Trop Dis 2015;9:e0003496. PMID:25632942 https://doi.org/10.1371/journal.pntd.0003496
McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. NCHS Data Brief 2018;304:1–8. PMID:29442994
Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992–2006. Sex Transm Infect 2009;85:416–9. PMID:19273479 https://doi.org/10.1136/sti.2008.033902
Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003;30:797–800. PMID:14520181 https://doi.org/10.1097/01.OLQ.0000092387.58746.C7
Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847–54. PMID:7978697 https://doi.org/10.7326/0003-4819-121-11-199412010-00004
Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003;30:174–7. PMID:12567178 https://doi.org/10.1097/00007435-200302000-00015
Masese L, Baeten JM, Richardson BA, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS 2015;29:1077–85. PMID:26125141 https://doi.org/10.1097/QAD.0000000000000646
Sam SS, Caliendo AM, Ingersoll J, Abdul-Ali D, Kraft CS. Performance evaluation of the Aptima HSV-1 and 2 assay for the detection of HSV in cutaneous and mucocutaneous lesion specimens. J Clin Virol 2018;99-100:1–4. PMID:29253834 https://doi.org/10.1016/j.jcv.2017.12.006
Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003;188:1345–51. PMID:14593592 https://doi.org/10.1086/379043
Van Der Pol B, Warren T, Taylor SN, et al. Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. J Clin Microbiol 2012;50:3466– 71. PMID:22875892 https://doi.org/10.1128/JCM.01685-12
Binnicker MJ, Espy MJ, Duresko B, Irish C, Mandrekar J. Automated processing, extraction and detection of herpes simplex virus types 1 and 2: a comparative evaluation of three commercial platforms using clinical specimens. J Clin Virol 2017;89:30–3. PMID:28226272 https://doi.org/10.1016/j.jcv.2017.02.006
Teo JW, Chiang D, Jureen R, Lin RT. Clinical evaluation of a helicase-dependant amplification (HDA)-based commercial assay for the simultaneous detection of HSV-1 and HSV-2. Diagn Microbiol Infect Dis 2015;83:261–2. PMID:26302856 https://doi.org/10.1016/j.diagmicrobio.2015.07.018
Gitman MR, Ferguson D, Landry ML. Comparison of Simplexa HSV 1 & 2 PCR with culture, immunofluorescence, and laboratory-developed TaqMan PCR for detection of herpes simplex virus in swab specimens. J Clin Microbiol 2013;51:3765–9. PMID:24006008 https://doi.org/10.1128/JCM.01413-13
Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983;98:973–83. PMID:6344713 https://doi.org/10.7326/0003-4819-98-6-958
Caviness AC, Oelze LL, Saz UE, Greer JM, Demmler-Harrison GJ. Direct immunofluorescence assay compared to cell culture for the diagnosis of mucocutaneous herpes simplex virus infections in children. J Clin Virol 2010;49:58–60. PMID:20620099 https://doi.org/10.1016/j.jcv.2010.06.006
Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. Sex Transm Infect 2004;80:113–7. PMID:15054171 https://doi.org/10.1136/sti.2003.006783
Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis 2001;28:99–104. PMID:11234793 https://doi.org/10.1097/00007435-200102000-00007
Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis 2004;31:665–9. PMID:15502674 https://doi.org/10.1097/01.olq.0000143089.77493.c2
Turner KR, Wong EH, Kent CK, Klausner JD. Serologic herpes testing in the real world: validation of new type-specific serologic herpes simplex virus tests in a public health laboratory. Sex Transm Dis 2002;29:422–5. PMID:12170133 https://doi.org/10.1097/00007435-200207000-00011
Eing BR, Lippelt L, Lorentzen EU, et al. Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2. J Clin Microbiol 2002;40:407–13. PMID:11825950 https://doi.org/10.1128/JCM.40.2.407-413.2002
Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, Wald A. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis 2005;32:771–7. PMID:16314775 https://doi.org/10.1097/01.olq.0000175377.88358.f3
Morrow RA, Friedrich D, Meier A, Corey L. Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis 2005;5:84. PMID:16225691 https://doi.org/10.1186/1471-2334-5-84
Ngo TD, Laeyendecker O, La H, Hogrefe W, Morrow RA, Quinn TC. Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam. Clin Vaccine Immunol 2008;15:382–4. PMID:18077617 https://doi.org/10.1128/CVI.00437-06
Agyemang E, Le QA, Warren T, et al. Performance of commercial enzyme-linked immunoassays for diagnosis of herpes simplex virus-1 and herpes simplex virus-2 infection in a clinical setting. Sex Transm Dis 2017;44:763–7. PMID:28876290 https://doi.org/10.1097/OLQ.0000000000000689
Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect 2006;12:463–9. PMID:16643524 https://doi.org/10.1111/j.1469-0691.2006.01370.x
Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006;20:1051–8. PMID:16603858 https://doi.org/10.1097/01.aids.0000222078.75867.77
Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis 2014;209:325–33. PMID:24136792 https://doi.org/10.1093/infdis/jit458
Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013;56:344–51. PMID:23087395 https://doi.org/10.1093/cid/cis891
Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958–62. PMID:11880962 https://doi.org/10.1086/339326
Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944–8. PMID:11880960 https://doi.org/10.1086/339325
Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8–13. PMID:16323085 https://doi.org/10.1086/498521
Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001;144:818–24. PMID:11298543 https://doi.org/10.1046/j.1365-2133.2001.04139.x
Bodsworth NJ, Crooks RJ, Borelli S, et al.; International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110–6. PMID:9215092
Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R; The Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481–6. PMID:9293612 https://doi.org/10.1097/00007435-199709000-00007
Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL; Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998;280:887–92. PMID:9739972 https://doi.org/10.1001/jama.280.10.887
Mertz GJ, Loveless MO, Levin MJ, et al.; Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997;157:343–9. PMID:9040303 https://doi.org/10.1001/archinte.1997.00440240109016
Reitano M, Tyring S, Lang W, et al.; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603–10. PMID:9728526 https://doi.org/10.1086/515385
Romanowski B, Marina RB, Roberts JN; Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003;30:226–31. PMID:12616141 https://doi.org/10.1097/00007435-200303000-00010
Corey L, Wald A, Patel R, et al.; Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20. PMID:14702423 https://doi.org/10.1056/NEJMoa035144
Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186(Suppl 1):S40–6. PMID:12353186 https://doi.org/10.1086/342966
Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol 2008;43:190–5. PMID:18621575 https://doi.org/10.1016/j.jcv.2008.06.004
Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011;305:1441–9. PMID:21486977 https://doi.org/10.1001/jama.2011.420
Bender Ignacio RA, Perti T, Magaret AS, et al. Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: a double-blind, randomized, cross-over trial. J Infect Dis 2015;212:1949–56. PMID:26044291 https://doi.org/10.1093/infdis/jiv317
Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529–33. PMID:16540883 https://doi.org/10.1097/01.olq.0000204723.15765.91
Johnston C, Magaret A, Stern M, et al. Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection. Sex Transm Infect 2019;95:A42.
Tang YW, Cleavinger PJ, Li H, Mitchell PS, Smith TF, Persing DH. Analysis of candidate-host immunogenetic determinants in herpes simplex virus-associated Mollaret's meningitis. Clin Infect Dis 2000;30:176–8. PMID:10619748 https://doi.org/10.1086/313616
Shalabi M, Whitley RJ. Recurrent benign lymphocytic meningitis. Clin Infect Dis 2006;43:1194–7. PMID:17029141 https://doi.org/10.1086/508281
Landry ML, Greenwold J, Vikram HR. Herpes simplex type-2 meningitis: presentation and lack of standardized therapy. Am J Med 2009;122:688–91. PMID:19559173 https://doi.org/10.1016/j.amjmed.2009.02.017
Aurelius E, Franzen-Röhl E, Glimåker M, et al.; HSV-2 Meningitis Study Group. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. Clin Infect Dis 2012;54:1304–13. PMID:22460966 https://doi.org/10.1093/cid/cis031
Magawa S, Tanaka H, Furuhashi F, et al. A literature review of herpes simplex virus hepatitis in pregnancy. J Matern Fetal Neonatal Med 2020;33:1774–9. PMID:30235956 https://doi.org/10.1080/14767058.2018.1527311
Masadeh M, Shen H, Lee Y, et al. A fatal case of herpes simplex virus hepatitis in a pregnant patient. Intractable Rare Dis Res 2017;6:124–7. PMID:28580213 https://doi.org/10.5582/irdr.2017.01013
Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009;169:1233–40. PMID:19597073 https://doi.org/10.1001/archinternmed.2009.177
Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143:707–13. PMID:16287791 https://doi.org/10.7326/0003-4819-143-10-200511150-00007
Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100–6. PMID:11427138 https://doi.org/10.1001/jama.285.24.3100
Magaret AS, Mujugira A, Hughes JP, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. Clin Infect Dis 2016;62:456–61. PMID:26578538
Mehta SD, Moses S, Agot K, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. J Infect Dis 2013;208:1869–76. PMID:23901089 https://doi.org/10.1093/infdis/jit371
Grund JM, Bryant TS, Jackson I, et al. Association between male circumcision and women's biomedical health outcomes: a systematic review. Lancet Glob Health 2017;5:e1113–22. PMID:29025633 https://doi.org/10.1016/S2214-109X(17)30369-8
Celum C, Morrow RA, Donnell D, et al.; Partners PrEP Study Team. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med 2014;161:11–9. PMID:24979446 https://doi.org/10.7326/M13-2471
Abdool Karim SS, Abdool Karim Q, Gengiah TN. Tenofovir gel to prevent HSV-2 infection. N Engl J Med 2015;373:1980–1. PMID:26559584 https://doi.org/10.1056/NEJMoa1410649
Marcus JL, Glidden DV, McMahan V, et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One 2014;9:e91513. PMID:24637511 https://doi.org/10.1371/journal.pone.0091513
Celum C, Hong T, Cent A, et al.; ACTG PEARLS/A5175 Team. Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS Study. J Infect Dis 2017;215:907–10. PMID:28453835 https://doi.org/10.1093/infdis/jix029
Gilbert LK, Wyand F. Genital herpes education and counselling: testing a one-page 'FAQ' intervention. Herpes 2009;15:51–6. PMID:19306603
Rosenthal SL, Zimet GD, Leichliter JS, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect 2006;82:154–7, discussion 157–8. PMID:16581745 https://doi.org/10.1136/sti.2005.016311
Miyai T, Turner KR, Kent CK, Klausner J. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transm Dis 2004;31:517–21. PMID:15480111 https://doi.org/10.1097/01.olq.0000137901.71284.6b
Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. Sex Transm Infect 2011;87:594–600. PMID:21903980 https://doi.org/10.1136/sextrans-2011-050099
Henry RE, Wegmann JA, Hartle JE, Christopher GW. Successful oral acyclovir desensitization. Ann Allergy 1993;70:386–8. PMID:8498729
Leeyaphan C, Surawan TM, Chirachanakul P, et al. Clinical characteristics of hypertrophic herpes simplex genitalis and treatment outcomes of imiquimod: a retrospective observational study. Int J Infect Dis 2015;33:165–70. PMID:25660091 https://doi.org/10.1016/j.ijid.2015.02.002
Keller MJ, Huber A, Espinoza L, et al. Impact of herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome. J Infect Dis 2019;220:852–61. PMID:31111902 https://doi.org/10.1093/infdis/jiz203
Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693–6. PMID:15272395 https://doi.org/10.1086/422755
Tobian AA, Grabowski MK, Serwadda D, et al.; Rakai Health Sciences Program. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013;208:839–46. PMID:23812240 https://doi.org/10.1093/infdis/jit252
Mujugira A, Magaret AS, Celum C, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis 2013;208:1366–74. PMID:23901094 https://doi.org/10.1093/infdis/jit333
Van Wagoner N, Geisler WM, Bachmann LH, Hook EW. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2. Int J STD AIDS 2015;26:574–81. PMID:25147236 https://doi.org/10.1177/0956462414546504
Reyes M, Shaik NS, Graber JM, et al.; Task Force on Herpes Simplex Virus Resistance. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76–80. PMID:12523920 https://doi.org/10.1001/archinte.163.1.76
Safrin S, Crumpacker C, Chatis P, et al.; The AIDS Clinical Trials Group. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551–5. PMID:1649971 https://doi.org/10.1056/NEJM199108223250805
Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39(Suppl 5):S248–57. PMID:15494896 https://doi.org/10.1086/422364
Tandon S, Singh J, Sinha S, Sharma DP. Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. Dermatol Ther (Heidelb) 2017;30:e12479. PMID:28261899 https://doi.org/10.1111/dth.12479
Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sex Transm Infect 2011;87:292–5. PMID:21406577 https://doi.org/10.1136/sti.2010.047431
McElhiney LF. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Compd 2006;10:324–8. PMID:23974309
Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;196:266–70. PMID:17570114 https://doi.org/10.1086/518938
Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509–15. PMID:9262493 https://doi.org/10.1056/NEJM199708213370801
Pinninti SG, Kimberlin DW. Maternal and neonatal herpes simplex virus infections. Am J Perinatol 2013;30:113–9. PMID:23303485 https://doi.org/10.1055/s-0032-1332802
Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247–52. PMID:1849612 https://doi.org/10.1056/NEJM199105023241804
Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203–9. PMID:12517231 https://doi.org/10.1001/jama.289.2.203
Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM; National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997–2007. Paediatr Perinat Epidemiol 2013;27:340–5. PMID:23772935 https://doi.org/10.1111/ppe.12064
Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res A Clin Mol Teratol 2004;70:201–7. PMID:15108247 https://doi.org/10.1002/bdra.20013
Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010;304:859–66. PMID:20736469 https://doi.org/10.1001/jama.2010.1206
Sheffield JS, Sánchez PJ, Wendel GD Jr, et al. Placental histopathology of congenital syphilis. Obstet Gynecol 2002;100:126–33. PMID:12100814
Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188:836–43. PMID:12634667 https://doi.org/10.1067/mob.2003.185
Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10:71–7. PMID:12530483 https://doi.org/10.1155/S1064744902000054
Pinninti SG, Angara R, Feja KN, et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr 2012;161:134–8.e1-3. PMID:22336576 https://doi.org/10.1016/j.jpeds.2011.12.053
ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. Obstet Gynecol 2007;109:1489–98. PMID:17569194 https://doi.org/10.1097/01.AOG.0000263902.31953.3e
Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011;20:699–707. PMID:21173170 https://doi.org/10.1158/1055-9965.EPI-10-1108
Ahmed N, Pillay A, Lawler M, Bobat R, Archary M. Donovanosis causing lymphadenitis, mastoiditis, and meningitis in a child. Lancet 2015;385:2644. PMID:26122163 https://doi.org/10.1016/S0140-6736(15)60992-8
Arora AK, Kumaran MS, Narang T, Saikia UN, Handa S. Donovanosis and squamous cell carcinoma: the relationship conundrum! Int J STD AIDS 2017;28:411–4. PMID:27535727 https://doi.org/10.1177/0956462416665996
Liverani CA, Lattuada D, Mangano S, et al. Hypertrophic donavanosis in a young pregnant woman. J Pediatr Adolesc Gynecol 2012;25:e81–3. PMID:22840941 https://doi.org/10.1016/j.jpag.2011.10.002
Magalhães BM, Veasey JV, Mayor SAS, Lellis RF. Donovanosis in a child victim of sexual abuse: response to doxycycline treatment. An Bras Dermatol 2018;93:592–4. https://doi.org/10.1590/abd1806-4841.20187948
Marfatia YS, Menon DS, Jose S, Patel BK. Nonhealing genital ulcer in AIDS: a diagnostic dilemma! Indian J Sex Transm Dis AIDS 2016 ;37 :197 –200 . PMID:27890958 https://doi.org/10.4103/0253-7184.192130
Narang T, Kanwar AJ. Genital elephantiasis due to donovanosis: forgotten but not gone yet. Int J STD AIDS 2012;23:835–6. PMID:23155109 https://doi.org/10.1258/ijsa.2012.012096
Pilani A, Vora R, Anjaneyan G. Granuloma inguinale mimicking as squamous cell carcinoma of penis. Indian J Sex Transm Dis AIDS 2014;35:56–8. PMID:24958990 https://doi.org/10.4103/0253-7184.132433
Ramdial PK, Sing Y, Ramburan A, et al. Infantile donovanosis presenting as external auditory canal polyps: a diagnostic trap. Am J Dermatopathol 2012;34:818–21. PMID:23169417 https://doi.org/10.1097/DAD.0b013e3182540ccb
Wahal SP, Tuli D. Donovanosis: an incidental finding on Pap test. J Cytol 2013;30:217–8. PMID:24130421 https://doi.org/10.4103/0970-9371.117638
Bowden FJ; National Donovanosis Eradication Advisory Committee. Donovanosis in Australia: going, going. Sex Transm Infect 2005;81:365–6. PMID:16199732 https://doi.org/10.1136/sti.2004.013227
Bright A. National Notifiable Diseases Surveillance System surveillance report: sexually transmissible infections in Aboriginal and Torres Strait Islander people. Commun Dis Intell Q Rep 2015;39:E584–9. PMID:26779731
O'Farrell N. Donovanosis. Sex Transm Infect 2002;78:452–7. PMID:12473810 https://doi.org/10.1136/sti.78.6.452
Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect 2002;78:90–2. PMID:12081191 https://doi.org/10.1136/sti.78.2.90
White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis 2009;22:57–66. PMID:19532081 https://doi.org/10.1097/QCO.0b013e328320a8ae
de Vries HJ, Zingoni A, White JA, Ross JD, Kreuter A. 2013 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens. Int J STD AIDS 2014;25:465–74. PMID:24352129 https://doi.org/10.1177/0956462413516100
Ward H, Martin I, Macdonald N, et al. Lymphogranuloma venereum in the United kingdom. Clin Infect Dis 2007;44:26–32. PMID:17143811 https://doi.org/10.1086/509922
Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis 2010;29:917–25. PMID:20509036 https://doi.org/10.1007/s10096-010-0959-2
de Voux A, Kent JB, Macomber K, et al. Notes from the field: cluster of lymphogranuloma venereum cases among men who have sex with men—Michigan, August 2015–April 2016. MMWR Morb Mortal Wkly Rep 2016;65:920–1. PMID:27583686 https://doi.org/10.15585/mmwr.mm6534a6
Pallawela SN, Sullivan AK, Macdonald N, et al. Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicentre case-control study in the U.K. Sex Transm Infect 2014;90:269–74. PMID:24687130 https://doi.org/10.1136/sextrans-2013-051401
de Vrieze NH, de Vries HJ. Lymphogranuloma venereum among men who have sex with men. An epidemiological and clinical review. Expert Rev Anti Infect Ther 2014;12:697–704. PMID:24655220 https://doi.org/10.1586/14787210.2014.901169
Koper NE, van der Sande MA, Gotz HM, Koedijk FD; Dutch STI Clinics. Lymphogranuloma venereum among men who have sex with men in the Netherlands: regional differences in testing rates lead to underestimation of the incidence, 2006–2012. Euro Surveill 2013;18:20561. PMID:23987831 https://doi.org/10.2807/1560-7917.ES2013.18.34.20561
Haar K, Dudareva-Vizule S, Wisplinghoff H, et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis 2013;19:488–92. PMID:23621949 https://doi.org/10.3201/eid1903.121028
Riera-Monroig J, Fuertes de Vega I. Lymphogranuloma venereum presenting as an ulcer on the tongue. Sex Transm Infect 2019;95:169–70. PMID:30554142 https://doi.org/10.1136/sextrans-2018-053787
Andrada MT, Dhar JK, Wilde H. Oral lymphogranuloma venereum and cervical lymphadenopathy. Case report. Mil Med 1974;139:99–101. PMID:4204816 https://doi.org/10.1093/milmed/139.2.99
Ilyas S, Richmond D, Burns G, et al. Orolabial lymphogranuloma venereum, Michigan, USA. Emerg Infect Dis 2019;25:2112–4. PMID:31625852 https://doi.org/10.3201/eid2511.190819
Kersh EN, Pillay A, de Voux A, Chen C. Laboratory processes for confirmation of lymphogranuloma venereum infection during a 2015 investigation of a cluster of cases in the United States. Sex Transm Dis 2017;44:691–4. PMID:28876314 https://doi.org/10.1097/OLQ.0000000000000667
CDC. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR Recomm Rep 2014;63(No. RR-2). PMID:24622331
Pathela P, Jamison K, Kornblum J, Quinlan T, Halse TA, Schillinger JA. Lymphogranuloma venereum: an increasingly common anorectal infection among men who have sex with men attending New York City sexual health clinics. Sex Transm Dis 2019;46:e14–7. PMID:30278027 https://doi.org/10.1097/OLQ.0000000000000921
Cohen S, Brosnan H, Kohn R, et al. P494 Diagnosis and management of lymphogranuloma venereum (LGV) in a municipal STD clinic, San Francisco, 2016–18. Sex Transm Infect 2019;95(Suppl 1):A229.
Leeyaphan C, Ong JJ, Chow EP, et al. Systematic review and meta-analysis of doxycycline efficacy for rectal lymphogranuloma venereum in men who have sex with men. Emerg Infect Dis 2016;22:1778–84. PMID:27513890 https://doi.org/10.3201/eid2210.160986
Cabello Úbeda A, Fernández Roblas R, García Delgado R, et al. Anorectal lymphogranuloma venereum in Madrid: a persistent emerging problem in men who have sex with men. Sex Transm Dis 2016;43:414–9. PMID:27322040 https://doi.org/10.1097/OLQ.0000000000000459
Simons R, Candfield S, French P, White JA. Observed treatment responses to short-course doxycycline therapy for rectal lymphogranuloma venereum in men who have sex with men. Sex Transm Dis 2018;45:406–8. PMID:29465660 https://doi.org/10.1097/OLQ.0000000000000772
Vall-Mayans M, Isaksson J, Caballero E, Sallés B, Herrmann B. Bubonic lymphogranuloma venereum with multidrug treatment failure. Int J STD AIDS 2014;25:306–8. PMID:24216037 https://doi.org/10.1177/0956462413501158
Blanco JL, Fuertes I, Bosch J, et al. Effective treatment of lymphogranuloma venereum (LGV) with 1g azithormycin administered weekly for 3 weeks in HIV-infected population. Presented at the Conference on Retroviruses and Opportunist Infections, Seattle, WA; February 23–26, 2015.
Kong FY, Rupasinghe TW, Simpson JA, et al. Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men. PLoS One 2017;12:e0174372. PMID:28350806 https://doi.org/10.1371/journal.pone.0174372
Elgalib A, Alexander S, Tong CY, White JA. Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection. Int J STD AIDS 2011;22:474–7. PMID:21764781 https://doi.org/10.1258/ijsa.2011.011134
Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? Diagn Microbiol Infect Dis 2019;93:238–42. PMID:30442509 https://doi.org/10.1016/j.diagmicrobio.2018.09.015
Towns JM, Leslie DE, Denham I, Azzato F, Fairley CK, Chen M. Painful and multiple anogenital lesions are common in men with Treponema pallidum PCR-positive primary syphilis without herpes simplex virus coinfection: a cross-sectional clinic-based study. Sex Transm Infect 2016;92:110–5. PMID:26378262 https://doi.org/10.1136/sextrans-2015-052219
Theel ES, Katz SS, Pillay A. Molecular and direct detection tests for Treponema pallidum subspecies pallidum: a review of the literature, 1964–2017. Clin Infect Dis 2020;71(Suppl 1):S4–12. PMID:32578865 https://doi.org/10.1093/cid/ciaa176
Tuddenham S, Katz SS, Ghanem KG. Syphilis laboratory guidelines: performance characteristics of nontreponemal antibody tests. Clin Infect Dis 2020;71(Suppl 1):S21–42. PMID:32578862 https://doi.org/10.1093/cid/ciaa306
Park IU, Tran A, Pereira L, Fakile Y. Sensitivity and specificity of treponemal-specific tests for the diagnosis of syphilis. Clin Infect Dis 2020;71(Suppl 1):S13–20. PMID:32578866 https://doi.org/10.1093/cid/ciaa349
Bristow CC, Klausner JD, Tran A. Clinical test performance of a rapid point-of-care syphilis treponemal antibody test: a systematic review and meta-analysis. Clin Infect Dis 2020;71(Suppl 1):S52–7. PMID:32578863 https://doi.org/10.1093/cid/ciaa350
Nandwani R, Evans DT. Are you sure it's syphilis? A review of false positive serology. Int J STD AIDS 1995;6:241–8. PMID:7548285 https://doi.org/10.1177/095646249500600404
Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ. Serologic response to treatment of infectious syphilis. Ann Intern Med 1991;114:1005–9. PMID:2029095 https://doi.org/10.7326/0003-4819-114-12-1005
CDC. Syphilis testing algorithms using treponemal tests for initial screening—four laboratories, New York City, 2005–2006. MMWR Morb Mortal Wkly Rep 2008;57:872–5. PMID:18701877
CDC. Discordant results from reverse sequence syphilis screening—five laboratories, United States, 2006–2010. MMWR Morb Mortal Wkly Rep 2011;60:133–7. PMID:21307823
Ortiz-Lopez N, Diez M, Diaz O, Simon F, Diaz A. Epidemiological surveillance of congenital syphilis in Spain, 2000–2010. Pediatr Infect Dis J 2012;31:988–90. PMID:22572752 https://doi.org/10.1097/INF.0b013e31825d3152
Ortiz DA, Shukla MR, Loeffelholz MJ. The traditional or reverse algorithm for diagnosis of syphilis: pros and cons. Clin Infect Dis 2020;71(Suppl 1):S43–51. PMID:32578864 https://doi.org/10.1093/cid/ciaa307
Berry GJ, Loeffelholz MJ. Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing. Sex Transm Dis 2016;43:737–40. PMID:27835625 https://doi.org/10.1097/OLQ.0000000000000524
Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis 2011;204:1297–304. PMID:21930610 https://doi.org/10.1093/infdis/jir524
Loeffelholz MJ, Wen T, Patel JA. Analysis of bioplex syphilis IgG quantitative results in different patient populations. Clin Vaccine Immunol 2011;18:2005–6. PMID:21880852 https://doi.org/10.1128/CVI.05335-11
Fakile YF, Jost H, Hoover KW, et al. Correlation of treponemal immunoassay signal strength values with reactivity of confirmatory treponemal testing. J Clin Microbiol 2017;56:e01165-17. PMID:29046410 https://doi.org/10.1128/JCM.01165-17
Wong EH, Klausner JD, Caguin-Grygiel G, et al. Evaluation of an IgM/IgG sensitive enzyme immunoassay and the utility of index values for the screening of syphilis infection in a high-risk population. Sex Transm Dis 2011;38:528–32. PMID:21233789 https://doi.org/10.1097/OLQ.0b013e318205491a
Dai S, Chi P, Lin Y, et al. Improved reverse screening algorithm for Treponema pallidum antibody using signal-to-cutoff ratios from chemiluminescence microparticle immunoassay. Sex Transm Dis 2014;41:29–34. PMID:24326578 https://doi.org/10.1097/OLQ.0000000000000066
Li Z, Feng Z, Liu P, Yan C. Screening for antibodies against Treponema pallidum with chemiluminescent microparticle immunoassay: analysis of discordant serology results and clinical characterization. Ann Clin Biochem 2016;53:588–92. PMID:26680646 https://doi.org/10.1177/0004563215623806
Yen-Lieberman B, Daniel J, Means C, Waletzky J, Daly TM. Identification of false-positive syphilis antibody results using a semiquantitative algorithm. Clin Vaccine Immunol 2011;18:1038–40. PMID:21508162 https://doi.org/10.1128/CVI.05066-11
Yimtae K, Srirompotong S, Lertsukprasert K. Otosyphilis: a review of 85 cases. Otolaryngol Head Neck Surg 2007;136:67–71. PMID:17210336 https://doi.org/10.1016/j.otohns.2006.08.026
Gleich LL, Linstrom CJ, Kimmelman CP. Otosyphilis: a diagnostic and therapeutic dilemma. Laryngoscope 1992;102:1255–9. PMID:1307698 https://doi.org/10.1288/00005537-199211000-00010
Lukehart SA, Hook EW 3rd, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988;109:855–62. PMID:3056164 https://doi.org/10.7326/0003-4819-109-11-855
Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. Sex Transm Dis 2012;39:291–7. PMID:22421696 https://doi.org/10.1097/OLQ.0b013e31824c0e62
Jaffe HW, Larsen SA, Peters M, Jove DF, Lopez B, Schroeter AL. Tests for treponemal antibody in CSF. Arch Intern Med 1978;138:252–5. PMID:343742 https://doi.org/10.1001/archinte.1978.03630260050016
Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004;189:369–76. PMID:14745693 https://doi.org/10.1086/381227
CDC. Inadvertent use of Bicillin C-R to treat syphilis infection—Los Angeles, California, 1999–2004. MMWR Morb Mortal Wkly Rep 2005;54:217–9. PMID:15758893
Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg 2017;96:46–52. PMID:28077740 https://doi.org/10.4269/ajtmh.16-0434
Rolfs RT, Joesoef MR, Hendershot EF, et al.; The Syphilis and HIV Study Group. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 1997;337:307–14. PMID:9235493 https://doi.org/10.1056/NEJM199707313370504
Yang CJ, Lee NY, Chen TC, et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS One 2014;9:e109667. PMID:25286091 https://doi.org/10.1371/journal.pone.0109667
Ganesan A, Mesner O, Okulicz JF, et al.; Infectious Disease Clinical Research Program HIV/STI Working Group. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin Infect Dis 2015;60:653–60. PMID:25389249 https://doi.org/10.1093/cid/ciu888
Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007;83:97–101. PMID:16943224 https://doi.org/10.1136/sti.2006.021402
Seña AC, Wolff M, Martin DH, et al. Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin Infect Dis 2011;53:1092–9. PMID:21998287 https://doi.org/10.1093/cid/cir671
Zhang RL, Wang QQ, Zhang JP, Yang LJ. Molecular subtyping of Treponema pallidum and associated factors of serofast status in early syphilis patients: identified novel genotype and cytokine marker. PLoS One 2017;12:e0175477. PMID:28410389 https://doi.org/10.1371/journal.pone.0175477
Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015;15:479. PMID:26511465 https://doi.org/10.1186/s12879-015-1209-0
Tong ML, Lin LR, Liu GL, et al. Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. PLoS One 2013;8:e70102. PMID:23894598 https://doi.org/10.1371/journal.pone.0070102
Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis 2013;56:420–2. PMID:23118269 https://doi.org/10.1093/cid/cis918
Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006;42:e45–9. PMID:16477545 https://doi.org/10.1086/500406
Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med 2008;121:903–8. PMID:18823862 https://doi.org/10.1016/j.amjmed.2008.04.042
Hook EW 3rd, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002;29:486–90. PMID:12172535 https://doi.org/10.1097/00007435-200208000-00010
Cao Y, Su X, Wang Q, et al. A multicenter study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu, China. Clin Infect Dis 2017;65:1683–8. PMID:29020150 https://doi.org/10.1093/cid/cix611
Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005;353:1236–44. PMID:16177249 https://doi.org/10.1056/NEJMoa044284
Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010;201:1729–35. PMID:20402591 https://doi.org/10.1086/652239
Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004;351:154–8. PMID:15247355 https://doi.org/10.1056/NEJMoa040216
Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004. Clin Infect Dis 2006;42:337–45. PMID:16392078 https://doi.org/10.1086/498899
A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis 2012;39:794–8. PMID:23001267
Rolfs RT, Joesoef MR, Hendershot EF, et al.; The Syphilis and HIV Study Group. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 1997;337:307–14. PMID:9235493 https://doi.org/10.1056/NEJM199707313370504
Collart P, Poitevin M, Milovanovic A, Herlin A, Durel J. Kinetic study of serum penicillin concentrations after single doses of benzathine and benethamine penicillins in young and old people. Br J Vener Dis 1980;56:355–62. PMID:7448577 https://doi.org/10.1136/sti.56.6.355
Hagdrup HK, Lange Wantzin G, Secher L, Rosdahl VT. Penicillin concentrations in serum following weekly injections of benzathine penicillin G. Chemotherapy 1986;32:99–101. PMID:3698728 https://doi.org/10.1159/000238397
Frentz G, Nielsen PB, Espersen F, Czartoryski A, Aastrup H. Penicillin concentrations in blood and spinal fluid after a single intramuscular injection of penicillin G benzathine. Eur J Clin Microbiol 1984;3:147–9. PMID:6723638 https://doi.org/10.1007/BF02014334
Nathan L, Bawdon RE, Sidawi JE, Stettler RW, McIntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol 1993;82:338–42. PMID:8355931
Marra CM, Maxwell CL, Tantalo LC, Sahi SK, Lukehart SA. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 2008;47:893–9. PMID:18715154 https://doi.org/10.1086/591534
Xiao Y, Tong ML, Lin LR, et al. Serological response predicts normalization of cerebrospinal fluid abnormalities at six months after treatment in HIV-negative neurosyphilis patients. Sci Rep 2017;7:9911. PMID:28855625 https://doi.org/10.1038/s41598-017-10387-x
Hook EW 3rd, Baker-Zander SA, Moskovitz BL, Lukehart SA, Handsfield HH. Ceftriaxone therapy for asymptomatic neurosyphilis. Case report and Western blot analysis of serum and cerebrospinal fluid IgG response to therapy. Sex Transm Dis 1986;13(Suppl):185–8. PMID:3764632 https://doi.org/10.1097/00007435-198607000-00018
Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex Transm Infect 2003;79:415–6. PMID:14573840 https://doi.org/10.1136/sti.79.5.415
Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol 2012;158:405–10. PMID:22487723 https://doi.org/10.1159/000333553
Park MA, Koch CA, Klemawesch P, Joshi A, Li JT. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol 2010;153:268–73. PMID:20484925 https://doi.org/10.1159/000314367
Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001;31:438–43. PMID:11260156 https://doi.org/10.1046/j.1365-2222.2001.00992.x
Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 2007;136:340–7. PMID:17321857 https://doi.org/10.1016/j.otohns.2006.10.007
Kingston AA, Vujevich J, Shapiro M, et al. Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Arch Dermatol 2005;141:431–3. PMID:15837859 https://doi.org/10.1001/archderm.141.4.431
CDC. Symptomatic early neurosyphilis among HIV-positive men who have sex with men—four cities, United States, January 2002–June 2004. MMWR Morb Mortal Wkly Rep 2007;56:625–8. PMID:17597693
Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008;22:1145–51. PMID:18525260 https://doi.org/10.1097/QAD.0b013e32830184df
Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008;47:258–65. PMID:18532887 https://doi.org/10.1086/589295
Tomkins A, Ahmad S, Cousins DE, Thng CM, Vilar FJ, Higgins SP. Screening for asymptomatic neurosyphilis in HIV patients after treatment of early syphilis: an observational study. Sex Transm Infect 2018;94:337–9. PMID:28196838 https://doi.org/10.1136/sextrans-2016-052938
Yang CJ, Chang SY, Hung CC. Sensitivity and specificity of lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 2009;49:162–3, author reply 162–3. PMID:19500029 https://doi.org/10.1086/599616
Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000;30:540–4. PMID:10722441 https://doi.org/10.1086/313725
Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med 1992;93:481–8. PMID:1442850 https://doi.org/10.1016/0002-9343(92)90574-U
Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS 2004;15:328–32. PMID:15117503 https://doi.org/10.1177/095646240401500511
Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol 2012;158:405–10. PMID:22487723 https://doi.org/10.1159/000333553
Trivedi S, Williams C, Torrone E, Kidd S. National trends and reported risk factors among pregnant women with syphilis in the United States, 2012–2016. Obstet Gynecol 2019;133:27–32. PMID:30531570 https://doi.org/10.1097/AOG.0000000000003000
Biswas HH, Chew Ng RA, Murray EL, et al. Characteristics associated with delivery of an infant with congenital syphilis and missed opportunities for prevention—California, 2012 to 2014. Sex Transm Dis 2018;45:435–41. PMID:29465666 https://doi.org/10.1097/OLQ.0000000000000782
Slutsker JS, Hennessy RR, Schillinger JA. Factors contributing to congenital syphilis cases—New York City, 2010–2016. MMWR Morb Mortal Wkly Rep 2018;67:1088–93. PMID:30286056 https://doi.org/10.15585/mmwr.mm6739a3
DiOrio D, Kroeger K, Ross A. Social vulnerability in congenital syphilis case mothers: qualitative assessment of cases in Indiana, 2014 to 2016. Sex Transm Dis 2018;45:447–51. PMID:29465662 https://doi.org/10.1097/OLQ.0000000000000783
Kimball A, Torrone E, Miele K, et al. Missed opportunities for prevention of congenital syphilis—United States, 2018. MMWR Morb Mortal Wkly Rep 2020;69:661–5. PMID:32497029 https://doi.org/10.15585/mmwr.mm6922a1
Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis 2011;204:1297–304. PMID:21930610 https://doi.org/10.1093/infdis/jir524
Mmeje O, Chow JM, Davidson L, Shieh J, Schapiro JM, Park IU. Discordant syphilis immunoassays in pregnancy: perinatal outcomes and implications for clinical management. Clin Infect Dis 2015;61:1049–53. PMID:26063719 https://doi.org/10.1093/cid/civ445
Alexander JM, Sheffield JS, Sanchez PJ, Mayfield J, Wendel GD Jr. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol 1999;93:5–8. PMID:9916946
Walker GJ. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database Syst Rev 2001;(3):CD001143. PMID:11686978
Wendel GD Jr, Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sánchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis 2002;35(Suppl 2):S200–9. PMID:12353207 https://doi.org/10.1086/342108
Zhu L, Qin M, Du L, Xie RH, Wong T, Wen SW. Maternal and congenital syphilis in Shanghai, China, 2002 to 2006. Int J Infect Dis 2010;14(Suppl 3):e45–8. PMID:20137991 https://doi.org/10.1016/j.ijid.2009.09.009
Hawkes S, Matin N, Broutet N, Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis 2011;11:684–91. PMID:21683653 https://doi.org/10.1016/S1473-3099(11)70104-9
Hollier LM, Harstad TW, Sanchez PJ, Twickler DM, Wendel GD Jr. Fetal syphilis: clinical and laboratory characteristics. Obstet Gynecol 2001;97:947–53. PMID:11384701
Rac MW, Bryant SN, McIntire DD, et al. Progression of ultrasound findings of fetal syphilis after maternal treatment. Am J Obstet Gynecol 2014;211:426.e1–6. PMID:24907700 https://doi.org/10.1016/j.ajog.2014.05.049
Zhou P, Gu Z, Xu J, Wang X, Liao K. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy. Sex Transm Dis 2005;32:495–8. PMID:16041252 https://doi.org/10.1097/01.olq.0000170443.70739.cd
Katanami Y, Hashimoto T, Takaya S, et al. Amoxicillin and ceftriaxone as treatment alternatives to penicillin for maternal syphilis. Emerg Infect Dis 2017;23:827–9. PMID:28418316 https://doi.org/10.3201/eid2305.161936
Kestenbaum LA, Ebberson J, Zorc JJ, Hodinka RL, Shah SS. Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. Pediatrics 2010;125:257–64. PMID:20064869 https://doi.org/10.1542/peds.2009-1181
Shah SS, Ebberson J, Kestenbaum LA, Hodinka RL, Zorc JJ. Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants. J Hosp Med 2011;6:22–7. PMID:20629018 https://doi.org/10.1002/jhm.711
Thomson J, Sucharew H, Cruz AT, et al.; Pediatric Emergency Medicine Collaborative Research Committee (PEM CRC) HSV Study Group. Cerebrospinal fluid reference values for young infants undergoing lumbar puncture. Pediatrics 2018;141:e20173405. PMID:29437883 https://doi.org/10.1542/peds.2017-3405
Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red book: 2018 report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. J Allergy Clin Immunol 2015;135:745–52.e5. PMID:25262461 https://doi.org/10.1016/j.jaci.2014.07.062
Macy E, Vyles D. Who needs penicillin allergy testing? Ann Allergy Asthma Immunol 2018;121:523–9. PMID:30092265 https://doi.org/10.1016/j.anai.2018.07.041
Annè S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 1995;74:167–70. PMID:7697478
Albin S, Agarwal S. Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population. Allergy Asthma Proc 2014;35:489–94. PMID:25584917 https://doi.org/10.2500/aap.2014.35.3791
Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet 2019;393:183–98. PMID:30558872 https://doi.org/10.1016/S0140-6736(18)32218-9
Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med 2009;122:778.e1–7. PMID:19635279 https://doi.org/10.1016/j.amjmed.2009.01.034
Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA 2019;321:188–99. PMID:30644987 https://doi.org/10.1001/jama.2018.19283
Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993;270:2456–63. PMID:8230623 https://doi.org/10.1001/jama.1993.03510200062033
Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol Pract 2013;1:258–63. PMID:24565482 https://doi.org/10.1016/j.jaip.2013.02.002
Jares EJ, Sánchez-Borges M, Cardona-Villa R, et al.; Latin America Drug Allergy Interest Group. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol 2014;113:282–9. PMID:25065979 https://doi.org/10.1016/j.anai.2014.06.019
Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study. J Allergy Clin Immunol 2014;133:790–6. PMID:24188976 https://doi.org/10.1016/j.jaci.2013.09.021
Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018;361:k2400. PMID:29950489 https://doi.org/10.1136/bmj.k2400
Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site infection risk. Clin Infect Dis 2018;66:329–36. PMID:29361015 https://doi.org/10.1093/cid/cix794
Tucker MH, Lomas CM, Ramchandar N, Waldram JD. Amoxicillin challenge without penicillin skin testing in evaluation of penicillin allergy in a cohort of Marine recruits. J Allergy Clin Immunol Pract 2017;5:813–5. PMID:28341170 https://doi.org/10.1016/j.jaip.2017.01.023
Goldberg A, Confino-Cohen R. Skin testing and oral penicillin challenge in patients with a history of remote penicillin allergy. Ann Allergy Asthma Immunol 2008;100:37–43. PMID:18254480 https://doi.org/10.1016/S1081-1206(10)60402-4
Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing. J Allergy Clin Immunol Pract 2019;7:236–43. PMID:29802906 https://doi.org/10.1016/j.jaip.2018.05.008
Cook DJ, Barbara DW, Singh KE, Dearani JA. Penicillin skin testing in cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1931–5. PMID:24530197 https://doi.org/10.1016/j.jtcvs.2014.01.019
McDanel DL, Azar AE, Dowden AM, et al. Screening for beta-lactam allergy in joint arthroplasty patients to improve surgical prophylaxis practice. J Arthroplasty 2017;32(9s):S101–8. PMID:28236547 https://doi.org/10.1016/j.arth.2017.01.012
Trubiano JA, Thursky KA, Stewardson AJ, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. Clin Infect Dis 2017;65:166–74. PMID:28520865 https://doi.org/10.1093/cid/cix244
Siew LQC, Li PH, Watts TJ, et al. Identifying low-risk beta-lactam allergy patients in a UK tertiary centre. J Allergy Clin Immunol Pract 2019;7:2173–2181.e1. PMID:30922992 https://doi.org/10.1016/j.jaip.2019.03.015
Chen JR, Tarver SA, Alvarez KS, Tran T, Khan DA. A proactive approach to penicillin allergy testing in hospitalized patients. J Allergy Clin Immunol Pract 2017;5:686–93. PMID:27888034 https://doi.org/10.1016/j.jaip.2016.09.045
Leis JA, Palmay L, Ho G, et al. Point-of-care β-lactam allergy skin testing by antimicrobial stewardship programs: a pragmatic multicenter prospective evaluation. Clin Infect Dis 2017;65:1059–65. PMID:28575226 https://doi.org/10.1093/cid/cix512
Banks TA, Tucker M, Macy E. Evaluating penicillin allergies without skin testing. Curr Allergy Asthma Rep 2019;19:27. PMID:30903298 https://doi.org/10.1007/s11882-019-0854-6
Pham MN, Ho HE, Desai M. Penicillin desensitization: treatment of syphilis in pregnancy in penicillin-allergic patients. Ann Allergy Asthma Immunol 2017;118:537–41. PMID:28477786 https://doi.org/10.1016/j.anai.2017.03.013
Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992;152:1025–32. PMID:1580706 https://doi.org/10.1001/archinte.1992.00400170105020
Solensky R, Jacobs J, Lester M, et al. Penicillin allergy evaluation: a prospective, multicenter, open-label evaluation of a comprehensive penicillin skin test kit. J Allergy Clin Immunol Pract 2019;7:1876–85. e3. PMID:30878711 https://doi.org/10.1016/j.jaip.2019.02.040
Heil EL, Bork JT, Schmalzle SA, et al. Implementation of an infectious disease fellow-managed penicillin allergy skin testing service. Open Forum Infect Dis 2016;3:ofw155. PMID:27704011 https://doi.org/10.1093/ofid/ofw155
du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labelling service in a public hospital. J Antimicrob Chemother 2019;74:1438–46. PMID:30753497 https://doi.org/10.1093/jac/dky575
Macy E, Blumenthal KG. Are cephalosporins safe for use in penicillin allergy without prior allergy evaluation? J Allergy Clin Immunol Pract 2018;6:82–9. PMID:28958745 https://doi.org/10.1016/j.jaip.2017.07.033
Zagursky RJ, Pichichero ME. Cross-reactivity in β-lactam allergy. J Allergy Clin Immunol Pract 2018;6:72–81.e1. PMID:29017833 https://doi.org/10.1016/j.jaip.2017.08.027
Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol 2015;115:294–300.e2. PMID:26070805 https://doi.org/10.1016/j.anai.2015.05.011
Kuruvilla M, Wolf F, Sexton M, Wiley Z, Thomas J. Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy. Surgery 2019;165:486–96. PMID:30001827 https://doi.org/10.1016/j.surg.2018.05.054
Lee P, Shanson D. Results of a UK survey of fatal anaphylaxis after oral amoxicillin. J Antimicrob Chemother 2007;60:1172–3. PMID:17761735 https://doi.org/10.1093/jac/dkm315
Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: a multihospital implementation. J Allergy Clin Immunol Pract 2017;5:616–25.e7. PMID:28483315 https://doi.org/10.1016/j.jaip.2017.02.019
Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized controlled trial. J Allergy Clin Immunol Pract 2019;7:2163–70. PMID:31170542 https://doi.org/10.1016/j.jaip.2019.05.037
Chastain DB, Hutzley VJ, Parekh J, Alegro JVG. Antimicrobial desensitization: a review of published protocols. Pharmacy (Basel) 2019;7:112. PMID:31405062 https://doi.org/10.3390/pharmacy7030112
Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985;312:1229–32. PMID:3921835 https://doi.org/10.1056/NEJM198505093121905
Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol 1987;80:314–9. PMID:3040836 https://doi.org/10.1016/0091-6749(87)90037-6
Legere HJ 3rd, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009;8:418–24. PMID:19740711 https://doi.org/10.1016/j.jcf.2009.08.002
Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health 2007;97:1118–25. PMID:17463380 https://doi.org/10.2105/AJPH.2005.074062
Ross JDC, Jensen JS. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect 2006;82:269–71. PMID:16877571 https://doi.org/10.1136/sti.2005.017368
Taylor-Robinson D, Gilroy CB, Thomas BJ, Hay PE. Mycoplasma genitalium in chronic non-gonococcal urethritis. Int J STD AIDS 2004;15:21–5. PMID:14769166 https://doi.org/10.1258/095646204322637209
Dupin N, Bijaoui G, Schwarzinger M, et al. Detection and quantification of Mycoplasma genitalium in male patients with urethritis. Clin Infect Dis 2003;37:602–5. PMID:12905147 https://doi.org/10.1086/376990
Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996;34:3120–8. PMID:8940458 https://doi.org/10.1128/JCM.34.12.3120-3128.1996
le Roux MC, Hoosen AA. Quantitative real-time polymerase chain reaction for the diagnosis of Mycoplasma genitalium infection in South African men with and without symptoms of urethritis. Sex Transm Dis 2017;44:17–20. PMID:27898565 https://doi.org/10.1097/OLQ.0000000000000540
Bachmann LH, Kirkcaldy RD, Geisler WM, et al.; the MAGNUM Laboratory Working Group. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Clin Infect Dis 2020;71:e624–32. PMID:32185385 https://doi.org/10.1093/cid/ciaa293
Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009;200:188.e1–7. PMID:19185101 https://doi.org/10.1016/j.ajog.2008.10.005
Bradshaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006;193:336–45. PMID:16388480 https://doi.org/10.1086/499434
Dombrowski JC, Harrington RD, Golden MR. Evidence for the long-term stability of HIV transmission-associated sexual behavior after HIV diagnosis. Sex Transm Dis 2013;40:41–5. PMID:23254116 https://doi.org/10.1097/OLQ.0b013e3182753327
Rane VS, Fairley CK, Weerakoon A, et al. Characteristics of acute nongonococcal urethritis in men differ by sexual preference. J Clin Microbiol 2014;52:2971–6. PMID:24899041 https://doi.org/10.1128/JCM.00899-14
Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis 2014;58:631–7. PMID:24280088 https://doi.org/10.1093/cid/cit752
Khatib N, Bradbury C, Chalker V, et al. Prevalence of Trichomonas vaginalis, Mycoplasma genitalium and Ureaplasma urealyticum in men with urethritis attending an urban sexual health clinic. Int J STD AIDS 2015;26:388–92. PMID:24925897 https://doi.org/10.1177/0956462414539464
Cox C, McKenna JP, Watt AP, Coyle PV. Ureaplasma parvum and Mycoplasma genitalium are found to be significantly associated with microscopy-confirmed urethritis in a routine genitourinary medicine setting. Int J STD AIDS 2016;27:861–7. PMID:26378187 https://doi.org/10.1177/0956462415597620
Li Y, Su X, Le W, et al. Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance. Clin Infect Dis 2020;70:805–10. PMID:30972419 https://doi.org/10.1093/cid/ciz294
Ito S, Hanaoka N, Shimuta K, et al. Male non-gonococcal urethritis: from microbiological etiologies to demographic and clinical features. Int J Urol 2016;23:325–31. PMID:26845624 https://doi.org/10.1111/iju.13044
Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women?—A position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol 2018;32:1845–51. PMID:29924422 https://doi.org/10.1111/jdv.15146
van der Veer C, van Rooijen MS, Himschoot M, de Vries HJ, Bruisten SM. Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Infect 2016;92:83–5. PMID:26283740 https://doi.org/10.1136/sextrans-2015-052118
Seike K, Maeda S, Kubota Y, Tamaki M, Yasuda M, Deguchi T. Prevalence and morbidity of urethral Trichomonas vaginalis in Japanese men with or without urethritis. Sex Transm Infect 2013;89:528–30. PMID:23349337 https://doi.org/10.1136/sextrans-2012-050702
Napierala M, Munson E, Wenten D, et al. Detection of Mycoplasma genitalium from male primary urine specimens: an epidemiologic dichotomy with Trichomonas vaginalis. Diagn Microbiol Infect Dis 2015;82:194–8. PMID:25934156 https://doi.org/10.1016/j.diagmicrobio.2015.03.016
Sviben M, Missoni EM, Meštrović T, Vojnović G, Galinović GM. Epidemiology and laboratory characteristics of Trichomonas vaginalis infection in Croatian men with and without urethritis syndrome: a case-control study. Sex Transm Infect 2015;91:360–4. PMID:25568091 https://doi.org/10.1136/sextrans-2014-051771
Rietmeijer CA, Mungati M, Machiha A, et al. The etiology of male urethral discharge in Zimbabwe: results from the Zimbabwe STI Etiology Study. Sex Transm Dis 2018;45:56–60. PMID:29240635 https://doi.org/10.1097/OLQ.0000000000000696
Bazan JA, Peterson AS, Kirkcaldy RD, et al. Notes from the field: increase in Neisseria meningitidis-associated urethritis among men at two sentinel clinics—Columbus, Ohio, and Oakland County, Michigan, 2015. MMWR Morb Mortal Wkly Rep 2016;65:550–2. PMID:27254649 https://doi.org/10.15585/mmwr.mm6521a5
Jannic A, Mammeri H, Larcher L, et al. Orogenital transmission of Neisseria meningitidis causing acute urethritis in men who have sex with men. Emerg Infect Dis 2019;25:175–6. PMID:30561300 https://doi.org/10.3201/eid2501.171102
Hayakawa K, Itoda I, Shimuta K, Takahashi H, Ohnishi M. Urethritis caused by novel Neisseria meningitidis serogroup W in man who has sex with men, Japan. Emerg Infect Dis 2014;20:1585–7. PMID:25154021 https://doi.org/10.3201/eid2009.140349
Bazan JA, Tzeng YL, Stephens DS, et al. Repeat episodes of symptomatic urethritis due to a uropathogenic meningococcal clade. Sex Transm Dis 2020;47:e1–4. PMID:31651709 https://doi.org/10.1097/OLQ.0000000000001079
Ong JJ, Morton AN, Henzell HR, et al. Clinical characteristics of herpes simplex virus urethritis compared with chlamydial urethritis among men. Sex Transm Dis 2017;44:121–5. PMID:28079748 https://doi.org/10.1097/OLQ.0000000000000547
Avolio M, De Rosa R, Modolo ML, Stano P, Camporese A. When should adenoviral non-gonococcal urethritis be suspected? Two case reports. New Microbiol 2014;37:109–12. PMID:24531179
You C, Hamasuna R, Ogawa M, et al. The first report: an analysis of bacterial flora of the first voided urine specimens of patients with male urethritis using the 16S ribosomal RNA gene-based clone library method. Microb Pathog 2016;95:95–100. PMID:27013259 https://doi.org/10.1016/j.micpath.2016.02.022
Deguchi T, Ito S, Hatazaki K, et al. Antimicrobial susceptibility of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis and/or epididymitis. J Infect Chemother 2017;23:804–7. PMID:28619239 https://doi.org/10.1016/j.jiac.2017.05.009
Ito S, Hatazaki K, Shimuta K, et al. Haemophilus influenzae isolated from men with acute urethritis: its pathogenic roles, responses to antimicrobial chemotherapies, and antimicrobial susceptibilities. Sex Transm Dis 2017;44:205–10. PMID:28282645 https://doi.org/10.1097/OLQ.0000000000000573
Horie K, Ito S, Hatazaki K, et al. 'Haemophilus quentini' in the urethra of men complaining of urethritis symptoms. J Infect Chemother 2018;24:71–4. PMID:28889986 https://doi.org/10.1016/j.jiac.2017.08.007
Frølund M, Falk L, Ahrens P, Jensen JS. Detection of ureaplasmas and bacterial vaginosis associated bacteria and their association with non-gonococcal urethritis in men. PLoS One 2019;14:e0214425. PMID:30946763 https://doi.org/10.1371/journal.pone.0214425
Deza G, Martin-Ezquerra G, Gómez J, Villar-García J, Supervia A, Pujol RM. Isolation of Haemophilus influenzae and Haemophilus parainfluenzae in urethral exudates from men with acute urethritis: a descriptive study of 52 cases. Sex Transm Infect 2016;92:29–31. PMID:26139207 https://doi.org/10.1136/sextrans-2015-052135
Magdaleno-Tapial J, Valenzuela-Oñate C, Giacaman-von der Weth MM, et al. Haemophilus species isolated in urethral exudates as a possible causative agent in acute urethritis: a study of 38 cases. Actas Dermosifiliogr 2019;110:38–42. PMID:30390917 https://doi.org/10.1016/j.adengl.2018.11.011
Abdolrasouli A, Roushan A. Corynebacterium propinquum associated with acute, nongonococcal urethritis. Sex Transm Dis 2013;40:829–31. PMID:24275738 https://doi.org/10.1097/OLQ.0000000000000027
Ongrádi J, Stercz B, Kövesdi V, Nagy K, Chatlynne L. Isolation of Kurthia gibsonii from non-gonorrheal urethritis: implications for the pathomechanism upon surveying the literature. Acta Microbiol Immunol Hung 2014;61:79–87. PMID:24631755 https://doi.org/10.1556/AMicr.61.2014.1.8
Gherardi G, Di Bonaventura G, Pompilio A, Savini V. Corynebacterium glucuronolyticum causing genitourinary tract infection: case report and review of the literature. IDCases 2015;2:56–8. PMID:26793456 https://doi.org/10.1016/j.idcr.2015.03.001
Meštrović T. A microbial game of whack-a-mole: clinical case series of the urethral uncloaking phenomenon caused by Corynebacterium glucuronolyticum in men treated for Chlamydia trachomatis urethritis. Infection 2019;47:121–4. PMID:30168068 https://doi.org/10.1007/s15010-018-1211-8
Frikh M, El Yaagoubi I, Lemnouer A, Elouennass M. Urethritis due to corynebacterium striatum: an emerging germ. Tunis Med 2015;93:43–4. PMID:25955369
Babaeer AA, Nader C, Iacoviello V, Tomera K. Necrotizing urethritis due to Aerococcus urinae. Case Rep Urol 2015;2015:136147. PMID:26171271 https://doi.org/10.1155/2015/136147
Grandolfo M, Vestita M, Bonamonte D, Filoni A. Acute urethritis and balonoposthitis associated to Neisseria elongata. Sex Transm Dis 2016;43:778–9. PMID:27832027 https://doi.org/10.1097/OLQ.0000000000000532
Frølund M, Lidbrink P, Wikström A, Cowan S, Ahrens P, Jensen JS. Urethritis-associated pathogens in urine from men with non-gonococcal urethritis: a case-control study. Acta Derm Venereol 2016;96:689–94. PMID:26658669 https://doi.org/10.2340/00015555-2314
Chambers LC, Morgan JL, Lowens MS, et al. Cross-sectional study of urethral exposures at last sexual episode associated with non-gonococcal urethritis among STD clinic patients. Sex Transm Infect 2019;95:212–8. PMID:30181326 https://doi.org/10.1136/sextrans-2018-053634
Manhart LE, Khosropour CM, Liu C, et al. Bacterial vaginosis-associated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis 2013;40:944–9. PMID:24220356 https://doi.org/10.1097/OLQ.0000000000000054
Ashraf J, Radford AR, Turner A, Subramaniam R. Preliminary experience with instillation of triamcinolone acetonide into the urethra for idiopathic urethritis: a prospective pilot study. J Laparoendosc Adv Surg Tech A 2017;27:1217–21. PMID:29023188 https://doi.org/10.1089/lap.2017.0064
Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram's stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis 2011;38:995–6. PMID:21992973 https://doi.org/10.1097/OLQ.0b013e318225f7c2
Rietmeijer CA, Mettenbrink CJ. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis 2012;39:18–20. PMID:22183839 https://doi.org/10.1097/OLQ.0b013e3182354da3
Geisler WM, Yu S, Hook EW 3rd. Chlamydial and gonococcal infection in men without polymorphonuclear leukocytes on Gram stain: implications for diagnostic approach and management. Sex Transm Dis 2005;32:630–4. PMID:16205305 https://doi.org/10.1097/01.olq.0000175390.45315.a1
Gottesman T, Yossepowitch O, Samra Z, Rosenberg S, Dan M. Prevalence of Mycoplasma genitalium in men with urethritis and in high risk asymptomatic males in Tel Aviv: a prospective study. Int J STD AIDS 2017;28:127–32. PMID:26826161 https://doi.org/10.1177/0956462416630675
Kim HJ, Park JK, Park SC, et al. The prevalence of causative organisms of community-acquired urethritis in an age group at high risk for sexually transmitted infections in Korean soldiers. J R Army Med Corps 2017;163:20–2. PMID:26607860 https://doi.org/10.1136/jramc-2015-000488
Libois A, Hallin M, Crucitti T, Delforge M, De Wit S. Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels, Belgium: an observational, cross-sectional study. PLoS One 2018;13:e0196217. PMID:29698421 https://doi.org/10.1371/journal.pone.0196217
Bachmann LH, Manhart LE, Martin DH, et al. Advances in the understanding and treatment of male urethritis. Clin Infect Dis 2015;61(Suppl 8):S763–9. PMID:26602615 https://doi.org/10.1093/cid/civ755
Samaraweera GR, Garcia K, Druce J, et al. Characteristics of adenovirus urethritis among heterosexual men and men who have sex with men: a review of clinical cases. Sex Transm Infect 2016;92:172–4. PMID:26574571 https://doi.org/10.1136/sextrans-2015-052243
Horner P, Blee K, O'Mahony C, Muir P, Evans C, Radcliffe K; Clinical Effectiveness Group of the British Association for Sexual Health and HIV. 2015 UK National Guideline on the management of non-gonococcal urethritis. Int J STD AIDS 2016;27:85–96. PMID:26002319 https://doi.org/10.1177/0956462415586675
Sarier M, Sepin N, Duman I, et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: which threshold value should be selected? Andrologia 2018;50:e13143. PMID:30238498 https://doi.org/10.1111/and.13143
Sarier M, Kukul E. Classification of non-gonococcal urethritis: a review. Int Urol Nephrol 2019;51:901–7. PMID:30953260 https://doi.org/10.1007/s11255-019-02140-2
Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014;59:193–205. PMID:24729507 https://doi.org/10.1093/cid/ciu220
Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev 2019;1:CD010871. PMID:30682211 https://doi.org/10.1002/14651858.CD010871.pub2
McIver R, Jalocon D, McNulty A, et al. Men who have sex with men with Mycoplasma genitalium-positive nongonococcal urethritis are more likely to have macrolide resistant strains than men with only female partners: a prospective study. Sex Transm Dis 2019;46:513–7. PMID:31295218 https://doi.org/10.1097/OLQ.0000000000001009
Lau A, Bradshaw CS, Lewis D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis 2015;61:1389–99. PMID:26240201 https://doi.org/10.1093/cid/civ644
Horner P. Mycoplasma genitalium nongonococcal urethritis is likely to increase in men who have sex with men who practice unsafe sex: what should we do? Sex Transm Dis 2019;46:518–20. PMID:31295219 https://doi.org/10.1097/OLQ.0000000000001030
Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009;36:478–89. PMID:19617871 https://doi.org/10.1097/OLQ.0b013e3181a2a933
Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007;83:304–9. PMID:17166889 https://doi.org/10.1136/sti.2006.024059
Kissinger PJ, White S, Manhart LE, et al. Azithromycin treatment failure for Chlamydia trachomatis among heterosexual men with nongonococcal urethritis. Sex Transm Dis 2016;43:599–602. PMID:27631353 https://doi.org/10.1097/OLQ.0000000000000489
Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens—a randomized clinical trial. Clin Infect Dis 2011;52:163–70. PMID:21288838 https://doi.org/10.1093/cid/ciq074
Manhart LE, Khosropour CM, Gillespie CW, Lowens MS, Golden MR, Totten PA. O02.3 Treatment outcomes for persistent Mycoplasma genitalium-associated NGU: evidence of moxifloxacin treatment failures. Sex Transm Infect 2013;89(Suppl 1):A29. https://doi.org/10.1136/sextrans-2013-051184.0091
Romano SS, Jensen JS, Lowens MS, et al. Long duration of asymptomatic Mycoplasma genitalium infection after syndromic treatment for nongonococcal urethritis. Clin Infect Dis 2019;69:113–20. PMID:30281079 https://doi.org/10.1093/cid/ciy843
Read TRH, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis 2019;68:554–60. PMID:29873691 https://doi.org/10.1093/cid/ciy477
Dowe G, Smikle M, King SD, Baum M, Chout R, Williams Y. Symptomatic and asymptomatic chlamydial non-gonococcal urethritis in Jamaica: the potential for HIV transmission. Int J STD AIDS 2000;11:187–90. PMID:10726944 https://doi.org/10.1258/0956462001915507
Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis aetiology and case definition: a study in Australian women attending sexually transmitted infection clinics. Sex Transm Infect 2016;92:175–81. PMID:26586777 https://doi.org/10.1136/sextrans-2015-052332
Lusk MJ, Konecny P. Cervicitis: a review. Curr Opin Infect Dis 2008;21:49–55. PMID:18192786
Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis 2007;44(Suppl 3):S102–10. PMID:17342663 https://doi.org/10.1086/511423
Manavi K, Young H, Clutterbuck D. Sensitivity of microscopy for the rapid diagnosis of gonorrhoea in men and women and the role of gonorrhoea serovars. Int J STD AIDS 2003;14:390–4. PMID:12816666 https://doi.org/10.1258/095646203765371277
Lillis RA, Martin DH, Nsuami MJ. Mycoplasma genitalium infections in women attending a sexually transmitted disease clinic in New Orleans. Clin Infect Dis 2019;69:459–65. PMID:30351348 https://doi.org/10.1093/cid/ciy922
Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015;61:418–26. PMID:25900174 https://doi.org/10.1093/cid/civ312
Oliphant J, Azariah S. Cervicitis: limited clinical utility for the detection of Mycoplasma genitalium in a cross-sectional study of women attending a New Zealand sexual health clinic. Sex Health 2013;10:263–7. PMID:23702105 https://doi.org/10.1071/SH12168
Sethi S, Rajkumari N, Dhaliwal L, Roy A. P3.294 Association of Mycoplasma genitalium with cervicitis in North Indian women attending gynecologic clinics. Sex Transm Infect 2013;89(Suppl 1):A240–1. https://doi.org/10.1136/sextrans-2013-051184.0749
Taylor SN, Lensing S, Schwebke J, et al. Prevalence and treatment outcome of cervicitis of unknown etiology. Sex Transm Dis 2013;40:379–85. PMID:23588127 https://doi.org/10.1097/OLQ.0b013e31828bfcb1
Mobley VL, Hobbs MM, Lau K, Weinbaum BS, Getman DK, Seña AC. Mycoplasma genitalium infection in women attending a sexually transmitted infection clinic: diagnostic specimen type, coinfections, and predictors. Sex Transm Dis 2012;39:706–9. PMID:22902666 https://doi.org/10.1097/OLQ.0b013e318255de03
Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006;193:617–24. PMID:16453256 https://doi.org/10.1086/500149
Gaydos C, Maldeis NE, Hardick A, Hardick J, Quinn TC. Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis 2009;36:598–606. PMID:19704398 https://doi.org/10.1097/OLQ.0b013e3181b01948
Clark LR, Atendido M. Group B streptococcal vaginitis in postpubertal adolescent girls. J Adolesc Health 2005;36:437–40. PMID:15837348 https://doi.org/10.1016/j.jadohealth.2004.03.009
Hester EE, Middleman AB. A clinical conundrum: chronic cervicitis. J Pediatr Adolesc Gynecol 2019;32:342–4. PMID:30582974 https://doi.org/10.1016/j.jpag.2018.12.004
Liu L, Cao G, Zhao Z, Zhao F, Huang Y. High bacterial loads of Ureaplasma may be associated with non-specific cervicitis. Scand J Infect Dis 2014;46:637–41. PMID:25017795 https://doi.org/10.3109/00365548.2014.922696
Leli C, Mencacci A, Latino MA, et al. Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: an Italian observational multicentre study. J Microbiol Immunol Infect 2018;51:220–5. PMID:28711440 https://doi.org/10.1016/j.jmii.2017.05.004
Manhart LE. Has the time come to systematically test for Mycoplasma genitalium? Sex Transm Dis 2009;36:607–8. PMID:19734818 https://doi.org/10.1097/OLQ.0b013e3181b9d825
Liu HL, Chen CM, Pai LW, Hwu YJ, Lee HM, Chung YC. Comorbidity profiles among women with postcoital bleeding: a nationwide health insurance database. Arch Gynecol Obstet 2017;295:935–41. PMID:28246983 https://doi.org/10.1007/s00404-017-4327-7
Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 2007;21:755–9. PMID:17413697 https://doi.org/10.1097/QAD.0b013e328012b838
Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008;35:946–59. PMID:18685546 https://doi.org/10.1097/OLQ.0b013e3181812d15
McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001;15:105–10. PMID:11192850 https://doi.org/10.1097/00002030-200101050-00015
Gatski M, Martin DH, Theall K, et al. Mycoplasma genitalium infection among HIV-positive women: prevalence, risk factors and association with vaginal shedding. Int J STD AIDS 2011;22:155–9. PMID:21464453 https://doi.org/10.1258/ijsa.2010.010320
Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS 2010;24:2733–7. PMID:20871388 https://doi.org/10.1097/QAD.0b013e32833f9f43
Kreisel KM, Weston EJ, St Cyr SB, Spicknall IH. Estimates of the prevalence and incidence of chlamydia and gonorrhea among US men and women, 2018. Sex Transm Dis 2021;48:222–31. PMID:33492094 https://doi.org/10.1097/OLQ.0000000000001382
Aghaizu A, Reid F, Kerry S, et al. Frequency and risk factors for incident and redetected Chlamydia trachomatis infection in sexually active, young, multi-ethnic women: a community based cohort study. Sex Transm Infect 2014;90:524–8. PMID:25100744 https://doi.org/10.1136/sextrans-2014-051607
Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in Chlamydia trachomatis infections and related outcomes in a U.S. managed care population. Sex Transm Dis 2012;39:81–8. PMID:22249294 https://doi.org/10.1097/OLQ.0b013e31823e3009
Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis 1996;23:384–91. PMID:8885069 https://doi.org/10.1097/00007435-199609000-00007
Rietmeijer CA, Hopkins E, Geisler WM, Orr DP, Kent CK. Chlamydia trachomatis positivity rates among men tested in selected venues in the United States: a review of the recent literature. Sex Transm Dis 2008;35(Suppl):S8–18. PMID:18449072 https://doi.org/10.1097/OLQ.0b013e31816938ba
Gift TL, Blake DR, Gaydos CA, Marrazzo JM. The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2008;35(Suppl):S51–60. PMID:18520977 https://doi.org/10.1097/OLQ.0b013e3181723dba
Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis 2008;35(Suppl):S66–75. PMID:18830137 https://doi.org/10.1097/OLQ.0b013e31818b64ac
Gopalappa C, Huang YL, Gift TL, Owusu-Edusei K, Taylor M, Gales V. Cost-effectiveness of screening men in Maricopa County jails for chlamydia and gonorrhea to avert infections in women. Sex Transm Dis 2013;40:776–83. PMID:24275727 https://doi.org/10.1097/OLQ.0000000000000023
Masek BJ, Arora N, Quinn N, et al. Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program. J Clin Microbiol 2009;47:1663–7. PMID:19386838 https://doi.org/10.1128/JCM.02387-08
Knox J, Tabrizi SN, Miller P, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis 2002;29:647–54. PMID:12438900 https://doi.org/10.1097/00007435-200211000-00006
Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725–8. PMID:16314767 https://doi.org/10.1097/01.olq.0000190092.59482.96
Doshi JS, Power J, Allen E. Acceptability of chlamydia screening using self-taken vaginal swabs. Int J STD AIDS 2008;19:507–9. PMID:18663033 https://doi.org/10.1258/ijsa.2008.008056
Chernesky MA, Jang D, Portillo E, et al. Self-collected swabs of the urinary meatus diagnose more Chlamydia trachomatis and Neisseria gonorrhoeae infections than first catch urine from men. Sex Transm Infect 2013;89:102–4. PMID:23024224 https://doi.org/10.1136/sextrans-2012-050573
Dize L, Barnes P Jr, Barnes M, et al. Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis 2016;86:131–5. PMID:27497595 https://doi.org/10.1016/j.diagmicrobio.2016.07.018
Berry L, Stanley B. Comparison of self-collected meatal swabs with urine specimens for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men. J Med Microbiol 2017;66:134–6. PMID:28068218 https://doi.org/10.1099/jmm.0.000428
Chernesky M, Freund GG, Hook E 3rd, Leone P, D'Ascoli P, Martens M. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in North American women by testing SurePath liquid-based Pap specimens in APTIMA assays. J Clin Microbiol 2007;45:2434–8. PMID:17581931 https://doi.org/10.1128/JCM.00013-07
Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008;35:637–42. PMID:18520976 https://doi.org/10.1097/OLQ.0b013e31817bdd7e
Mimiaga MJ, Mayer KH, Reisner SL, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis 2008;35:495–8. PMID:18354345 https://doi.org/10.1097/OLQ.0b013e31816471ae
Bachmann LH, Johnson RE, Cheng H, Markowitz LE, Papp JR, Hook EW 3rd. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol 2009;47:902–7. PMID:19193848 https://doi.org/10.1128/JCM.01581-08
Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010;48:1827–32. PMID:20335410 https://doi.org/10.1128/JCM.02398-09
Cosentino LA, Danby CS, Rabe LK, et al. Use of nucleic acid amplification testing for diagnosis of extragenital sexually transmitted infections. J Clin Microbiol 2017;55:2801–7. PMID:28679521 https://doi.org/10.1128/JCM.00616-17
Food and Drug Administration. Microbiology Devices Panel of the Medical Devices Advisory Committee meeting annoucement [Internet]. Silver Spring, MD: US Department of Agriculture, Food and Drug Administration; 2019. https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-8-2019- microbiology-devices-panel-medical-devices-advisory-committee-meeting-announcement#event-materials
Sexton ME, Baker JJ, Nakagawa K, et al. How reliable is self-testing for gonorrhea and chlamydia among men who have sex with men? J Fam Pract 2013;62:70–8. PMID:23405376
Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD. A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol 2016;2016:4386127. Epub May 26, 2016. PMID:27313440 https://doi.org/10.1155/2016/4386127
Rivard KR, Dumkow LE, Draper HM, Brandt KL, Whalen DW, Egwuatu NE. Impact of rapid diagnostic testing for chlamydia and gonorrhea on appropriate antimicrobial utilization in the emergency department. Diagn Microbiol Infect Dis 2017;87:175–9. PMID:27836225 https://doi.org/10.1016/j.diagmicrobio.2016.10.019
Wingrove I, McOwan A, Nwokolo N, Whitlock G. Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation. Sex Transm Infect 2014;90:474. PMID:25118322 https://doi.org/10.1136/sextrans-2014-051580
Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW 3rd. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008;35:119–23. PMID:17898680 https://doi.org/10.1097/OLQ.0b013e318151497d
Dukers-Muijrers NHTM, Wolffs PFG, De Vries H, et al. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: a multicentre observational study (FemCure). Clin Infect Dis 2019;69:1946–54. PMID:30689759 https://doi.org/10.1093/cid/ciz050
Dombrowski JC, Wierzbicki MR, Newman LM, et al. Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial. Clin Infect Dis 2021;ciab153. PMID:33606009 https://doi.org/10.1093/cid/ciab153
Dukers-Muijrers NH, Schachter J, van Liere GA, Wolffs PF, Hoebe CJ. What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion. BMC Infect Dis 2015;15:533. PMID:26576538 https://doi.org/10.1186/s12879-015-1280-6
Marcus JL, Kohn RP, Barry PM, Philip SS, Bernstein KT. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra. Sex Transm Dis 2011;38:372–3. PMID:21183864 https://doi.org/10.1097/OLQ.0b013e3182029008
Manavi K, Hettiarachchi N, Hodson J. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. Int J STD AIDS 2016;27:1303–8. PMID:26511655 https://doi.org/10.1177/0956462415614723
Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in Chlamydia-infected individuals. Clin Infect Dis 2015;60:1585–6. PMID:25648236 https://doi.org/10.1093/cid/civ079
Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis 2012;55:82–8. PMID:22431798 https://doi.org/10.1093/cid/cis291
Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011;8:69–73. PMID:21371385 https://doi.org/10.1071/SH10030
Lazenby GB, Korte JE, Tillman S, Brown FK, Soper DE. A recommendation for timing of repeat Chlamydia trachomatis test following infection and treatment in pregnant and nonpregnant women. Int J STD AIDS 2017;28:902–9. PMID:27864473 https://doi.org/10.1177/0956462416680438
Dunne EF, Chapin JB, Rietmeijer CA, et al. Rate and predictors of repeat Chlamydia trachomatis infection among men. Sex Transm Dis 2008;35(Suppl):S40–4. PMID:18520978 https://doi.org/10.1097/OLQ.0b013e31817247b2
Kjaer HO, Dimcevski G, Hoff G, Olesen F, Ostergaard L. Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 weeks' prospective follow up study. Sex Transm Infect 2000;76:169–72. PMID:10961191 https://doi.org/10.1136/sti.76.3.169
Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001;28:117–23. PMID:11234786 https://doi.org/10.1097/00007435-200102000-00011
Kapil R, Press CG, Hwang ML, Brown L, Geisler WM. Investigating the epidemiology of repeat Chlamydia trachomatis detection after treatment by using C. trachomatis OmpA genotyping. J Clin Microbiol 2015;53:546–9. PMID:25472488 https://doi.org/10.1128/JCM.02483-14
Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001;184:1352–6. PMID:11408852 https://doi.org/10.1067/mob.2001.115050
Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol 2001;9:197–202. PMID:11916175 https://doi.org/10.1155/S1064744901000321
Rahangdale L, Guerry S, Bauer HM, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis 2006;33:106–10. PMID:16432482 https://doi.org/10.1097/01.olq.0000187226.32145.ea
Aggarwal A, Spitzer RF, Caccia N, Stephens D, Johnstone J, Allen L. Repeat screening for sexually transmitted infection in adolescent obstetric patients. J Obstet Gynaecol Can 2010;32:956–61. PMID:21176304 https://doi.org/10.1016/S1701-2163(16)34683-7
Phillips Campbell R, Kintner J, Whittimore J, Schoborg RV. Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice. Microbes Infect 2012;14:1177–85. PMID:22943883 https://doi.org/10.1016/j.micinf.2012.07.017
Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010;201(Suppl 2):S88–95. PMID:20470046 https://doi.org/10.1086/652394
Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis. PLoS One 2019;14:e0212212. PMID:30779772 https://doi.org/10.1371/journal.pone.0212212
Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ 2020;368:m331. Erratum in: BMJ 2020;368:m766. PMID:32075790 https://doi.org/10.1136/bmj.m331
Mallah N, Tohidinik HR, Etminan M, Figueiras A, Takkouche B. Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis. Drug Saf 2020;43:211–21. PMID:31721138 https://doi.org/10.1007/s40264-019-00884-5
Hammerschlag MR, Cummings C, Roblin PM, Williams TH, Delke I. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med 1989;320:769–72. PMID:2922026 https://doi.org/10.1056/NEJM198903233201204
Zikic A, Schünemann H, Wi T, Lincetto O, Broutet N, Santesso N. Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis. J Pediatric Infect Dis Soc 2018;7:e107–15. PMID:30007329 https://doi.org/10.1093/jpids/piy060
Hammerschlag MR, Chandler JW, Alexander ER, English M, Koutsky L. Longitudinal studies on chlamydial infections in the first year of life. Pediatr Infect Dis 1982;1:395–401. PMID:7163029 https://doi.org/10.1097/00006454-198211000-00007
Beem MO, Saxon E, Tipple MA. Treatment of chlamydial pneumonia of infancy. Pediatrics 1979;63:198–203. PMID:440807
Brownell AD, Shapiro RA, Hammerschlag MR. Caution is required when using non-Food and Drug Administration-cleared assays to diagnose sexually transmitted infections in children. J Pediatr 2019;206:280–2. PMID:30466791 https://doi.org/10.1016/j.jpeds.2018.10.038
Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis 2021;48:208–14. PMID:33492089 https://doi.org/10.1097/OLQ.0000000000001355
Lunny C, Taylor D, Hoang L, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One 2015;10:e0132776. PMID:26168051 https://doi.org/10.1371/journal.pone.0132776
Schick V, Van Der Pol B, Dodge B, Baldwin A, Fortenberry JD. A mixed methods approach to assess the likelihood of testing for STI using self-collected samples among behaviourally bisexual women. Sex Transm Infect 2015;91:329–33. PMID:25637328 https://doi.org/10.1136/sextrans-2014-051842
Mustanski B, Feinstein BA, Madkins K, Sullivan P, Swann G. Prevalence and risk factors for rectal and urethral sexually transmitted infections from self-collected samples among young men who have sex with men participating in the Keep It Up! 2.0 randomized controlled trial. Sex Transm Dis 2017;44:483–8. PMID:28703727 https://doi.org/10.1097/OLQ.0000000000000636
Salow KR, Cohen AC, Bristow CC, McGrath MR, Klausner JD. Comparing mail-in self-collected specimens sent via United States Postal Service versus clinic-collected specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in extra-genital sites. PLoS One 2017;12:e0189515. PMID:29240781 https://doi.org/10.1371/journal.pone.0189515
Drake C, Barenfanger J, Lawhorn J, Verhulst S. Comparison of Easy-Flow Copan Liquid Stuart's and Starplex Swab transport systems for recovery of fastidious aerobic bacteria. J Clin Microbiol 2005;43:1301–3. PMID:15750099 https://doi.org/10.1128/JCM.43.3.1301-1303.2005
Wade JJ, Graver MA. Survival of six auxotypes of Neisseria gonorrhoeae in transport media. J Clin Microbiol 2003;41:1720–1. PMID:12682168 https://doi.org/10.1128/JCM.41.4.1720-1721.2003
Arbique JC, Forward KR, LeBlanc J. Evaluation of four commercial transport media for the survival of Neisseria gonorrhoeae. Diagn Microbiol Infect Dis 2000;36:163–8. PMID:10729658 https://doi.org/10.1016/S0732-8893(99)00134-0
Hook EW 3rd, Kirkcaldy RD. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. Clin Infect Dis 2018;67:1294–9. PMID:29659749 https://doi.org/10.1093/cid/ciy271
Unemo M, Shafer WM. Future treatment of gonorrhea—novel emerging drugs are essential and in progress? Expert Opin Emerg Drugs 2015;20:357–60. PMID:25907334 https://doi.org/10.1517/14728214.2015.1039981
Sánchez-Busó L, Golparian D, Corander J, et al. The impact of antimicrobials on gonococcal evolution. Nat Microbiol 2019;4:1941–50. PMID:31358980 https://doi.org/10.1038/s41564-019-0501-y
Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA 1990;264:1413–7. PMID:2144026 https://doi.org/10.1001/jama.1990.03450110059027
CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007;56:332–6. PMID:17431378
CDC. Sexually transmitted disease surveillance 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2014. https://www.cdc.gov/std/stats/archive/Surv2013-Print.pdf
Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001;45:3603–6. PMID:11709349 https://doi.org/10.1128/AAC.45.12.3603-3606.2001
Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275–7. PMID:17953118
Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52:3564–7. PMID:18663018 https://doi.org/10.1128/AAC.00198-08
Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003;9:35–9. PMID:12673405 https://doi.org/10.1007/s10156-002-0204-8
Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16:19792. PMID:21329645
Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15:19721. PMID:21144442 https://doi.org/10.2807/ese.15.47.19721-en
Unemo M, Golparian D, Potočnik M, Jeverica S. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012;17:20200. PMID:22748003
Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:19833. PMID:21492528
Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011;22:296–7. PMID:21571983 https://doi.org/10.1258/ijsa.2009.009191
Lewis DA, Sriruttan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013;68:1267–70. PMID:23416957 https://doi.org/10.1093/jac/dkt034
Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis 2009;48:1237–43. PMID:19323630 https://doi.org/10.1086/597586
Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013;309:163–70. PMID:23299608 https://doi.org/10.1001/jama.2012.176575
Chen MY, Stevens K, Tideman R, et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013;68:1445–7. PMID:23390207 https://doi.org/10.1093/jac/dkt017
Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58:683–7. PMID:19369534 https://doi.org/10.1099/jmm.0.007641-0
Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011;17:148–9. PMID:21192886 https://doi.org/10.3201/eid1701.100397
Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56:1273– 80. PMID:22155830 https://doi.org/10.1128/AAC.05760-11
CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590–4. PMID:22874837
Wind CM, de Vries E, Schim van der Loeff MF, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin. Clin Infect Dis 2017;65:37–45. PMID:28510723 https://doi.org/10.1093/cid/cix249
Kong FYS, Horner P, Unemo M, Hocking JS. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother 2019;74:1157–66. PMID:30649333 https://doi.org/10.1093/jac/dky548
CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–6. PMID:33332296 https://doi.org/10.15585/mmwr.mm6950a6
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Clinical and Laboratory Standards Institute document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
CDC. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. https://www.cdc.gov/std/treatment/Ceph-R-ResponsePlanJuly30-2012.pdf
Poncin T, Merimeche M, Braille A, et al. Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019. Euro Surveill 2019;24:1900528. PMID:31507264 https://doi.org/10.2807/1560-7917.ES.2019.24.36.1900528
Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT; Gonococcus Antimicrobial Resistance Surveillance Working Group. First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. Enferm Infecc Microbiol Clin 2012;30:218–9. PMID:22244992 https://doi.org/10.1016/j.eimc.2011.11.010
Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012;67:1858–60. PMID:22566592 https://doi.org/10.1093/jac/dks162
Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018;23:1800323. PMID:29991383 https://doi.org/10.2807/1560-7917.ES.2018.23.27.1800323
Fifer H, Hughes G, Whiley D, Lahra MM. Lessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia. Lancet Infect Dis 2020;20:276–8. PMID:32112753 https://doi.org/10.1016/S1473-3099(20)30055-4
Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141–8. PMID:20693173 https://doi.org/10.1093/jac/dkq289
Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob Agents Chemother 2019;63:e01644-18. PMID:30642924 https://doi.org/10.1128/AAC.01644-18
Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004;16(Suppl 3):1–19. PMID:15334827 https://doi.org/10.1080/1120009X.2004.11782371
Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl 1):S47–65. PMID:7795109 https://doi.org/10.1093/clinids/20. Supplement_1.S47
Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. Methods Mol Biol 2019;1997:37–58. PMID:31119616 https://doi.org/10.1007/978-1-4939-9496-0_3
Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014;59:1083–91. PMID:25031289 https://doi.org/10.1093/cid/ciu521
Ross JDC, Brittain C, Cole M, et al.; G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet 2019;393:2511–20. PMID:31056291 https://doi.org/10.1016/S0140-6736(18)32817-4
Singh V, Bala M, Bhargava A, Kakran M, Bhatnagar R. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS One 2018;13:e0193678. PMID:29509792 https://doi.org/10.1371/journal.pone.0193678
Mayer KH, Klausner JD, Handsfield HH. Intersecting epidemics and educable moments: sexually transmitted disease risk assessment and screening in men who have sex with men. Sex Transm Dis 2001;28:464–7. PMID:11473219 https://doi.org/10.1097/00007435-200108000-00008
Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of pharyngeal gonorrhoea. Int J STD AIDS 2008;19:656–9. PMID:18824615 https://doi.org/10.1258/ijsa.2008.008127
Johnson Jones ML, Chapin-Bardales J, Bizune D, et al.; National HIV Behavioral Surveillance Sexually Transmitted Infection Study Group. Extragenital chlamydia and gonorrhea among community venue-attending men who have sex with men—five cities, United States, 2017. MMWR Morb Mortal Wkly Rep 2019;68:321–5. PMID:30973847 https://doi.org/10.15585/mmwr.mm6814a1
Chow EP, Williamson DA, Fortune R, et al. Prevalence of genital and oropharyngeal chlamydia and gonorrhoea among female sex workers in Melbourne, Australia, 2015–2017: need for oropharyngeal testing. Sex Transm Infect 2019;95:398–401. PMID:31113904 https://doi.org/10.1136/sextrans-2018-053957
Cornelisse VJ, Williamson D, Zhang L, et al. Evidence for a new paradigm of gonorrhoea transmission: cross-sectional analysis of Neisseria gonorrhoeae infections by anatomical site in both partners in 60 male couples. Sex Transm Infect 2019;95:437–42. PMID:30996106 https://doi.org/10.1136/sextrans-2018-053803
Kissinger PJ, Reilly K, Taylor SN, Leichliter JS, Rosenthal S, Martin DH. Early repeat Chlamydia trachomatis and Neisseria gonorrhoeae infections among heterosexual men. Sex Transm Dis 2009;36:498–500. PMID:19617870 https://doi.org/10.1097/OLQ.0b013e3181a4d147
Berenger BM, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta, Canada, 2018. Emerg Infect Dis 2019;25:1660–7. PMID:31407661 https://doi.org/10.3201/eid2509.190407
Rob F, Klubalová B, Nyčová E, Hercogová J, Unemo M. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect 2020;26:207–12. PMID:31419483 https://doi.org/10.1016/j.cmi.2019.08.004
Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010;126:994–9. PMID:20888035 https://doi.org/10.1016/j.jaci.2010.06.052
American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee opinion No. 717: sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol 2017;130:e150–2. PMID:28832488 https://doi.org/10.1097/AOG.0000000000002300
Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989;107:511–4. PMID:2496606 https://doi.org/10.1016/0002-9394(89)90495-9
Bleich AT, Sheffield JS, Wendel GD Jr, Sigman A, Cunningham FG. Disseminated gonococcal infection in women. Obstet Gynecol 2012;119:597–602. PMID:22353959 https://doi.org/10.1097/AOG.0b013e318244eda9
Belkacem A, Caumes E, Ouanich J, et al.; Working Group FRA-DGI. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009–2011. Sex Transm Infect 2013;89:613–5. PMID:23920397 https://doi.org/10.1136/sextrans-2013-051119
Birrell JM, Gunathilake M, Singleton S, Williams S, Krause V. Characteristics and impact of disseminated gonococcal infection in the "Top End" of Australia. Am J Trop Med Hyg 2019;101:753–60. PMID:31392956 https://doi.org/10.4269/ajtmh.19-0288
Crew PE, Abara WE, McCulley L, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis 2019;69:596–600. PMID:30418536 https://doi.org/10.1093/cid/ciy958
Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Ocular prophylaxis for gonococcal ophthalmia neonatorum: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2019;321:394–8. PMID:30694327 https://doi.org/10.1001/jama.2018.21367
Kreisel K, Weston E, Braxton J, Llata E, Torrone E. Keeping an eye on chlamydia and gonorrhea conjunctivitis in infants in the United States, 2010–2015. Sex Transm Dis 2017;44:356–8. PMID:28499285 https://doi.org/10.1097/OLQ.0000000000000613
Scott WJ, Eck CD. Povidone-iodine and ophthalmia neonatorum. Ophthalmology 2012;119:653–4. PMID:22385492 https://doi.org/10.1016/j.ophtha.2011.11.037
David M, Rumelt S, Weintraub Z. Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology 2011;118:1454–8. PMID:21439642 https://doi.org/10.1016/j.ophtha.2010.12.003
Binenbaum G, Bruno CJ, Forbes BJ, et al. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns. J Pediatr 2010;156:320–1. PMID:20105641 https://doi.org/10.1016/j.jpeds.2009.11.060
Nathawad R, Mendez H, Ahmad A, et al. Severe ocular reactions after neonatal ocular prophylaxis with gentamicin ophthalmic ointment. Pediatr Infect Dis J 2011;30:175–6. PMID:20885334 https://doi.org/10.1097/INF.0b013e3181f6c2e5
Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev 2011;24:498–514. PMID:21734246 https://doi.org/10.1128/CMR.00006-11
Seña AC, Lensing S, Rompalo A, et al. Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis 2012;206:357–65. PMID:22615318 https://doi.org/10.1093/infdis/jis356
Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Hobbs MM. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. Sex Transm Dis 2008;35:250–4. PMID:18490867 https://doi.org/10.1097/OLQ.0b013e31815abac6
Mena L, Wang X, Mroczkowski TF, Martin DH. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis 2002;35:1167–73. PMID:12410476 https://doi.org/10.1086/343829
Falk L. The overall agreement of proposed definitions of mucopurulent cervicitis in women at high risk of Chlamydia infection. Acta Derm Venereol 2010;90:506–11. PMID:20814628 https://doi.org/10.2340/00015555-0924
Anagrius C, Loré B, Jensen JS. Mycoplasma genitalium: prevalence, clinical significance, and transmission. Sex Transm Infect 2005;81:458–62. PMID:16326846 https://doi.org/10.1136/sti.2004.012062
Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003;187:650–7. PMID:12599082 https://doi.org/10.1086/367992
Lusk MJ, Konecny P, Naing ZW, Garden FL, Cumming RG, Rawlinson WD. Mycoplasma genitalium is associated with cervicitis and HIV infection in an urban Australian STI clinic population. Sex Transm Infect 2011;87:107–9. PMID:21071566 https://doi.org/10.1136/sti.2010.045138
Dehon PM, McGowin CL. The immunopathogenesis of Mycoplasma genitalium infections in women: a narrative review. Sex Transm Dis 2017;44:428–32. PMID:28608793 https://doi.org/10.1097/OLQ.0000000000000621
Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. BJOG 2010;117:361–4. PMID:20015303 https://doi.org/10.1111/j.1471-0528.2009.02455.x
Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol 2012;206:476.e1–8. PMID:22483084 https://doi.org/10.1016/j.ajog.2012.02.036
Taylor BD, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Darville T. Risk factors for Mycoplasma genitalium endometritis and incident infection: a secondary data analysis of the T cell Response Against Chlamydia (TRAC) Study. Sex Transm Infect 2018;94:414–20. PMID:29563165 https://doi.org/10.1136/sextrans-2017-053376
Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect 2005;81:463–6. PMID:16326847 https://doi.org/10.1136/sti.2005.015701
Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol 2006;2006:30184. PMID:17485798 https://doi.org/10.1155/IDOG/2006/30184
Short VL, Totten PA, Ness RB, Astete SG, Kelsey SF, Haggerty CL. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009;48:41–7. PMID:19025498 https://doi.org/10.1086/594123
Simms I, Eastick K, Mallinson H, et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis, and pelvic inflammatory disease. Sex Transm Infect 2003;79:154–6. PMID:12690141 https://doi.org/10.1136/sti.79.2.154
Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the "New Chlamydia?" A community-based prospective cohort study. Clin Infect Dis 2010;51:1160–6. PMID:20942656 https://doi.org/10.1086/656739
Wiesenfeld HC, Hillier SL, Meyn L, et al. Mycoplasma genitalium—is it a pathogen in acute pelvic inflammatory disease (PID)? Sex Transm Infect 2013;89(Suppl 1):A34. https://doi.org/10.1136/sextrans-2013-051184.0106
Møller BR, Taylor-Robinson D, Furr PM, Freundt EA. Acute upper genital-tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Exp Pathol 1985;66:417–26. PMID:4027175
Wiesenfeld HC, Manhart LE. Mycoplasma genitalium in women: current knowledge and research priorities for this recently emerged pathogen. J Infect Dis 2017;216(suppl_2):S389–95.
Clausen HF, Fedder J, Drasbek M, et al. Serological investigation of Mycoplasma genitalium in infertile women. Hum Reprod 2001;16:1866–74. PMID:11527890 https://doi.org/10.1093/humrep/16.9.1866
Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility—a prospective study. Fertil Steril 2008;90:513–20. PMID:17548070 https://doi.org/10.1016/j.fertnstert.2006.12.056
Idahl A, Jurstrand M, Olofsson JI, Fredlund H. Mycoplasma genitalium serum antibodies in infertile couples and fertile women. Sex Transm Infect 2015;91:589–91. PMID:25921018 https://doi.org/10.1136/sextrans-2015-052011
Edwards RK, Ferguson RJ, Reyes L, Brown M, Theriaque DW, Duff P. Assessing the relationship between preterm delivery and various microorganisms recovered from the lower genital tract. J Matern Fetal Neonatal Med 2006;19:357–63. PMID:16801313 https://doi.org/10.1080/00207170600712071
Vandepitte J, Bukenya J, Hughes P, et al. Clinical characteristics associated with Mycoplasma genitalium infection among women at high risk of HIV and other STI in Uganda. Sex Transm Dis 2012;39:487–91. PMID:22592838 https://doi.org/10.1097/OLQ.0b013e31824b1cf3
Rowlands S, Danielewski JA, Tabrizi SN, Walker SP, Garland SM. Microbial invasion of the amniotic cavity in midtrimester pregnancies using molecular microbiology. Am J Obstet Gynecol 2017;217:71. e1–5. PMID:28268197 https://doi.org/10.1016/j.ajog.2017.02.051
Jurstrand M, Jensen JS, Magnuson A, Kamwendo F, Fredlund H. A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy. Sex Transm Infect 2007;83:319–23. PMID:17475688 https://doi.org/10.1136/sti.2007.024752
Ashshi AM, Batwa SA, Kutbi SY, Malibary FA, Batwa M, Refaat B. Prevalence of 7 sexually transmitted organisms by multiplex real-time PCR in Fallopian tube specimens collected from Saudi women with and without ectopic pregnancy. BMC Infect Dis 2015;15:569. PMID:26666587 https://doi.org/10.1186/s12879-015-1313-1
Bissessor M, Tabrizi SN, Bradshaw CS, et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin Microbiol Infect 2016;22:260–5. PMID:26686807 https://doi.org/10.1016/j.cmi.2015.11.016
Ong JJ, Aung E, Read TRH, et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex Transm Dis 2018;45:522–6. PMID:29465653 https://doi.org/10.1097/OLQ.0000000000000793
Read TRH, Murray GL, Danielewski JA, et al. symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis 2019;25:719–27. PMID:30882306 https://doi.org/10.3201/eid2504.181258
Cina M, Baumann L, Egli-Gany D, et al. Mycoplasma genitalium incidence, persistence, concordance between partners and progression: systematic review and meta-analysis. Sex Transm Infect 2019;95:328–35. PMID:31055469 https://doi.org/10.1136/sextrans-2018-053823
Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect 2018;94:255–62. PMID:29440466 https://doi.org/10.1136/sextrans-2017-053384
Vandepitte J, Weiss HA, Bukenya J, et al. Association between Mycoplasma genitalium infection and HIV acquisition among female sex workers in Uganda: evidence from a nested case-control study. Sex Transm Infect 2014;90:545–9. PMID:24687129 https://doi.org/10.1136/sextrans-2013-051467
Ferré VM, Ekouevi DK, Gbeasor-Komlanvi FA, et al. Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. Clin Microbiol Infect 2019;25:1560. e1–7. PMID:31051265 https://doi.org/10.1016/j.cmi.2019.04.015
Mavedzenge SN, Van Der Pol B, Weiss HA, et al. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS 2012;26:617–24. PMID:22210630 https://doi.org/10.1097/QAD.0b013e32834ff690
Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis 2014;59:24–30. PMID:24729494 https://doi.org/10.1093/cid/ciu217
Wold C, Sorthe J, Hartgill U, Olsen AO, Moghaddam A, Reinton N. Identification of macrolide-resistant Mycoplasma genitalium using real-time PCR. J Eur Acad Dermatol Venereol 2015;29:1616–20. PMID:25622510 https://doi.org/10.1111/jdv.12963
Gesink D, Racey CS, Seah C, et al. Mycoplasma genitalium in Toronto, Ont: estimates of prevalence and macrolide resistance. Can Fam Physician 2016;62:e96–101. PMID:27331225
Kristiansen GQ, Lisby JG, Schønning K. 5' nuclease genotyping assay for identification of macrolide-resistant Mycoplasma genitalium in clinical specimens. J Clin Microbiol 2016;54:1593–7. PMID:27053672 https://doi.org/10.1128/JCM.00012-16
Braam JF, Slotboom B, Van Marm S, et al. High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands. J Antimicrob Chemother 2017;72:1529–30. PMID:28158595 https://doi.org/10.1093/jac/dkw584
Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis 2017;23:809–12. PMID:28418319 https://doi.org/10.3201/eid2305.161745
Chernesky MA, Jang D, Martin I, et al.; Canadian MG Study Group. Mycoplasma genitalium antibiotic resistance-mediating mutations in Canadian women with or without Chlamydia trachomatis infection. Sex Transm Dis 2017;44:433–5. PMID:28608794 https://doi.org/10.1097/OLQ.0000000000000617
Barberá MJ, Fernández-Huerta M, Jensen JS, Caballero E, Andreu A. Mycoplasma genitalium macrolide and fluoroquinolone resistance: prevalence and risk factors among a 2013–2014 cohort of patients in Barcelona, Spain. Sex Transm Dis 2017;44:457–62. PMID:28703723 https://doi.org/10.1097/OLQ.0000000000000631
Sweeney EL, Trembizki E, Bletchly C, et al. Levels of Mycoplasma genitalium antimicrobial resistance differ by both region and gender in the state of Queensland, Australia: implications for treatment guidelines. J Clin Microbiol 2019;57:e01555-18. PMID:30602443 https://doi.org/10.1128/JCM.01555-18
Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis 2015;60:1228–36. PMID:25537875 https://doi.org/10.1093/cid/ciu1162
Piñeiro L, Idigoras P, de la Caba I, López-Olaizola M, Cilla G. Guided antibiotic therapy for Mycoplasma genitalium infections: analysis of mutations associated with resistance to macrolides and fluoroquinolones [Spanish]. Enferm Infecc Microbiol Clin 2019;37:394–7. PMID:30396750
Dionne-Odom J, Geisler WM, Aaron KJ, et al. High prevalence of multidrug-resistant Mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama. Clin Infect Dis 2018;66:796–8. PMID:29028993 https://doi.org/10.1093/cid/cix853
Pitt R, Fifer H, Woodford N, Alexander S. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England. Sex Transm Infect 2018;94:9–13. PMID:28717051 https://doi.org/10.1136/sextrans-2017-053164
Unemo M, Salado-Rasmussen K, Hansen M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect 2018;24:533–9. PMID:28923377 https://doi.org/10.1016/j.cmi.2017.09.006
Anderson T, Coughlan E, Werno A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand. J Clin Microbiol 2017;55:3242–8. PMID:28878004 https://doi.org/10.1128/JCM.01087-17
Shimada Y, Deguchi T, Nakane K, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance. Int J Antimicrob Agents 2010;36:255–8. PMID:20580532 https://doi.org/10.1016/j.ijantimicag.2010.05.011
Muller EE, Mahlangu MP, Lewis DA, Kularatne RS. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007–2014. BMC Infect Dis 2019;19:148. PMID:30760230 https://doi.org/10.1186/s12879-019-3797-6
Chambers LC, Jensen JS, Morgan JL, et al. Lack of association between the S83I ParC mutation in Mycoplasma genitalium and treatment outcomes among men who have sex with men with nongonococcal urethritis. Sex Transm Dis 2019;46:805–9. PMID:31259853 https://doi.org/10.1097/OLQ.0000000000001035
Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline- 2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020;71:1461–8. PMID:31629365 https://doi.org/10.1093/cid/ciz1031
Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int J STD AIDS 2017;28:1106–14. PMID:28118803 https://doi.org/10.1177/0956462416688562
Mondeja BA, Couri J, Rodríguez NM, Blanco O, Fernández C, Jensen JS. Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem. BMC Infect Dis 2018;18:601. PMID:30486786 https://doi.org/10.1186/s12879-018-3523-9
Glaser AM, Geisler WM, Ratliff AE, Xiao L, Waites KB, Gaisa M. Two cases of multidrug-resistant genitourinary Mycoplasma genitalium infection successfully eradicated with minocycline. Int J STD AIDS 2019;30:512–4. PMID:30999836 https://doi.org/10.1177/0956462418816757
Xiao L, Waites KB, Van Der Pol B, Aaron KJ, Hook EW 3rd, Geisler WM. Mycoplasma genitalium infections with macrolide and fluoroquinolone resistance-associated mutations in heterosexual African American couples in Alabama. Sex Transm Dis 2019;46:18–24. PMID:29979336 https://doi.org/10.1097/OLQ.0000000000000891
Slifirski JB, Vodstrcil LA, Fairley CK, et al. Mycoplasma genitalium infection in adults reporting sexual contact with infected partners, Australia, 2008–2016. Emerg Infect Dis 2017;23:1826–33. PMID:29047422 https://doi.org/10.3201/eid2311.170998
Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004;291:1368–79. PMID:15026404 https://doi.org/10.1001/jama.291.11.1368
Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005;106:1013–23. PMID:16260520 https://doi.org/10.1097/01.AOG.0000183594.45524.d2
Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis 2010;202:1907–15. PMID:21067371 https://doi.org/10.1086/657320
Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis 2019;46:304–11. PMID:30624309 https://doi.org/10.1097/OLQ.0000000000000972
Kenyon CR, Buyze J, Klebanoff M, Brotman RM. Association between bacterial vaginosis and partner concurrency: a longitudinal study. Sex Transm Infect 2018;94:75–7. PMID:27645157 https://doi.org/10.1136/sextrans-2016-052652
Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004;191:1898–906. PMID:15592270 https://doi.org/10.1016/j.ajog.2004.06.089
Ness RB, Soper DE, Holley RL, et al.; PID Evaluation and Clinical Health (PEACH) Study Investigators. Douching and endometritis: results from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis 2001;28:240–5. PMID:11318257 https://doi.org/10.1097/00007435-200104000-00010
Gondwe T, Ness R, Totten PA, et al. Novel bacterial vaginosis-associated organisms mediate the relationship between vaginal douching and pelvic inflammatory disease. Sex Transm Infect 2020;96:439–44. PMID:31810995 https://doi.org/10.1136/sextrans-2019-054191
Abbai NS, Reddy T, Ramjee G. Prevalent bacterial vaginosis infection—a risk factor for incident sexually transmitted infections in women in Durban, South Africa. Int J STD AIDS 2016;27:1283–8. PMID:26538552 https://doi.org/10.1177/0956462415616038
Morris BJ, Hankins CA, Banerjee J, et al. Does male circumcision reduce women's risk of sexually transmitted infections, cervical cancer, and associated conditions? Front Public Health 2019;7:4. PMID:30766863 https://doi.org/10.3389/fpubh.2019.00004
Srinivasan S, Liu C, Mitchell CM, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One 2010;5:e10197. PMID:20419168 https://doi.org/10.1371/journal.pone.0010197
Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012;4:132ra52. PMID:22553250 https://doi.org/10.1126/scitranslmed.3003605
Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 2009;200:1662–70. PMID:19863439 https://doi.org/10.1086/648092
Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota. Am J Obstet Gynecol 2018;218:622.e1–10. PMID:29505773 https://doi.org/10.1016/j.ajog.2018.02.017
Vodstrcil LA, Plummer ME, Fairley CK, et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Sci Rep 2019;9:3555. PMID:30837554 https://doi.org/10.1038/s41598-019-39879-8
Brooks JP, Edwards DJ, Blithe DL, et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception 2017;95:405–13. PMID:27913230 https://doi.org/10.1016/j.contraception.2016.11.006
Moore KR, Harmon QE, Baird DD. Serum 25-hydroxyvitamin D and risk of self-reported bacterial vaginosis in a prospective cohort study of young African American women. J Womens Health (Larchmt) 2018;27:1278–84. PMID:29897832 https://doi.org/10.1089/jwh.2017.6804
Lokken EM, Balkus JE, Kiarie J, et al. Association of recent bacterial vaginosis with acquisition of Mycoplasma genitalium. Am J Epidemiol 2017;186:194–201. PMID:28472225 https://doi.org/10.1093/aje/kwx043
Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol 2019;221:9–18.e8. PMID:30550767 https://doi.org/10.1016/j.ajog.2018.12.011
Abbai NS, Nyirenda M, Naidoo S, Ramjee G. Prevalent herpes simplex virus-2 increases the risk of incident bacterial vaginosis in women from South Africa. AIDS Behav 2018;22:2172–80. PMID:28956191 https://doi.org/10.1007/s10461-017-1924-1
Laxmi U, Agrawal S, Raghunandan C, Randhawa VS, Saili A. Association of bacterial vaginosis with adverse fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study. J Matern Fetal Neonatal Med 2012;25:64–7. PMID:21557693 https://doi.org/10.3109/14767058.2011.565390
Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2006;33:747–52. PMID:16691155 https://doi.org/10.1097/01.olq.0000218869.52753.c7
Nelson DB, Hanlon A, Hassan S, et al. Preterm labor and bacterial vaginosis-associated bacteria among urban women. J Perinat Med 2009;37:130–4. PMID:18999913 https://doi.org/10.1515/JPM.2009.026
Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008;22:1493–501. PMID:18614873 https://doi.org/10.1097/QAD.0b013e3283021a37
Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 2017;46:29–37. PMID:28087240 https://doi.org/10.1016/j.immuni.2016.12.013
McClelland RS, Lingappa JR, Srinivasan S, et al. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis 2018;18:554– 64. PMID:29396006 https://doi.org/10.1016/S1473-3099(18)30058-6
Johnston C, Magaret A, Srinivasan S, et al. P239 Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study. Sex Transm Infect 2019;95(Suppl 1):A148.
Zozaya M, Ferris MJ, Siren JD, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome 2016;4:16. PMID:27090518 https://doi.org/10.1186/s40168-016-0161-6
Liu CM, Hungate BA, Tobian AA, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. MBio 2015;6:e00589. PMID:26081632 https://doi.org/10.1128/mBio.00589-15
Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis 2012;39:822–30. PMID:23007709 https://doi.org/10.1097/OLQ.0b013e3182631d89
Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22. PMID:6600371 https://doi.org/10.1016/0002-9343(83)91112-9
Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297–301. PMID:1706728 https://doi.org/10.1128/JCM.29.2.297-301.1991
Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal Gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996;88:573–6. PMID:8841221 https://doi.org/10.1016/0029-7844(96)00233-5
Coleman JS, Gaydos CA. Molecular diagnosis of bacterial vaginosis: an update. J Clin Microbiol 2018;56:e00342-18. PMID:29769280 https://doi.org/10.1128/JCM.00342-18
Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. J Clin Microbiol 2003;41:1925–8. PMID:12734228 https://doi.org/10.1128/JCM.41.5.1925-1928.2003
Bradshaw CS, Morton AN, Garland SM, Horvath LB, Kuzevska I, Fairley CK. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol 2005;43:1304–8. PMID:15750100 https://doi.org/10.1128/JCM.43.3.1304-1308.2005
West B, Morison L, Schim van der Loeff M, et al. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in The Gambia. Sex Transm Dis 2003;30:483–9. PMID:12782948 https://doi.org/10.1097/00007435-200306000-00003
Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007;45:3270–6. PMID:17687006 https://doi.org/10.1128/JCM.01272-07
Gaydos CA, Beqaj S, Schwebke JR, et al. Clinical validation of a test for the diagnosis of vaginitis. Obstet Gynecol 2017;130:181–9. PMID:28594779 https://doi.org/10.1097/AOG.0000000000002090
Cartwright CP, Lembke BD, Ramachandran K, et al. Development and validation of a semiquantitative, multitarget PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol 2012;50:2321–9. PMID:22535982 https://doi.org/10.1128/JCM.00506-12
Hilbert DW, Smith WL, Chadwick SG, et al. Development and validation of a highly accurate quantitative real-time PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol 2016;54:1017–24. Erratum in: J Clin Microbiol 2016;54:1930. PMID:26818677 https://doi.org/10.1128/JCM.03104-15
Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007;196:517. e1–6. PMID:17547876 https://doi.org/10.1016/j.ajog.2007.02.048
Fjeld H, Raknes G. Is combining metronidazole and alcohol really hazardous? [Norwegian]. Tidsskr Nor Laegeforen 2014;134:1661–3. PMID:25223673 https://doi.org/10.4045/tidsskr.14.0081
Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2017;130:379–86. PMID:28697102 https://doi.org/10.1097/AOG.0000000000002135
Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol 2017;217:678.e1–9. Erratum in: Am J Obstet Gynecol 2018;219;110. PMID:28867602 https://doi.org/10.1016/j.ajog.2017.08.017
Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis. J Womens Health (Larchmt) 2018;27:492–7. PMID:29323627 https://doi.org/10.1089/jwh.2017.6500
Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2007;110:302–9. PMID:17666604 https://doi.org/10.1097/01.AOG.0000275282.60506.3d
Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341–6. PMID:11565074 https://doi.org/10.1086/323034
Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis 2015;19:129–34. PMID:24983350 https://doi.org/10.1097/LGT.0000000000000062
Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm Dis 2015;42:376–81. PMID:26222750 https://doi.org/10.1097/OLQ.0000000000000300
Faro S, Skokos CK; Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol 2005;13:155–60. PMID:16240515 https://doi.org/10.1080/10647440500148321
Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis 2019;68:803–9. PMID:30184181 https://doi.org/10.1093/cid/ciy554
Antonio MA, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic Lactobacillus crispatus CTV- 05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis 2009;199:1506–13. PMID:19331578 https://doi.org/10.1086/598686
Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009;(4):CD006289. PMID:19821358 https://doi.org/10.1002/14651858.CD006289.pub2
Abad CL, Safdar N. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections—a systematic review. J Chemother 2009;21:243–52. PMID:19567343 https://doi.org/10.1179/joc.2009.21.3.243
Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Mi c robiol Infect 2009;15:67–74. PMID:19046169 https://doi.org/10.1111/j.1469-0691.2008.02112.x
Hemmerling A, Harrison W, Schroeder A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis 2010;37:745–50. PMID:20644497 https://doi.org/10.1097/OLQ.0b013e3181e50026
Bunge KE, Beigi RH, Meyn LA, Hillier SL. The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis. Sex Transm Dis 2009;36:711–3. PMID:19652628 https://doi.org/10.1097/OLQ.0b013e3181af6cfd
Aguin T, Akins RA, Sobel JD. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis 2014;41:290–1. PMID:24722380 https://doi.org/10.1097/OLQ.0000000000000123
Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006;194:1283–9. PMID:16647911 https://doi.org/10.1016/j.ajog.2005.11.041
Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009;36:732–4. PMID:19704395 https://doi.org/10.1097/OLQ.0b013e3181b08456
McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008;197:1361–8. PMID:18444793 https://doi.org/10.1086/587490
Schwebke J, Carter B, Waldbaum A, et al. Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis. Am J Obstet Gynecol 2019;221:672–3. https://doi.org/10.1016/j.ajog.2019.10.087
Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020;382:1906–15. PMID:32402161 https://doi.org/10.1056/NEJMoa1915254
Turner AN, Carr Reese P, Fields KS, et al. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet Gynecol 2014;211:479. e1–13. PMID:24949544 https://doi.org/10.1016/j.ajog.2014.06.023
Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: acceptability, tolerability and impact on the genital microbiota of couples—a pilot study. PLoS One 2018;13:e0190199. PMID:29293559 https://doi.org/10.1371/journal.pone.0190199
Schwebke JR, Lensing SY, Lee J, et al. Treatment of male sexual partners of women with bacterial vaginosis (BV): a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2020; Epub December 31, 2020. PMID: 33383580
Koumans EH, Kendrick JS; CDC Bacterial Vaginosis Working Group. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis 2001;28:292–7. PMID:11354269 https://doi.org/10.1097/00007435-200105000-00011
Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333:1732–6. PMID:7491136 https://doi.org/10.1056/NEJM199512283332603
Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994;171:345–9. PMID:8059811 https://doi.org/10.1016/S0002-9378(94)70033-8
Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003;102:527–34. PMID:12962937
Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004;104:114–9. PMID:15229009 https://doi.org/10.1097/01.AOG.0000130068.21566.4e
Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525–9. PMID:7856680 https://doi.org/10.1016/0002-9378(95)90567-7
Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348–52. PMID:8355932
Sheehy O, Santos F, Ferreira E, Berard A. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf 2015;10:170–9. PMID:25986038 https://doi.org/10.2174/1574886310021505151 24548
Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde- Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;205:177–90. PMID:22071048 https://doi.org/10.1016/j.ajog.2011.03.047
Odendaal HJ, Popov I, Schoeman J, Smith M, Grové D. Preterm labour—is bacterial vaginosis involved? S Afr Med J 2002;92:231–4. PMID:12040953
Carey JC, Klebanoff MA, Hauth JC, et al.; National Institute of Child Health and Human Development Network of Maternal- Fetal Medicine Units. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534–40. PMID:10684911 https://doi.org/10.1056/NEJM200002243420802
Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol 1999;106:652–7. PMID:10428520 https://doi.org/10.1111/j.1471-0528.1999.tb08363.x
McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997;104:1391–7. PMID:9422018 https://doi.org/10.1111/j.1471-0528.1997.tb11009.x
Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003;361:983–8. PMID:12660054 https://doi.org/10.1016/S0140-6736(03)12823-1
Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 2018;392:2171–9. PMID:30322724 https://doi.org/10.1016/S0140-6736(18)31617-9
Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. Obstet Gynecol 1981;57:48–50. PMID:7454176
Passmore CM, McElnay JC, Rainey EA, D'Arcy PF. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol 1988;26:45–51. PMID:3203060 https://doi.org/10.1111/j.1365-2125.1988.tb03362.x
United Kingdom National Health Service. Medicines Q&A: metronidazole—is it safe to use with breastfeeding? [Internet]. London, England: United Kingdom National Health Service, UK Medicines Information; 2012. https://studylib.net/doc/7341270/metronidazole-in-breastfeeding-mothers
Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656–63. PMID:11576584 https://doi.org/10.1097/00006250-200110000-00023
Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 2019;97:548–562P. PMID:31384073 https://doi.org/10.2471/BLT.18.228486
Hoots BE, Peterman TA, Torrone EA, Weinstock H, Meites E, Bolan GA. A Trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis 2013;40:113–6. PMID:23321992 https://doi.org/10.1097/OLQ.0b013e31827c08c3
Flagg EW, Meites E, Phillips C, Papp J, Torrone EA. Prevalence of Trichomonas vaginalis among civilian, noninstitutionalized male and female population aged 14 to 59 years: United States, 2013 to 2016. Sex Transm Dis 2019;46:e93–6. PMID:31517807 https://doi.org/10.1097/OLQ.0000000000001013
Daugherty M, Glynn K, Byler T. Prevalence of Trichomonas vaginalis infection among US males, 2013–2016. Clin Infect Dis 2019;68:460–5. PMID:29893808 https://doi.org/10.1093/cid/ciy499c
Alcaide ML, Feaster DJ, Duan R, et al. The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect 2016;92:58–62. PMID:26071390 https://doi.org/10.1136/sextrans-2015-052010
Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis 2014;59:834–41. PMID:24928292 https://doi.org/10.1093/cid/ciu446
Meites E, Llata E, Braxton J, et al. Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis 2013;40:865–9. PMID:24113409 https://doi.org/10.1097/OLQ.0000000000000038
Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012;50:2601–8. PMID:22622447 https://doi.org/10.1128/JCM.00748-12
Shuter J, Bell D, Graham D, Holbrook KA, Bellin EY. Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis 1998;25:303–7. PMID:9662764 https://doi.org/10.1097/00007435-199807000-00006
Sosman JM, MacGowan RJ, Margolis AD, et al.; Project START Study Group. Screening for sexually transmitted diseases and hepatitis in 18–29-year-old men recently released from prison: feasibility and acceptability. Int J STD AIDS 2005;16:117–22. PMID:15825246 https://doi.org/10.1258/0956462053057594
Rogers SM, Turner CF, Hobbs M, et al. Epidemiology of undiagnosed trichomoniasis in a probability sample of urban young adults. PLoS One 2014;9:e90548. PMID:24626058 https://doi.org/10.1371/journal.pone.0090548
Mayer KH, Bush T, Henry K, et al.; SUN Investigators. Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. Sex Transm Dis 2012;39:1–7. PMID:22183836 https://doi.org/10.1097/OLQ.0b013e31823b1922
Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007;44:13–22. PMID:17143809 https://doi.org/10.1086/511144
Kelley CF, Rosenberg ES, O'Hara BM, Sanchez T, del Rio C, Sullivan PS. Prevalence of urethral Trichomonas vaginalis in black and white men who have sex with men. Sex Transm Dis 2012;39:739. PMID:22902674 https://doi.org/10.1097/OLQ.0b013e318264248b
Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis 2007;45:1319–26. PMID:17968828 https://doi.org/10.1086/522532
Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM Jr; RESPECT-2 Study Group. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis 2009;48:259–60. PMID:19113985 https://doi.org/10.1086/595706
Wølner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA 1989;261:571–6. PMID:2783346 https://doi.org/10.1001/jama.1989.03420040109029
Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009;200:42.e1–7. PMID:18976733 https://doi.org/10.1016/j.ajog.2008.07.069
Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex Transm Infect 2009;85:116–20. PMID:19074928 https://doi.org/10.1136/sti.2008.032334
Tsai CS, Shepherd BE, Vermund SH. Does douching increase risk for sexually transmitted infections? A prospective study in high-risk adolescents. Am J Obstet Gynecol 2009;200:38.e1–8. PMID:18667177 https://doi.org/10.1016/j.ajog.2008.06.026
Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis 2014;41:369–76. PMID:24825333 https://doi.org/10.1097/OLQ.0000000000000134
Yang S, Zhao W, Wang H, Wang Y, Li J, Wu X. Trichomonas vaginalis infection-associated risk of cervical cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018;228:166–73. PMID:29980111 https://doi.org/10.1016/j.ejogrb.2018.06.031
Najafi A, Chaechi Nosrati MR, Ghasemi E, et al. Is there association between Trichomonas vaginalis infection and prostate cancer risk?: A systematic review and meta-analysis. Microb Pathog 2019;137:103752. PMID:31539586 https://doi.org/10.1016/j.micpath.2019.103752
Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001;183:1017–22. PMID:11237825 https://doi.org/10.1086/319287
Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009;36:11–6. PMID:19008776 https://doi.org/10.1097/OLQ.0b013e318186decf
Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984;150:965–72. PMID:6391179 https://doi.org/10.1016/0002-9378(84)90392-2
Cotch MF, Pastorek JG 2nd, Nugent RP, et al.; The Vaginal Infections and Prematurity Study Group. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 1997;24:353–60. PMID:9243743 https://doi.org/10.1097/00007435-199707000-00008
Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002;34:519–22. PMID:11797180 https://doi.org/10.1086/338399
Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005–2006. Sex Transm Dis 2008;35:797–800. PMID:18607317 https://doi.org/10.1097/OLQ.0b013e318177ec39
Hollman D, Coupey SM, Fox AS, Herold BC. Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs. J Pediatr Adolesc Gynecol 2010;23:312–6. PMID:20493735 https://doi.org/10.1016/j.jpag.2010.03.004
Roth AM, Williams JA, Ly R, et al. Changing sexually transmitted infection screening protocol will result in improved case finding for Trichomonas vaginalis among high-risk female populations. Sex Transm Dis 2011;38:398–400. PMID:21217417 https://doi.org/10.1097/OLQ.0b013e318203e3ce
Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect 2013;89:434–8. PMID:23633669 https://doi.org/10.1136/sextrans-2013-051057
Kingston MA, Bansal D, Carlin EM. 'Shelf life' of Trichomonas vaginalis. Int J STD AIDS 2003;14:28–9. PMID:12590789 https://doi.org/10.1258/095646203321043228
Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011;49:4106–11. PMID:21940475 https://doi.org/10.1128/JCM.01291-11
Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007;45:194–8. PMID:17578778 https://doi.org/10.1086/518851
Van Der Pol B, Williams JA, Taylor SN, et al. Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. J Clin Microbiol 2014;52:885–9. PMID:24391200 https://doi.org/10.1128/JCM.02966-13
Van Der Pol B, Williams JA, Fuller D, Taylor SN, Hook EW 3rd. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. J Clin Microbiol 2016;55:155–64. PMID:27795343 https://doi.org/10.1128/JCM.01766-16
Schwebke JR, Gaydos CA, Davis T, et al. Clinical evaluation of the Cepheid Xpert TV Assay for detection of Trichomonas vaginalis with prospectively collected specimens from men and women. J Clin Microbiol 2018;56:e01091-17. PMID:29167292 https://doi.org/10.1128/JCM.01091-17
Campbell L, Woods V, Lloyd T, Elsayed S, Church DL. Evaluation of the OSOM Trichomonas rapid test versus wet preparation examination for detection of Trichomonas vaginalis vaginitis in specimens from women with a low prevalence of infection. J Clin Microbiol 2008;46:3467–9. PMID:18685008 https://doi.org/10.1128/JCM.00671-08
Huppert JS, Hesse E, Kim G, et al. Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians. Sex Transm Infect 2010;86:514–9. PMID:20595142 https://doi.org/10.1136/sti.2009.042168
Sheele JM, Crandall CJ, Arko BL, et al. The OSOM® Trichomonas Test is unable to accurately diagnose Trichomonas vaginalis from urine in men. Am J Emerg Med 2019;37:1002–3. PMID:30361151 https://doi.org/10.1016/j.ajem.2018.10.022
Gaydos CA, Schwebke J, Dombrowski J, et al. Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women. Expert Rev Mol Diagn 2017;17:303–6. PMID:28092466 https://doi.org/10.1080/14737159.2017.1282823
Gaydos CA, Hobbs M, Marrazzo J, et al. Rapid diagnosis of Trichomonas vaginalis by testing vaginal swabs in an isothermal helicase-dependent AmpliVue Assay. Sex Transm Dis 2016;43:369–73. PMID:27196258 https://doi.org/10.1097/OLQ.0000000000000447
Patil MJ, Nagamoti JM, Metgud SC. Diagnosis of Trichomonas vaginalis from vaginal specimens by wet mount microscopy, In Pouch TV culture system, and PCR. J Glob Infect Dis 2012;4:22–5. PMID:22529623 https://doi.org/10.4103/0974-777X.93756
Lawing LF, Hedges SR, Schwebke JR. Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 2000;38:3585–8. PMID:11015368 https://doi.org/10.1128/JCM.38.10.3585-3588.2000
Mohamed OA, Cohen CR, Kungu D, et al. Urine proves a poor specimen for culture of Trichomonas vaginalis in women. Sex Transm Infect 2001;77:78–9. PMID:11158705 https://doi.org/10.1136/sti.77.1.78
Rivers CA, Muzny CA, Schwebke JR. Diagnostic rates differ on the basis of the number of read days with the use of the InPouch culture system for Trichomonas vaginalis screening. J Clin Microbiol 2013;51:3875–6. PMID:24006006 https://doi.org/10.1128/JCM.02006-13
Audisio T, Pigini T, de Riutort SV, et al. Validity of the Papanicolaou smear in the diagnosis of Candida spp., Trichomonas vaginalis, and bacterial vaginosis. J Low Genit Tract Dis 2001;5:223–5. PMID:17050980
Loo SK, Tang WY, Lo KK. Clinical significance of Trichomonas vaginalis detected in Papanicolaou smear: a survey in female Social Hygiene Clinic. Hong Kong Med J 2009;15:90–3. PMID:19342733
Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis 2017;44:29–34. PMID:27898571 https://doi.org/10.1097/OLQ.0000000000000537
Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010;55:565–71. PMID:21423852 https://doi.org/10.1097/QAI.0b013e3181eda955
Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis 1975;51:51–3. PMID:1092424 https://doi.org/10.1136/sti.51.1.51
Viitanen J, Haataja H, Männistö PT. Concentrations of metronidazole and tinidazole in male genital tissues. Antimicrob Agents Chemother 1985;28:812–4. PMID:4083864 https://doi.org/10.1128/AAC.28.6.812
Gabriel G, Robertson E, Thin RN. Single dose treatment of trichomoniasis. J Int Med Res 1982;10:129–30. PMID:7067925 https://doi.org/10.1177/030006058201000212
Mati JK, Wallace RJ. The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth. East Afr Med J 1974;51:883–8. PMID:4616829
Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res 1977;5:438–41. PMID:590601
Apte VV, Packard RS. Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study. Drugs 1978;15(Suppl 1):43–8. PMID:657995 https://doi.org/10.2165/00003495-197800151-00009
O-Prasertsawat P, Jetsawangsri T. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 1992;19:295–7. PMID:1411848 https://doi.org/10.1097/00007435-199209000-00011
Kawamura N. Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men. Br J Vener Dis 1978;54:81–3. PMID:305809 https://doi.org/10.1136/sti.54.2.81
Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;(2):CD000218. PMID:12804391
Cu-Uvin S, Ko H, Jamieson DJ, et al.; HIV Epidemiology Research Study (HERS) Group. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002;34:1406–11. PMID:11981738 https://doi.org/10.1086/340264
Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006;50:4209–10. PMID:17000740 https://doi.org/10.1128/AAC.00814-06
Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192:2039–44. PMID:16288365 https://doi.org/10.1086/498217
Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis 2012;18:939–43. PMID:22608054 https://doi.org/10.3201/eid1806.111590
Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003;47:1407–9. PMID:12654679 https://doi.org/10.1128/AAC.47.4.1407-1409.2003
Muzny CA, Mena L, Lillis RA, et al. A comparison of 2 g single-dose versus 7-day 500 mg twice daily metronidazole for the treatment trichomoniasis in women by selected clinical factors. Am J Obstet Gynecol 2019;221:669. https://doi.org/10.1016/j.ajog.2019.10.079
Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341–6. PMID:11565074 https://doi.org/10.1086/323034
Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis 2011;38:962–3. PMID:21934573 https://doi.org/10.1097/OLQ.0b013e31822037e4
Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health 2012;9:389–91. PMID:22877600 https://doi.org/10.1071/SH11114
Aggarwal A, Shier RM. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can 2008;30:55–8. PMID:18198069 https://doi.org/10.1016/S1701-2163(16)32714-1
Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis 2007;34:813–4. PMID:17551415 https://doi.org/10.1097/NMD.0b013e31802f5d9a
Seña AC, Bachmann LH, Hobbs MM. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther 2014;12:673–85. PMID:24555561 https://doi.org/10.1586/14787210.2014.887440
Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008;198:370.e1–7. PMID:18221927 https://doi.org/10.1016/j.ajog.2007.10.795
Gendelman SR, Pien LC, Gutta RC, Abouhassan SR. Modified oral metronidazole desensitization protocol. Allergy Rhinol (Providence) 2014;5:66–9. PMID:24612959 https://doi.org/10.2500/ar.2014.5.0080
Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998;26:986–8. PMID:9564487 https://doi.org/10.1086/513951
Klebanoff MA, Carey JC, Hauth JC, et al.; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487–93. PMID:11519502 https://doi.org/10.1056/NEJMoa003329
Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. S Afr Med J 2010;100:58–64. PMID:20429491
Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997;44:179–82. PMID:9278206 https://doi.org/10.1046/j.1365-2125.1997.00660.x
Gülmezoglu AM. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev 2002;(3):CD000220. PMID:12137609
Goldenberg RL, Mwatha A, Read JS, et al.; Hptn024 Team. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006;194:650–61. PMID:16522393 https://doi.org/10.1016/j.ajog.2006.01.004
Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J. Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Womens Health (Larchmt) 2009;18:493–7. PMID:19361316 https://doi.org/10.1089/jwh.2008.0964
Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg 2008;78:17–9. PMID:18187779 https://doi.org/10.4269/ajtmh.2008.78.17
Trintis J, Epie N, Boss R, Riedel S. Neonatal Trichomonas vaginalis infection: a case report and review of literature. Int J STD AIDS 2010;21:606–7. PMID:20975098 https://doi.org/10.1258/ijsa.2010.010174
Miller M, Liao Y, Wagner M, Korves C. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex Transm Dis 2008;35:696–702. PMID:18418289 https://doi.org/10.1097/OLQ.0b013e31816b1fb8
Anderson BL, Firnhaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis 2012;39:638–42. PMID:22797689 https://doi.org/10.1097/OLQ.0b013e31825725ad
Masese LN, Graham SM, Gitau R, et al. A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy. BMC Infect Dis 2011;11:307. PMID:22047086 https://doi.org/10.1186/1471-2334-11-307
Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis 2013;40:499–505. PMID:23677023 https://doi.org/10.1097/OLQ.0b013e31828fce34
Gumbo FZ, Duri K, Kandawasvika GQ, et al. Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting. J Perinatol 2010;30:717–23. PMID:20336078 https://doi.org/10.1038/jp.2010.31
Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441–58. PMID:19361301 https://doi.org/10.1086/598327
Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009;64:354–6. PMID:19501794 https://doi.org/10.1016/j.diagmicrobio.2009.03.021
Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012;120:1407–14. PMID:23168767 https://doi.org/10.1097/AOG.0b013e31827307b2
Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis 2018;18:e339–47. PMID:30078662 https://doi.org/10.1016/S1473-3099(18)30103-8
Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance antifungal therapy. J Low Genit Tract Dis 2018;22:382–6. PMID:29975334 https://doi.org/10.1097/LGT.0000000000000413
Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by non-albicans Candida species: new insights. Curr Infect Dis Rep 2010;12:465–70. PMID:21308556 https://doi.org/10.1007/s11908-010-0137-9
Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297–300. PMID:14634557 https://doi.org/10.1067/S0002-9378(03)00726-9
Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016;315:58–67. PMID:26746458 https://doi.org/10.1001/jama.2015.17844
Bérard A, Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ 2019;191:E179–87. PMID:30782643 https://doi.org/10.1503/cmaj.180963
Ohmit SE, Sobel JD, Schuman P, et al.; HIV Epidemiology Research Study (HERS) Group. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003;188:118–27. PMID:12825180 https://doi.org/10.1086/375746
Duerr A, Heilig CM, Meikle SF, et al.; HER Study Group. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. Obstet Gynecol 2003;101:548–56. PMID:12636961 https://doi.org/10.1097/00006250-200303000-00022
Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001;33:1069–75. PMID:11528582 https://doi.org/10.1086/322641
Darville T; Pelvic Inflammatory Disease Workshop Proceedings Committee. Pelvic inflammatory disease: identifying research gaps— proceedings of a workshop sponsored by Department of Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseases, November 3–4, 2011. Sex Transm Dis 2013;40:761–7. PMID:24275724 https://doi.org/10.1097/OLQ.0000000000000028
Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005;32:400–5. PMID:15976596 https://doi.org/10.1097/01.olq.0000154508.26532.6a
Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 2012;120:37–43. PMID:22678036 https://doi.org/10.1097/AOG.0b013e31825a6bc9
Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37. PMID:12015517 https://doi.org/10.1067/mob.2002.121625
Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med 2012;30:1114–7. PMID:22030186 https://doi.org/10.1016/j.ajem.2011.07.014
Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease. Clin Infect Dis 2021;72:1181–9. PMID:32052831 https://doi.org/10.1093/cid/ciaa101
Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005;162:585–90. PMID:16093289 https://doi.org/10.1093/aje/kwi243
Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362–6. PMID:8614421 https://doi.org/10.1056/NEJM199605233342103
Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (Prevention of Pelvic Infection) trial. BMJ 2010;340:c1642. PMID:20378636 https://doi.org/10.1136/bmj. c1642
Peipert JF, Ness RB, Blume J, et al.; Pelvic Inflammatory Disease Evaluation and Clinical Health Study Investigators. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol 2001;184:856–64. PMID:11303192 https://doi.org/10.1067/mob.2001.113847
Gaitán H, Angel E, Diaz R, Parada A, Sanchez L, Vargas C. Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease. Infect Dis Obstet Gynecol 2002;10:171–80. PMID:12648310 https://doi.org/10.1155/S1064744902000194
Vicetti Miguel RD, Chivukula M, Krishnamurti U, et al. Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research. Pathol Res Pract 2011;207:680–5. PMID:21996319 https://doi.org/10.1016/j. prp.2011.08.007
Jacobson L, Weström L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostic value of routine laparoscopy. Am J Obstet Gynecol 1969;105:1088–98. PMID:4242830 https://doi.org/10.1016/0002-9378(69)90132-X
Sellors J, Mahony J, Goldsmith C, et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol 1991;164:113–20. PMID:1824740 https://doi.org/10.1016/0002-9378(91)90639-9
Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol 1995;102:407–14. PMID:7612536 https://doi.org/10.1111/j.1471-0528.1995.tb11294.x
Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011;2011:753037. PMID:21822367 https://doi.org/10.1155/2011/753037
Sweet RL. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011;2011:561909. PMID:22228985 https://doi.org/10.1155/2011/561909
Smith KJ, Ness RB, Wiesenfeld HC, Roberts MS. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis 2007;34:960–6. PMID:18077847 https://doi.org/10.1097/01.olq.0000225321.61049.13
Petrina MAB, Cosentino LA, Wiesenfeld HC, Darville T, Hillier SL. Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. Anaerobe 2019;56:61–5. PMID:30753898 https://doi.org/10.1016/j.anaerobe.2019.02.005
Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003;188:141–8. PMID:12548208 https://doi.org/10.1067/mob.2003.87
Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect 2016;92:441–6. PMID:26825087 https://doi.org/10.1136/sextrans-2015-052285
Ness RB, Randall H, Richter HE, et al.; Pelvic Inflammatory Disease Evaluation and Clinical Health Study Investigators. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004;94:1327–9. PMID:15284036 https://doi.org/10.2105/AJPH.94.8.1327
McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994;83:998–1004. PMID:8190448 https://doi.org/10.1097/00006250-199406000-00020
Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003;31:45–54. PMID:12635534 https://doi.org/10.1177/147323000303100108
Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009;20:690–5. PMID:19815913 https://doi.org/10.1258/ijsa.2008.008495
Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010;21:195–7. PMID:20215625 https://doi.org/10.1258/ijsa.2009.009374
Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010;117:1475–84. PMID:20716255 https://doi.org/10.1111/j.1471-0528.2010.02687.x
Korn AP. Pelvic inflammatory disease in women infected with HIV. AIDS Patient Care STDS 1998;12:431–4. PMID:11361990 https://doi.org/10.1089/apc.1998.12.431
Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000;95:525–34. PMID:10725484
Bukusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999;181:1374–81. PMID:10601915 https://doi.org/10.1016/S0002-9378(99)70378-9
Mugo NR, Kiehlbauch JA, Nguti R, et al. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol 2006;107:807–12. PMID:16582116 https://doi.org/10.1097/01.AOG.0000207597.70524.e8
Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013–9. PMID:11041414 https://doi.org/10.1016/S0140-6736(00)02699-4
Viberga I, Odlind V, Lazdane G, Kroica J, Berglund L, Olofsson S. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol 2005;13:183–90. PMID:16338777 https://doi.org/10.1155/2005/376830
Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception 2017;95:17–39. PMID:27771475 https://doi.org/10.1016/j. contraception.2016.10.006
Chen MJ, Kim CR, Whitehouse KC, Berry-Bibee E, Gaffield ME. Development, updates, and future directions of the World Health Organization Selected Practice Recommendations for Contraceptive Use. Int J Gynaecol Obstet 2017;136:113–9. PMID:28099730 https://doi.org/10.1002/ijgo.12064
Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception 2013;87:655–60. PMID:23040135 https://doi.org/10.1016/j. contraception.2012.08.011
Louette A, Krahn J, Caine V, Ha S, Lau TTY, Singh AE. Treatment of acute epididymitis: a systematic review and discussion of the implications for treatment based on etiology. Sex Transm Dis 2018;45:e104–8. PMID:30044339 https://doi.org/10.1097/OLQ.0000000000000901
Pilatz A, Hossain H, Kaiser R, et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol 2015;68:428–35. PMID:25542628 https://doi.org/10.1016/j.eururo.2014.12.005
Hongo H, Kikuchi E, Matsumoto K, et al. Novel algorithm for management of acute epididymitis. Int J Urol 2017;24:82–7. PMID:27714879 https://doi.org/10.1111/iju.13236
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17–27. PMID:15183049 https://doi.org/10.1016/j.virol.2004.03.033
Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158–71. PMID:10905528 https://doi.org/10.1093/oxfordjournals.aje.a010166
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014;41:660–4. PMID:25299412 https://doi.org/10.1097/OLQ.0000000000000193
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204. PMID:15830458 https://doi.org/10.1016/S1470-2045(05)70086-3
Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers—United States, 2012–2016. MMWR Morb Mortal Wkly Rep 2019;68:724–8. PMID:31437140 https://doi.org/10.15585/mmwr.mm6833a3
Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012;30:6016–9. PMID:22867718 https://doi.org/10.1016/j.vaccine.2012.07.056
Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013;208:385–93. PMID:23785124 https://doi.org/10.1093/infdis/jit192
Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013;103:1428–35. PMID:23763409 https://doi.org/10.2105/AJPH.2012.301182
McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health 2019;65:715–22. PMID:31515134 https://doi.org/10.1016/j.jadohealth.2019.07.003
Drolet M, Bénard É, Pérez N, et al.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394:497–509. PMID:31255301 https://doi.org/10.1016/S0140-6736(19)30298-3
Mayhew A, Mullins TL, Ding L, et al. Risk perceptions and subsequent sexual behaviors after HPV vaccination in adolescents. Pediatrics 2014;133:404–11. PMID:24488747 https://doi.org/10.1542/peds.2013-2822
Brouwer AF, Delinger RL, Eisenberg MC, et al. HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health 2019;19:821. PMID:31238911 https://doi.org/10.1186/s12889-019-7134-1
Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805–14. PMID:19199546 https://doi.org/10.1086/597071
Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health 2018;108:112–9. PMID:29161070 https://doi.org/10.2105/AJPH.2017.304119
Hariri S, Schuler MS, Naleway AL, et al. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. Am J Epidemiol 2018;187:298–305. PMID:28641366 https://doi.org/10.1093/aje/kwx253
Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Hum Vaccin Immunother 2016;12:1357–62. PMID:27217191 https://doi.org/10.1080/216 45515.2016.1172754
Swedish KA, Goldstone SE. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One 2014;9:e93393. PMID:24714693 https://doi.org/10.1371/journal.pone.0093393
Sandø N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women—an ecological study. Acta Derm Venereol 2014;94:288–92. PMID:24150529 https://doi.org/10.2340/00015555-1721
Herweijer E, Ploner A, Sparén P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine 2018;36:1917–20. PMID:29523448 https://doi.org/10.1016/j.vaccine.2018.02.097
Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One 2014;9:e105967. PMID:25180698 https://doi.org/10.1371/journal.pone.0105967
Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect 2017;93:125–8. PMID:27365492 https://doi.org/10.1136/sextrans-2016-052626
Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2015;91:214–9. PMID:25305210 https://doi.org/10.1136/sextrans-2014-051813
Petrosky EY, Liu G, Hariri S, Markowitz LE. Human papillomavirus vaccination and age at first sexual activity, National Health and Nutrition Examination Survey. Clin Pediatr (Phila) 2017;56:363–70. PMID:27609513 https://doi.org/10.1177/0009922816660541
Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008;35:346–51. PMID:18360317 https://doi.org/10.1097/OLQ.0b013e31815ea8d1
Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol 2011;2011:806105. PMID:21876641 https://doi.org/10.1155/2011/806105
Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 2008;33:74–6. PMID:17979992
Domingues E, Chaney KC, Scharf MJ, Wiss K. Imiquimod reactivation of lichen planus. Cutis 2012;89:276–7, 283. PMID:22838091
Patel U, Mark NM, Machler BC, Levine VJ. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011;164:670–2. PMID:21062268 https://doi.org/10.1111/j.1365-2133.2010.10124.x
Kumar B, Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation. Sex Transm Infect 2011;87:432. PMID:21606474 https://doi.org/10.1136/sextrans-2011-050025
Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008;158:1329–38. PMID:18363746 https://doi.org/10.1111/j.1365-2133.2008.08520.x
Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol 2007;21:1404–12. PMID:17958849 https://doi.org/10.1111/j.1468-3083.2007.02441.x
Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008;111:1371–9. PMID:18515521 https://doi.org/10.1097/AOG.0b013e3181719b60
National Institute for Occupational Safety and Health. Control of smoke from laser/electric surgical procedures. Washington, DC: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 1996. https://www.cdc.gov/niosh/docs/hazardcontrol/pdfs/hc11.pdf?id=10.26616/NIOSHPUB96128
Filley CM, Graff-Richard NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology 1982;32:308–11. PMID:7199647 https://doi.org/10.1212/WNL.32.3.308
Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg 1990;71:191–3. PMID:2375521 https://doi.org/10.1213/00000539-199008000-00013
Karol MD, Conner CS, Watanabe AS, Murphrey KJ. Podophyllum: suspected teratogenicity from topical application. Clin Toxicol 1980;16:283–6. PMID:7398215 https://doi.org/10.3109/15563658008989950
Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003;101:645–52. PMID:12681865
Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS 2008;22:1213–9. PMID:18525267 https://doi.org/10.1097/QAD.0b013e3283021aa3
Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002;29:427–35. PMID:12172526 https://doi.org/10.1097/00007435-200208000-00001
De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002;29:121–5. PMID:11875372 https://doi.org/10.1097/00007435-200203000-00001
Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002;359:108–13. PMID:11809252 https://doi.org/10.1016/S0140-6736(02)07368-3
Schlecht HP, Fugelso DK, Murphy RK, et al. Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis 2010;51:107–10. PMID:20482370 https://doi.org/10.1086/653426
Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol 2013;37:53–60. PMID:23026935 https://doi.org/10.1097/PAS.0b013e318263cda6
Massad LS, Xie X, Darragh T, et al.; Women's Interagency HIV Study Collaborative Study Group. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol 2011;118:831–9. PMID:21934446 https://doi.org/10.1097/AOG.0b013e31821a0f4d
Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl 5):F12–23. PMID:23199955 https://doi.org/10.1016/j.vaccine.2012.07.055
Darragh TM, Colgan TJ, Cox JT, et al.; Members of LAST Project Work Groups. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136:1266–97. PMID:22742517 https://doi.org/10.5858/arpa.LGT200570
Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 168 Summary: Cervical cancer screening and prevention. Obstet Gynecol 2016;128:923–5. PMID:27661643 https://doi.org/10.1097/AOG.0000000000001699
Perkins RB, Guido RL, Saraiya M, et al. Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016–2020. J Womens Health (Larchmt) 2021;30:5–13. PMID:33464997 https://doi.org/10.1089/jwh.2020.8918
Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA 2018;320:706–14. PMID:30140882 https://doi.org/10.1001/jama.2017.19872
Sawaya GF, Sanstead E, Alarid-Escudero F, et al. Estimated quality of life and economic outcomes associated with 12 cervical cancer screening strategies: a cost-effectiveness analysis. JAMA Intern Med 2019;179:867–78. PMID:31081851 https://doi.org/10.1001/jamainternmed.2019.0299
Saslow D, Solomon D, Lawson HW, et al.; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72. PMID:22422631 https://doi.org/10.3322/caac.21139
Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 131: Screening for cervical cancer. Obstet Gynecol 2012;120:1222–38. PMID:23090560 https://doi.org/10.1097/AOG.0b013e318277c92a
Meyerson BE, Sayegh MA, Davis A, et al. Cervical cancer screening in a sexually transmitted disease clinic: screening adoption experiences from a midwestern clinic. Am J Public Health 2015;105(Suppl 2):e8–14. PMID:25689199 https://doi.org/10.2105/AJPH.2014.302272
Perkins RB, Guido RS, Castle PE, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31. PMID:32243307 https://doi.org/10.1097/LGT.0000000000000525
Saraiya M, Lee NC, Blackman D, Smith MJ, Morrow B, McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol 2001;98:269–78. PMID:11506844
Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA 2004;291:2990–3. PMID:15213211 https://doi.org/10.1001/jama.291.24.2990
Stokes-Lampard H, Wilson S, Waddell C, Ryan A, Holder R, Kehoe S. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG 2006;113:1354–65. PMID:17081187 https://doi.org/10.1111/j.1471-0528.2006.01099.x
Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:133–9. PMID:17573762 https://doi.org/10.1111/j.1365-2303.2007.00464.x
Daley E, Perrin K, Vamos C, et al. Confusion about Pap smears: lack of knowledge among high-risk women. J Womens Health (Larchmt) 2013;22:67–74. PMID:23215902 https://doi.org/10.1089/jwh.2012.3667
Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565–80. PMID:25744474 https://doi.org/10.1016/S1473-3099(14)71073-4
Ogbechie OA, Hacker MR, Dodge LE, Patil MM, Ricciotti HA. Confusion regarding cervical cancer screening and chlamydia screening among sexually active young women. Sex Transm Infect 2012;88:35–7. PMID:22123163 https://doi.org/10.1136/sextrans-2011-050289
Dunne EF, Friedman A, Datta SD, Markowitz LE, Workowski KA. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2011;53(Suppl 3):S143–52. PMID:22080267 https://doi.org/10.1093/cid/cir703
Fry AM, Ferries-Rowe EA, Learman LA, Haas DM. Pap smear versus speculum examination: can we teach providers to educate patients? J Womens Health (Larchmt) 2010;19:1715–9. PMID:20662627 https://doi.org/10.1089/jwh.2009.1862
Adab P, Marshall T, Rouse A, Randhawa B, Sangha H, Bhangoo N. Randomised controlled trial of the effect of evidence based information on women's willingness to participate in cervical cancer screening. J Epidemiol Community Health 2003;57:589–93. PMID:12883063 https://doi.org/10.1136/jech.57.8.589
Drolet M, Brisson M, Maunsell E, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2012;21:1071–81. PMID:21695747 https://doi.org/10.1002/pon.2003
McCaffery KJ, Irwig L, Turner R, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. BMJ 2010;340(feb23 1):b4491. PMID:20179125 https://doi.org/10.1136/bmj.b4491
Daley EM, Perrin KM, McDermott RJ, et al. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women. J Health Psychol 2010;15:279–90. PMID:20207671 https://doi.org/10.1177/1359105309351249
Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009;85:508–13. PMID:19703844 https://doi.org/10.1136/sti.2009.037028
Lin L, Benard VB, Greek A, Roland KB, Hawkins NA, Saraiya M. Communication practices about HPV testing among providers in Federally Qualified Health Centers. Prev Med Rep 2015;2:436–9. PMID:26213683 https://doi.org/10.1016/j.pmedr.2015.05.006
Kapeu AS, Luostarinen T, Jellum E, et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 2009;169:480–8. PMID:19074773 https://doi.org/10.1093/aje/kwn354
Plummer M, Herrero R, Franceschi S, et al.; IARC Multi-centre Cervical Cancer Study Group. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003;14:805–14. PMID:14682438 https://doi.org/10.1023/B:CACO.0000003811.98261.3e
de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol 2018;47:2–13. PMID:28964706 https://doi.org/10.1016/j. bpobgyn.2017.08.015
Louie KS, Castellsague X, de Sanjose S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol Biomarkers Prev 2011;20:1379–90. PMID:21610224 https://doi.org/10.1158/1055-9965.EPI-11-0284
Nelson HD, Cantor A, Wagner J, et al. Effectiveness of patient navigation to increase cancer screening in populations adversely affected by health disparities: a meta-analysis. J Gen Intern Med 2020;35:3026–35. PMID:32700218 https://doi.org/10.1007/s11606-020-06020-9
Stillson T, Knight AL, Elswick RK Jr. The effectiveness and safety of two cervical cytologic techniques during pregnancy. J Fam Pract 1997;45:159–63. PMID:9267375
Foster JC, Smith HL. Use of the Cytobrush for Papanicolaou smear screens in pregnant women. J Nurse Midwifery 1996;41:211–7. PMID:8708804 https://doi.org/10.1016/0091-2182(96)00013-4
Paraiso MF, Brady K, Helmchen R, Roat TW. Evaluation of the endocervical Cytobrush and Cervex-Brush in pregnant women. Obstet Gynecol 1994;84:539–43. PMID:8090390
Silverberg MJ, Leyden WA, Chi A, et al. Human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol 2018;131:47–55. PMID:29215531 https://doi.org/10.1097/AOG.0000000000002371
Videla S, Tarrats A, Ornelas A, et al. Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up. Int J STD AIDS 2019;30:56–63. PMID:30170532 https://doi.org/10.1177/0956462418792653
Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018;32:795–808. PMID:29369827 https://doi.org/10.1097/QAD.0000000000001765
Sawaya GF, Lamar R, Perkins RB. Managing minimally abnormal cervical cancer screening test results. JAMA 2020;324:1557. PMID:32975557 https://doi.org/10.1001/jama.2020.12488
Silverberg MJ, Lau B, Justice AC, et al.; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026–34. PMID:22291097 https://doi.org/10.1093/cid/cir1012
Tomassi MJ, Abbas MA, Klaristenfeld DD. Expectant management surveillance for patients at risk for invasive squamous cell carcinoma of the anus: a large US healthcare system experience. Int J Colorectal Dis 2019;34:47–54. PMID:30244347 https://doi.org/10.1007/s00384-018-3167-7
Colón-López V, Shiels MS, Machin M, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol 2018;36:68–75. PMID:29140774 https://doi.org/10.1200/JCO.2017.74.9291
Machalek DA, Grulich AE, Jin F, Templeton DJ, Poynten IM. The epidemiology and natural history of anal human papillomavirus infection in men who have sex with men. Sex Health 2012;9:527–37. PMID:23380235 https://doi.org/10.1071/SH12043
Deshmukh AA, Suk R, Shiels MS, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001–2015. J Natl Cancer Inst 2020;112:829–38. PMID:31742639 https://doi.org/10.1093/jnci/djz219
Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 2007;8:311–6. PMID:17395104 https://doi.org/10.1016/S1470-2045(07)70043-8
Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634–43. PMID:17971527 https://doi.org/10.1093/jnci/djm201
Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open 2018;1:e181999. PMID:30646145 https://doi.org/10.1001/jamanetworkopen.2018.1999
Hillman RJ, Berry-Lawhorn JM, Ong JJ, et al.; International Anal Neoplasia Society. International Anal Neoplasia Society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis 2019;23:138–46. PMID:30907777 https://doi.org/10.1097/LGT.0000000000000458
Ong JJ, Grulich A, Walker S, et al. Baseline findings from the Anal Cancer Examination (ACE) study: screening using digital ano-rectal examination in HIV-positive men who have sex with men. J Med Screen 2016;23:70–6. PMID:26462726 https://doi.org/10.1177/0969141315604658
Read TR, Vodstrcil L, Grulich AE, et al. Acceptability of digital anal cancer screening examinations in HIV-positive homosexual men. HIV Med 2013;14:491–6. PMID:23590621 https://doi.org/10.1111/hiv.12035
Jin F, Grulich AE, Poynten IM, et al.; SPANC Study Team. The performance of anal cytology as a screening test for anal HSILs in homosexual men. Cancer Cytopathol 2016;124:415–24. PMID:26915346 https://doi.org/10.1002/cncy.21702
Silva M, Peixoto A, Sarmento JA, Coelho R, Macedo G. Anal cytology, histopathology and anoscopy in an anal dysplasia screening program: is anal cytology enough? Rev Esp Enferm Dig 2018;110:109–14. PMID:29168646 https://doi.org/10.17235/reed.2018.5678/2018
Iribarren Díaz M, Ocampo Hermida A, González-Carreró Fojón J, et al. Preliminary results of a screening program for anal cancer and its precursors for HIV-infected men who have sex with men in Vigo-Spain [Spanish]. Rev Esp Enferm Dig 2017;109:242–9. PMID:28229612 https://doi.org/10.17235/reed.2017.4274/2016
Burgos J, Hernández-Losa J, Landolfi S, et al. The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. AIDS 2017;31:2227–33. PMID:28723712 https://doi.org/10.1097/QAD.0000000000001605
Cheng SH, Wang CC, Chang SL, Chu FY, Hsueh YM. Oncogenic human papillomavirus is not helpful for cytology screening of the precursor lesions of anal cancers in Taiwanese men who are infected with human immunodeficiency virus. Int J Clin Oncol 2015;20:943– 51. PMID:25712159 https://doi.org/10.1007/s10147-015-0804-9
Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, et al. The role of polymerase chain reaction of high-risk human papilloma virus in the screening of high-grade squamous intraepithelial lesions in the anal mucosa of human immunodeficiency virus-positive males having sex with males. PLoS One 2015;10:e0123590. PMID:25849412 https://doi.org/10.1371/journal.pone.0123590
Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 2013;14:346–53. PMID:23499546 https://doi.org/10.1016/S1470-2045(13)70067-6
Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum 2014;57:316–23. PMID:24509453 https://doi.org/10.1097/DCR.0000000000000058
Tong WW, Shepherd K, Garland S, et al.; Study of the Prevention of Anal Cancer (SPANC) team. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions. J Infect Dis 2015;211:405–15. PMID:25139018 https://doi.org/10.1093/infdis/jiu461
Tong WW, Jin F, McHugh LC, et al. Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. AIDS 2013;27:2233–43. PMID:24157904 https://doi.org/10.1097/QAD.0b013e3283633111
Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Cold Spring Harb Perspect Med 2018;8:a031708. PMID:29440324 https://doi.org/10.1101/cshperspect.a031708
Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020;69(No. RR-5). PMID:32614811 https://doi.org/10.15585/mmwr.rr6905a1
Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A virus infections—United States, 2013–2018. MMWR Morb Mortal Wkly Rep 2019;68:413–5. PMID:31071072 https://doi.org/10.15585/mmwr.mm6818a2
Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis 2000;182:12–7. PMID:10882576 https://doi.org/10.1086/315701
Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(Suppl 1):S44–9. PMID:7876648 https://doi.org/10.1093/infdis/171.Supplement_1.S44
Sharapov UM, Bulkow LR, Negus SE, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology 2012;56:516–22. PMID:22371069 https://doi.org/10.1002/hep.25687
Mosites E, Gounder P, Snowball M, et al. Hepatitis A vaccine immune response 22 years after vaccination. J Med Virol 2018;90:1418–22. PMID:29663458 https://doi.org/10.1002/jmv.25197
Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 2015;33:5723–7. PMID:26190091 https://doi.org/10.1016/j.vaccine.2015.07.008
Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014;32:1507–13. PMID:24508042 https://doi.org/10.1016/j. vaccine.2013.10.088
Mosites E, Seeman S, Negus S, et al. Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. Vaccine 2020;38:4940–3. PMID:32535018 https://doi.org/10.1016/j.vaccine.2020.05.069
Yin S, Barker L, Ly KN, et al. Susceptibility to hepatitis A virus infection in the United States, 2007–2016. Clin Infect Dis 2020;71:e571–9. PMID:32193542 https://doi.org/10.1093/cid/ciaa298
Moro PL, Arana J, Marquez PL, et al. Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017. Vaccine 2019;37:3730–4. PMID:31155414 https://doi.org/10.1016/j.vaccine.2019.04.088
Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992;14:580–6. PMID:1554845 https://doi.org/10.1093/clinids/14.2.580
Alter HJ, Purcell RH, Gerin JL, et al. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect Immun 1977;16:928–33. PMID:892901 https://doi.org/10.1128/IAI.16.3.928-933.1977
Villarejos VM, Visoná KA, Gutiérrez A, Rodríguez A. Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med 1974;291:1375–8. PMID:4427641 https://doi.org/10.1056/NEJM197412262912602
Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol (Berl) 2015;204:5–10. PMID:25540037 https://doi.org/10.1007/s00430-014-0369-7
Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992–1000. PMID:7795104 https://doi.org/10.1093/clinids/20.4.992
Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329–39. PMID:16249217 https://doi.org/10.1093/ije/dyi206
Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med 2009;150:33–9. PMID:19124818 https://doi.org/10.7326/0003-4819-150-1-200901060-00007
Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889–93. PMID:2564960 https://doi.org/10.1016/S0140-6736(89)92876-6
Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 1998;147:478–87. PMID:9525535 https://doi.org/10.1093/oxfordjournals.aje.a009474
CDC. Healthcare-associated hepatitis B and C outbreaks (≥2 cases) reported to the CDC 2008–2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/hepatitis/outbreaks/pdfs/HealthcareInvestigationTable.pdf
Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep 2018;67:455–8. PMID:29672472 https://doi.org/10.15585/mmwr.mm6715a5
Lu PJ, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009. Vaccine 2011;29:7049–57. PMID:21782873 https://doi.org/10.1016/j.vaccine.2011.07.030
Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ 2017;66(No. SS-11). PMID:28472027 https://doi.org/10.15585/mmwr.ss6611a1
CDC. Hepatitis B vaccination coverage among adults—United States, 2004. MMWR Morb Mortal Wkly Rep 2006;55:509–11. PMID:16691181
MacKellar DA, Valleroy LA, Secura GM, et al.; Young Men's Survey Study Group. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001;91:965–71. PMID:11392942 https://doi.org/10.2105/AJPH.91.6.965
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560–99. PMID:29405329 https://doi.org/10.1002/hep.29800
Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP) [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC, Advisory Committee on Immunization Practices; 2020. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016;214:16–22. PMID:26802139 https://doi.org/10.1093/infdis/jiv748
McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011;54:801–7. PMID:21618565 https://doi.org/10.1002/hep.24442
Simons BC, Spradling PR, Bruden DJ, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis 2016;214:273–80. PMID:27056956 https://doi.org/10.1093/infdis/jiw142
Bohlke K, Davis RL, Marcy SM, et al.; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003;112:815–20. PMID:14523172 https://doi.org/10.1542/peds.112.4.815
André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87(3A):14S–20. PMID:2528292 https://doi.org/10.1016/0002-9343(89)90525-1
Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017;167:794–804. PMID:29159414 https://doi.org/10.7326/M17-1106
Minuk GY, Bohme CE, Bowen TJ, et al. Efficacy of commercial condoms in the prevention of hepatitis B virus infection. Gastroenterology 1987;93:710–4. PMID:3040512 https://doi.org/10.1016/0016-5085(87)90431-8
Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology 2019;69:1020–31. PMID:30398671 https://doi.org/10.1002/hep.30297
Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. Curr Opin Infect Dis 2019;32:31–7. PMID:30531370 https://doi.org/10.1097/QCO.0000000000000515
Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013;57:881–9. PMID:23175457 https://doi.org/10.1002/hep.26164
Price JC, McKinney JE, Crouch PC, et al. Sexually acquired hepatitis C infection in HIV-uninfected men who have sex with men using preexposure prophylaxis against HIV. J Infect Dis 2019;219:1373–6. PMID:30462305 https://doi.org/10.1093/infdis/jiy670
Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis 2012;54:1167–78. PMID:22291098 https://doi.org/10.1093/cid/cir991
Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood 1992;80:540–3. PMID:1627805 https://doi.org/10.1182/blood.V80.2.540.540
Kao JH, Hwang YT, Chen PJ, et al. Transmission of hepatitis C virus between spouses: the important role of exposure duration. Am J Gastroenterol 1996;91:2087–90. PMID:8855726
Fierer DS, Mullen MP, Dieterich DT, Isabel Fiel M, Branch AD. Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis 2012;55:887–8, author reply 888–9. PMID:22677713 https://doi.org/10.1093/cid/cis538
van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196:230–8. PMID:17570110 https://doi.org/10.1086/518796
Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22(Suppl 6):e25348. PMID:31468692 https://doi.org/10.1002/jia2.25348
Todesco E, Day N, Amiel C, et al. High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. Int J Antimicrob Agents 2019;53:678–81. PMID:30742957 https://doi.org/10.1016/j.ijantimicag.2019.02.002
Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. Sex Health 2017;14:28–41. PMID:27712618 https://doi.org/10.1071/SH16141
Hegazi A, Lee MJ, Whittaker W, et al. Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics. Int J STD AIDS 2017;28:362–6. Erratum in: Int J STD AIDS 2017;28:423. PMID:27178067 https://doi.org/10.1177/0956462416651229
Page EE, Nelson M. Hepatitis C and sex. Clin Med (Lond) 2016;16:189–92. PMID:27037392 https://doi.org/10.7861/clinmedicine.16-2-189
Apers L, Vanden Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr 2015;68:585–93. PMID:25763786 https://doi.org/10.1097/QAI.0000000000000528
Daskalopoulou M, Rodger AJ, Phillips AN, et al.; ASTRA Study Group. Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sex Transm Infect 2017;93:590–8. PMID:28679630 https://doi.org/10.1136/sextrans-2016-053029
Vanhommerig JW, Lambers FA, Schinkel J, et al.; MOSAIC (MSM Observational Study of Acute Infection With Hepatitis C) Study Group. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis 2015;2:ofv115. PMID:26634219 https://doi.org/10.1093/ofid/ofv115
Turner SS, Gianella S, Yip MJ, et al. Shedding of hepatitis C virus in semen of human immunodeficiency virus-infected men. Open Forum Infect Dis 2016;3:ofw057.
Foster AL, Gaisa MM, Hijdra RM, et al. Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis 2017;64:284–8. PMID:28013267 https://doi.org/10.1093/cid/ciw740
Hammer GP, Kellogg TA, McFarland WC, et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997–2000. Sex Transm Dis 2003;30:919–24. PMID:14646642 https://doi.org/10.1097/01.OLQ.0000091152.31366.E6
Roy KM, Goldberg DJ, Hutchinson S, Cameron SO, Wilson K, MacDonald L. Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users. J Med Virol 2004;74:62–6. PMID:15258969 https://doi.org/10.1002/jmv.20146
Mele A, Stroffolini T, Tosti ME, et al. Heterosexual transmission of hepatitis C in It a l y. J Med Vi rol 1999;57:111–3. PMID:9892393 https://doi.org/10.1002/(SICI)1096-9071(199902)57:2:111::AID-JMV4:3.0.CO;2-C
Rauch A, Rickenbach M, Weber R, et al.; Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395–402. PMID:16007539 https://doi.org/10.1086/431486
Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004;80:326–7. PMID:15295139 https://doi.org/10.1136/sti.2003.008532
Danta M, Brown D, Bhagani S, et al.; HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983–91. PMID:17457092 https://doi.org/10.1097/QAD.0b013e3281053a0c
Ghosn J, Pierre-François S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004;5:303–6. PMID:15236621 https://doi.org/10.1111/j.1468-1293.2004.00225.x
van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009;136:1609–17. PMID:19422083 https://doi.org/10.1053/j.gastro.2009.02.006
Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, et al.; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative, MOSAIC study group. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS 2017;31:1603–10. PMID:28657964 https://doi.org/10.1097/QAD.0000000000001522
Gras J, Mahjoub N, Charreau I, et al.; IPERGAY Study Group. Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis. AIDS 2020;34:47–52. PMID:31789889 https://doi.org/10.1097/QAD.0000000000002364
Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(Suppl 1):15S–20S. PMID:9305658 https://doi.org/10.1002/hep.510260703
Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33:321–7. PMID:11172332 https://doi.org/10.1053/jhep.2001.22112
Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899–905. PMID:1280771 https://doi.org/10.1056/NEJM199212313272702
Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98–104. PMID:1646962 https://doi.org/10.1056/NEJM199107113250205
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296–305. PMID:10681285 https://doi.org/10.7326/0003-4819-132-4-200002150-00008
Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383–98, vi. PMID:16023972 https://doi.org/10.1016/j. cld.2005.05.003
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(Suppl):S58–68. PMID:25443346 https://doi.org/10.1016/j.jhep.2014.07.012
Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012;26:119–28. PMID:21871776 https://doi.org/10.1016/j.tmrv.2011.07.007
Bixler D, Annambholta P, Abara WE, et al. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014–2017. Am J Transplant 2019;19:2570–82. PMID:30861300 https://doi.org/10.1111/ajt.15352
CDC. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362–5. PMID:23657112
Marincovich B, Castilla J, del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003;79:160–2. PMID:12690143 https://doi.org/10.1136/sti.79.2.160
Tahan V, Karaca C, Yildirim B, et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005;100:821–4. PMID:15784025 https://doi.org/10.1111/j.1572-0241.2005.40879.x
Vandelli C, Renzo F, Romanò L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004;99:855–9. PMID:15128350 https://doi.org/10.1111/j.1572-0241.2004.04150.x
Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008;198:683–6. PMID:18627270 https://doi.org/10.1086/590430
Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:109–13. PMID:23437438 https://doi.org/10.7326/0003-4819-158-2-201301150-00575
Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880–9. PMID:16267758 https://doi.org/10.1086/497701
Barbosa C, Fraser H, Hoerger TJ, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction 2019;114:2267–78. PMID:31307116 https://doi.org/10.1111/add.14731
Lambers FA, Prins M, Thomas X, et al.; MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011;25:F21–7. PMID:21857492 https://doi.org/10.1097/QAD.0b013e32834bac44
Martin TC, Singh GJ, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: a pragmatic approach. Hepatology 2015;61:1437. PMID:25147047 https://doi.org/10.1002/hep.27391
Ingiliz P, Martin TC, Rodger A, et al.; NEAT study group. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017;66:282–7. PMID:27650285 https://doi.org/10.1016/j.jhep.2016.09.004
Briat A, Dulioust E, Galimand J, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005;19:1827–35. PMID:16227790 https://doi.org/10.1097/01.aids.0000189847.98569.2d
Bissessor M, Fairley CK, Read T, Denham I, Bradshaw C, Chen M. The etiology of infectious proctitis in men who have sex with men differs according to HIV status. Sex Transm Dis 2013;40:768–70. PMID:24275725 https://doi.org/10.1097/OLQ.0000000000000022
Gutierrez-Fernandez J, Medina V, Hidalgo-Tenorio C, Abad R. Two cases of Neisseria meningitidis proctitis in HIV-positive men who have sex with men. Emerg Infect Dis 2017;23:542–3. PMID:28221124 https://doi.org/10.3201/eid2303.161039
Levy I, Gefen-Halevi S, Nissan I, et al. Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases. Int J Infect Dis 2018;75:34–8. PMID:30125691 https://doi.org/10.1016/j.ijid.2018.08.004
Lebari D. Syphilis presenting as colorectal cancer [Abstract 34216]. Sex Transm Dis 2014;41(Suppl 1):S4.
Hines JZ, Pinsent T, Rees K, et al. Notes from the field: shigellosis outbreak among men who have sex with men and homeless persons—Oregon, 2015–2016. MMWR Morb Mortal Wkly Rep 2016;65:812–3. PMID:27513523 https://doi.org/10.15585/mmwr.mm6531a5
Marchand-Senécal X, Bekal S, Pilon PA, Sylvestre JL, Gaudreau C. Campylobacter fetus cluster among men who have sex with men, Montreal, Quebec, Canada, 2014–2016. Clin Infect Dis 2017;65:1751–3. PMID:29020280 https://doi.org/10.1093/cid/cix610
Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004;38:300–2. PMID:14699467 https://doi.org/10.1086/380838
Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: clinical presentation, diagnosis, and treatment. Clin Infect Dis 2015;61(Suppl 8):S865–73. PMID:26602624 https://doi.org/10.1093/cid/civ756
Mohrmann G, Noah C, Sabranski M, Sahly H, Stellbrink HJ. Ongoing epidemic of lymphogranuloma venereum in HIV-positive men who have sex with men: how symptoms should guide treatment. J Int AIDS Soc 2014;17(Suppl 3):19657. PMID:25394161 https://doi.org/10.7448/IAS.17.4.19657
Hoffmann C, Sahly H, Jessen A, et al. High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM. Infection 2013;41:999–1003. PMID:23852945 https://doi.org/10.1007/s15010-013-0501-4
Heiman KE, Karlsson M, Grass J, et al.; CDC. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men—United States, 2002–2013. MMWR Morb Mortal Wkly Rep 2014;63:132–3. PMID:24522098
Galiczynski EM Jr, Elston DM. What's eating you? Pubic lice (Pthirus pubis). Cutis 2008;81:109–14. PMID:18441761
Meinking TL, Serrano L, Hard B, et al. Comparative in vitro pediculicidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol 2002;138:220–4. PMID:11843643 https://doi.org/10.1001/archderm.138.2.220
Yoon KS, Gao JR, Lee SH, Clark JM, Brown L, Taplin D. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Arch Dermatol 2003;139:994–1000. PMID:12925385 https://doi.org/10.1001/archderm.139.8.994
Burkhart CG, Burkhart CN. Oral ivermectin for Phthirus pubis. J Am Acad Dermatol 2004;51:1037–8. PMID:15583618 https://doi.org/10.1016/j.jaad.2004.04.041
Scott GR, Chosidow O; IUSTI/WHO. European guideline for the management of pediculosis pubis, 2010. Int J STD AIDS 2011;22:304–5. PMID:21680662 https://doi.org/10.1258/ijsa.2011.011114
Goldust M, Rezaee E, Raghifar R, Hemayat S. Comparing the efficacy of oral ivermectin vs malathion 0.5% lotion for the treatment of scabies. Skinmed 2014;12:284–7. PMID:25632646
Veraldi S, Schianchi R, Ramoni S, Nazzaro G. Pubic hair removal and Phthirus pubis infestation. Int J STD AIDS 2018;29:103–4. PMID:29130406 https://doi.org/10.1177/0956462417740292
Leung AKC, Lam JM, Leong KF. Scabies: a neglected global disease. Curr Pediatr Rev 2020;16:33–42. PMID:31544694 https://doi.org/10.2174/1573396315666190717114131
Engelman D, Cantey PT, Marks M, et al. The public health control of scabies: priorities for research and action. Lancet 2019;394:81–92. PMID:31178154 https://doi.org/10.1016/S0140-6736(19)31136-5
Shimose L, Munoz-Price LS. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep 2013;15:426–31. PMID:23904181 https://doi.org/10.1007/s11908-013-0354-0
Walter B, Heukelbach J, Fengler G, Worth C, Hengge U, Feldmeier H. Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol 2011;147:468–73. PMID:21482897 https://doi.org/10.1001/archdermatol.2011.51
Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: advances in noninvasive diagnosis. PLoS Negl Trop Dis 2016;10:e0004691. PMID:27311065 https://doi.org/10.1371/journal.pntd.0004691
Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007;(3):CD000320. PMID:17636630
Abdel-Raheem TA, Méabed EM, Nasef GA, Abdel Wahed WY, Rohaim RM. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatolog Treat 2016;27:473–9. PMID:27027929 https://doi.org/10.3109/09546634.2016.1151855
Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol 2015;61:79–84. PMID:26342502
Al Jaff DAA, Amin MHM. Comparison of the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies. Res J Pharm Biol Chem Sci 2018;9:670–6.
Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol 2013;59:79–84. PMID:24171301
Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther (Heidelb) 2016;29:58–63. PMID:26555785 https://doi.org/10.1111/dth.12310
Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010;362:717–25. PMID:20181973 https://doi.org/10.1056/NEJMct0910329
Chiu S, Argaez C. Ivermectin for parasitic skin infections of scabies: a review of comparative clinical effectiveness, cost-effectiveness, and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019. https://www.ncbi.nlm.nih.gov/books/NBK545083/
Nol an K, Kamrath J, Levitt J. Lindane toxicity: a comprehensive review of the medical literature. Pediatr Dermatol 2012;29:141–6. PMID:21995612 https://doi.org/10.1111/j.1525-1470.2011.01519.x
Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol 2008;3:57–66. PMID:18230034 https://doi.org/10.2217/17460913.3.1.57
Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol 2009;145:840–1. PMID:19620572 https://doi.org/10.1001/archdermatol.2009.125
Mounsey KE, McCarthy JS, Walton SF. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol 2013;29:35–42. PMID:23088958 https://doi.org/10.1016/j.pt.2012.09.006
van der Linden N, van Gool K, Gardner K, et al. A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions. PLoS Negl Trop Dis 2019;13:e0007182. PMID:30849124 https://doi.org/10.1371/journal.pntd.0007182
Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect 2005;50:375–81. PMID:15907543 https://doi.org/10.1016/j.jinf.2004.08.033
Ortega-Loayza AG, McCall CO, Nunley JR. Crusted scabies and multiple dosages of ivermectin. J Drugs Dermatol 2013;12:584–5. PMID:23652958
Bouvresse S, Chosidow O. Scabies in healthcare settings. Curr Opin Infect Dis 2010;23:111–8. PMID:20075729 https://doi.org/10.1097/QCO.0b013e328336821b
Marotta M, Toni F, Dallolio L, Toni G, Leoni E. Management of a family outbreak of scabies with high risk of spread to other community and hospital facilities. Am J Infect Control 2018;46:808–13. PMID:29397231 https://doi.org/10.1016/j.ajic.2017.12.004
Romani L, Whitfeld MJ, Koroivueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med 2015;373:2305–13. PMID:26650152 https://doi.org/10.1056/NEJMoa1500987
Ackerman DR, Sugar NF, Fine DN, Eckert LO. Sexual assault victims: factors associated with follow-up care. Am J Obstet Gynecol 2006;194:1653–9. PMID:16635464 https://doi.org/10.1016/j. ajog.2006.03.014
Parekh V, Beaumont Brown C. Follow up of patients who have been recently sexually assaulted. Sex Transm Infect 2003;79:349. PMID:12902602 https://doi.org/10.1136/sti.79.4.349-a
Vrees RA. Evaluation and management of female victims of sexual assault. Obstet Gynecol Surv 2017;72:39–53. PMID:28134394 https://doi.org/10.1097/OGX.0000000000000390
Unger ER, Fajman NN, Maloney EM, et al. Anogenital human papillomavirus in sexually abused and nonabused children: a multicenter study. Pediatrics 2011;128:e658–65. PMID:21844060 https://doi.org/10.1542/peds.2010-2247
Kreimer AR, Rodriguez AC, Hildesheim A, et al.; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444–51. PMID:21908768 https://doi.org/10.1093/jnci/djr319
Claydon E, Murphy S, Osborne EM, Kitchen V, Smith JR, Harris JR. Rape and HIV. Int J STD AIDS 1991;2:200–1. PMID:1863649 https://doi.org/10.1177/095646249100200310
Murphy S, Kitchen V, Harris JR, Forster SM. Rape and subsequent seroconversion to HIV. BMJ 1989;299:718. PMID:2508885 https://doi.org/10.1136/bmj.299.6701.718
Cardo DM, Culver DH, Ciesielski CA, et al.; CDC Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485–90. PMID:9366579 https://doi.org/10.1056/NEJM199711203372101
Kuhar DT, Henderson DK, Struble KA, et al.; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013;34:875–92. PMID:23917901 https://doi.org/10.1086/672271
Du Mont J, Myhr TL, Husson H, Macdonald S, Rachlis A, Loutfy MR. HIV postexposure prophylaxis use among Ontario female adolescent sexual assault victims: a prospective analysis. Sex Transm Dis 2008;35:973–8. PMID:18836390
Neu N, Heffernan-Vacca S, Millery M, Stimell M, Brown J. Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center. Sex Transm Dis 2007;34:65–8. PMID:16794560 https://doi.org/10.1097/01.olq.0000225329.07765.d8
Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther 2008;13:87–95. PMID:18389902
Inciarte A, Leal L, Masfarre L, et al.; Sexual Assault Victims Study Group. Post-exposure prophylaxis for HIV infection in sexual assault victims. HIV Med 2020;21:43–52. PMID:31603619 https://doi.org/10.1111/hiv.12797
Announcement: Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV—United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:458. PMID:27149423 https://doi.org/10.15585/mmwr.mm6517a5
Ford N, Venter F, Irvine C, Beanland RL, Shubber Z. Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review. Clin Infect Dis 2015;60(Suppl 3):S182–6. PMID:25972501 https://doi.org/10.1093/cid/civ093
Jenny C, Crawford-Jakubiak JE; Committee on Child Abuse and Neglect; American Academy of Pediatrics. The evaluation of children in the primary care setting when sexual abuse is suspected. Pediatrics 2013;132:e558–67. PMID:23897912 https://doi.org/10.1542/peds.2013-1741
Girardet RG, Lahoti S, Howard LA, et al. Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics 2009;124:79–86. PMID:19564286 https://doi.org/10.1542/peds.2008-2947
Black CM, Driebe EM, Howard LA, et al. Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J 2009;28:608–13. PMID:19451856 https://doi.org/10.1097/INF.0b013e31819b592e
Trotman GE, Young-Anderson C, Deye KP. Acute sexual assault in the pediatric and adolescent population. J Pediatr Adolesc Gynecol 2016;29:518–26. PMID:26702774 https://doi.org/10.1016/j.jpag.2015.05.001
Schwandt A, Williams C, Beigi RH. Perinatal transmission of Trichomonas vaginalis: a case report. J Reprod Med 2008;53:59–61. PMID:18251366
Bell TA, Stamm WE, Wang SP, Kuo CC, Holmes KK, Grayston JT. Chronic Chlamydia trachomatis infections in infants. JAMA 1992;267:400–2. PMID:1727964 https://doi.org/10.1001/jama.1992.03480030078041
Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in pregnancy: the global challenge of preventing adverse pregnancy and infant outcomes in sub-Saharan Africa and Asia. BioMed Res Int 2016;2016:9315757. PMID:27144177 https://doi.org/10.1155/2016/9315757
Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA 1986;255:3374–7. PMID:3712696 https://doi.org/10.1001/jama.1986.03370240044034
Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J 2007;26:836–40. PMID:17721381 https://doi.org/10.1097/INF.0b013e318124a4ae
Sabeena S, Bhat P, Kamath V, Arunkumar G. Possible non-sexual modes of transmission of human papilloma virus. J Obstet Gynaecol Res 2017;43:429–35. PMID:28165175 https://doi.org/10.1111/jog.13248
Adams JA, Farst KJ, Kellogg ND. Interpretation of medical findings in suspected child sexual abuse: an update for 2018. J Pediatr Adolesc Gynecol 2018;31:225–31. PMID:29294380 https://doi.org/10.1016/j.jpag.2017.12.011
Kellogg ND, Melville JD, Lukefahr JL, Nienow SM, Russell EL. Genital and extragenital gonorrhea and chlamydia in children and adolescents evaluated for sexual abuse. Pediatr Emerg Care 2018;34:761–6. PMID:28072668 https://doi.org/10.1097/PEC.0000000000001014
Gavril AR, Kellogg ND, Nair P. Value of follow-up examinations of children and adolescents evaluated for sexual abuse and assault. Pediatrics 2012;129:282–9. PMID:22291113 https://doi.org/10.1542/peds.2011-0804
Bandea CI, Joseph K, Secor EW, et al. Development of PCR assays for detection of Trichomonas vaginalis in urine specimens. J Clin Microbiol 2013;51:1298–300. PMID:23390274 https://doi.org/10.1128/JCM.03101-12
Gallion HR, Dupree LJ, Scott TA, Arnold DH. Diagnosis of Trichomonas vaginalis in female children and adolescents evaluated for possible sexual abuse: a comparison of the InPouch TV culture method and wet mount microscopy. J Pediatr Adolesc Gynecol 2009;22:300–5. PMID:19576816 https://doi.org/10.1016/j.jpag.2008.12.006
Lalor K, McElvaney R. Child sexual abuse, links to later sexual exploitation/high-risk sexual behavior, and prevention/treatment programs. Trauma Violence Abuse 2010;11:159–77. PMID:20679329 https://doi.org/10.1177/1524838010378299
Girardet RG, Lemme S, Biason TA, Bolton K, Lahoti S. HIV post-exposure prophylaxis in children and adolescents presenting for reported sexual assault. Child Abuse Negl 2009;33:173–8. PMID:19324415 https://doi.org/10.1016/j.chiabu.2008.05.010
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Washington, DC: US Department of Health and Human Services, National Institutes of Health, AIDSinfo; 2020. https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf

CME / ABIM MOC / CE

Sexually Transmitted Infections Treatment Guidelines, 2021

Authors: Kimberly A. Workowski, MD; Laura H. Bachmann, MD; Philip A. Chan, MD; Christine M. Johnston, MD; Christina A. Muzny, MD; Ina Park, MD; Hilary Reno, MD, PhD; Jonathan M. Zenilman, MD; Gail A. Bolan, MD
CME / ABIM MOC / CE Released: 10/27/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/27/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for family medicine clinicians, internists, adolescent medicine clinicians, obstetricians/gynecologists, emergency medicine clinicians, infectious disease clinicians, and other clinicians caring for patients with or at risk for sexually transmitted infections (STIs).

The goal of this activity is to describe on-site STI treatment and partner services, operational determinants of quality services in various clinical settings, and indications for consultation with or referral to a specialist for patients with STI-related conditions, according to updated Centers for Disease Control and Prevention (CDC) guidelines.

Upon completion of this activity, participants will:

Describe treatment recommendations for sexually transmitted infections (STIs), according to updated Centers for Disease Control and Prevention (CDC) guidelines
Determine vaccine and other preventive strategy recommendations for STIs, according to updated CDC guidelines
Identify diagnostic and counseling recommendations for STIs, according to updated CDC guidelines

Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Kimberly A. Workowski, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention (CDC)
Department of Medicine, Emory University
Atlanta, Georgia

Disclosures

Disclosure: Kimberly A. Workowski, MD, has disclosed no relevant financial relationships.

Laura H. Bachmann, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention (CDC)
Atlanta, Georgia

Disclosures

Disclosure: Laura H. Bachmann, MD, has disclosed no relevant financial relationships.

Philip A. Chan, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
Brown University
Providence, Rhode Island

Disclosures

Disclosure: Philip A. Chan, MD, has disclosed no relevant financial relationships.

Christine M. Johnston, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
University of Washington
Seattle, Washington

Disclosures

Disclosure: Christine M. Johnston, MD, has disclosed the following relevant financial relationships:
Serve(d) as advisor or consultant for: AbbVie, Inc.; Gilead Sciences, Inc.; MedPace, Inc.
Received grants for clinical research from: Bill and Melinda Gates Foundation
Other (Royalties for HSV sections): UpToDate

Christina A. Muzny, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
University of Alabama at Birmingham

Disclosures

Disclosure: Christina A. Muzny, MD, has disclosed the following relevant financial relationships:
Serve(d) as advisor or consultant for: Abbott Laboratories; Becton, Dickinson and Co.; Cepheid; Lupin Pharmaceuticals, Inc.; PhagoMed Biopharma GmbH; Roche Diagnostics
Received grants for clinical research from: Lupin Pharmaceuticals, Inc.

Ina Park, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
University of California San Francisc

Disclosures

Disclosure: Ina Park, MD, has disclosed no relevant financial relationships.

Hilary Reno, MD, PhD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
Washington University
St Louis, Missouri

Disclosures

Disclosure: Hilary Reno, MD, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Hologics, Inc.

Jonathan M. Zenilman, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
Johns Hopkins University
Baltimore, Maryland
Participation by Dr. Jonathan M. Zenilman does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Disclosures

Disclosure: Jonathan M. Zenilman, MD, has disclosed no relevant financial relationships.

Gail A. Bolan, MD

Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Disclosure: Gail A. Bolan, MD, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD

Freelance writer and reviewer
Medscape, LLC

Disclosures

Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance
Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For Nurses

Awarded 3.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 3.0 contact hour(s) ( 0.300 CEUs) (Universal Activity Number: JA0007105-0000-21-456-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Morbidity & Mortality Weekly Report

CME / ABIM MOC / CE

Sexually Transmitted Infections Treatment Guidelines, 2021

Authors: Kimberly A. Workowski, MD; Laura H. Bachmann, MD; Philip A. Chan, MD; Christine M. Johnston, MD; Christina A. Muzny, MD; Ina Park, MD; Hilary Reno, MD, PhD; Jonathan M. Zenilman, MD; Gail A. Bolan, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 10/27/2021

Valid for credit through: 10/27/2022, 11:59 PM EST

processing....

Summary

These guidelines for the treatment of persons who have or are at risk for sexually transmitted infections (STIs) were updated by CDC after consultation with professionals knowledgeable in the field of STIs who met in Atlanta, Georgia, June 11–14, 2019. The information in this report updates the 2015 guidelines. These guidelines discuss 1) updated recommendations for treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis; 2) addition of metronidazole to the recommended treatment regimen for pelvic inflammatory disease; 3) alternative treatment options for bacterial vaginosis; 4) management of Mycoplasma genitalium; 5) human papillomavirus vaccine recommendations and counseling messages; 6) expanded risk factors for syphilis testing among pregnant women; 7) one-time testing for hepatitis C infection; 8) evaluation of men who have sex with men after sexual assault; and 9) two-step testing for serologic diagnosis of genital herpes simplex virus. Physicians and other health care providers can use these guidelines to assist in prevention and treatment of STIs.

Introduction

The term "sexually transmitted infection" (STI) refers to a pathogen that causes infection through sexual contact, whereas the term "sexually transmitted disease" (STD) refers to a recognizable disease state that has developed from an infection. Physicians and other health care providers have a crucial role in preventing and treating STIs. These guidelines are intended to assist with that effort. Although the guidelines emphasize treatment, prevention strategies and diagnostic recommendations also are discussed.

This report updates Sexually Transmitted Diseases Treatment Guidelines, 2015^[1] and should be regarded as a source of clinical guidance rather than prescriptive standards. Health care providers should always consider the clinical circumstances of each person in the context of local disease prevalence. These guidelines are applicable to any patient care setting that serves persons at risk for STIs, including family planning clinics, HIV care clinics, correctional health care settings, private physicians' offices, Federally Qualified Health Centers, clinics for adolescent care, and other primary care facilities. These guidelines are focused on treatment and counseling and do not address other community services and interventions that are essential to STI and HIV prevention efforts.

These STI treatment guidelines complement Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020^[2] regarding quality clinical services for STIs in primary care and STD specialty care settings. This guidance specifies operational determinants of quality services in various clinical settings, describes on-site treatment and partner services, and indicates when STI-related conditions should be managed through consultation with or referral to a specialist.

Page 1 of 20

Methods

CME / ABIM MOC / CE Information

References

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Medscape, LLC

Table 1.

Table 2.

Table 3.

Table 4.

Table 5.

Table 6.

Table 7.

Table 8.

Box 1.

Box 2.

Box 3.

Box 4.

Box 5.

References

Faculty and Disclosures

Faculty

Kimberly A. Workowski, MD

Laura H. Bachmann, MD

Philip A. Chan, MD

Christine M. Johnston, MD

Christina A. Muzny, MD

Ina Park, MD

Hilary Reno, MD, PhD

Jonathan M. Zenilman, MD

Gail A. Bolan, MD

CME Author

Laurie Barclay, MD

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

CME / ABIM MOC / CE

Sexually Transmitted Infections Treatment Guidelines, 2021

Target Audience and Goal Statement

Disclosures

Faculty

Kimberly A. Workowski, MD

Laura H. Bachmann, MD

Philip A. Chan, MD

Christine M. Johnston, MD

Christina A. Muzny, MD

Ina Park, MD

Hilary Reno, MD, PhD

Jonathan M. Zenilman, MD

Gail A. Bolan, MD

CME Author

Laurie Barclay, MD

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Sexually Transmitted Infections Treatment Guidelines, 2021

Summary

Introduction

Table of Contents